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Abstract 
 
 
Cellular senescence is an end point of a signal transduction programme leading 
to irreversible cell cycle arrest accompanied by characteristic alterations to cell 
morphology, biochemical properties and gene expression profile. This phenotype 
can  be  triggered  by  a  variety  of  stimuli  including  telomere  shortening,  DNA 
damage  or  activated  oncogenes.  Senescence  is  now  recognised  as  a  tumour 
suppressor mechanism mediated by p53 and pRB pathways which act to prevent 
the proliferation of cells that are at risk of tumourigenic transformation. 
RUNX1  is  a  transcription  factor  essential  for  definitive  hematopoiesis  and  is 
frequently  targeted  in  human  leukaemias  by  chromosomal  rearrangements. 
RUNX1 has been also demonstrated to act as a dominant oncogene in mice and 
the ectopic expression of RUNX1 in murine embryonic fibroblasts has been shown 
to cause senescence. 
The central aim of this study was to investigate the mechanism of senescence 
induction  by  RUNX1  and  its  fusion  derived  leukaemogenic  oncoproteins  in 
primary fibroblasts.   
My work showed that RUNX1 induces a strong senescence like response in murine 
and  human  primary  fibroblasts  that  requires  intact  DNA  binding,  CBFβ 
interaction  and  C terminal  transcriptional  activation/repression  domains.  
However, surprising differences were found between  the major RUNX1  fusion 
oncoprotein  derivatives.    The  N terminal  fusion  protein  TEL RUNX1  fails  to 
induce  senescence  despite  retention  of  a  virtually  full length  RUNX1  moiety, 
while  the  senescence inducing  potential  is  exaggerated  in  the  truncated  C 
terminal  fusion  protein  RUNX1 ETO  (AML1 ETO).  The  potential  to  drive 
senescence  is  retained  by  the  deletion  mutant  RUNX1 ETO∆469  which  lacks  
critical corepressor binding sites suggesting that the repression of target genes 
may  be  a  primary  mechanism  implicated  in  RUNX1 ETO  induced  senescence.  
Interestingly, CBFβ MYH11 fusion oncoprotein that affects RUNX1 indirectly by 
targeting CBFβ can also induce senescence when ectopically expressed in human 
primary cells. The RUNX1 and RUNX1 ETO induced senescent phenotypes differ 
from  archetypal  H Ras
V12  as  arrest  occurs  without  a  preliminary  phase  of 
proliferation and the arrested cells lack prominent foci of DNA strand breaks and 
chromatin  condensation.    Notably  however,  RUNX1  and  RUNX1 ETO  display xiv 
differences  in  their  potency  and  the  extent  of  engagement  of  p53  and  Rb 
effector pathways.  RUNX1 ETO is highly dependent on p53 function and unlike 
RUNX1 drives senescence in cells lacking intact p16Ink4a.  RUNX1 ETO appears to 
exert its unique effects through potent induction of reactive oxygen species and 
p38MAPK  phosphorylation.    These  findings  illustrate  the  heterogeneous 
manifestations  of  senescence like  growth  arrest  and  elucidate  the  distinctive 
biology  and  oncogenic  properties  of  RUNX1  and  its  fusion  derivatives.15 
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1  Introduction 
1.1 Characteristics of RUNX transcription factors 
The RUNX (Runt related transcription factor) genes encode the DNA binding a 
chain  partners  of  the  CBF  (core  binding  factor)  complexes  that  play  crucial 
lineage specific roles in cell proliferation and differentiation. The Runx proteins 
form heterodimers with a non DNA binding partner, CBFb that is encoded by a 
single gene in mammals and lacks intrinsic DNA binding activity but profoundly 
enhances the affinity of its a chain partner for DNA and confers stability on the 
complex(Blyth et al 2005; Ito 2004; Ogawa et al 1993a; Ogawa et al 1993b; Wang 
et al 1993). 
The  Drosophila  regulatory  gene  runt,  which  functions  in  establishing 
segmentation patterns during embryogenesis as well as in sex determination and 
neurogenesis, was the first member of RUNX family to be identified twenty years 
ago (Duffy et al 1991; Duffy and Gergen 1991; Gergen and Butler 1988). Other 
invertebrate species with well characterized RUNX transcription factors include 
the  nematode  Caenorhabditis  elegans  and  the  sea  urchin  Strongylocentrotus 
purpuratus (Nam et al 2002; Robertson et al 2002). Some lower organisms have 
only a single RUNX gene but in vertebrates multiplication of RUNX genes through 
gene  duplication  has  occurred  (Rennert  et  al  2003).  Three  highly  conserved 
human and mouse RUNX genes: RUNX1, RUNX2 and RUNX3 were identified and 
localized on human chromosomes 21, 6 and 1 and on mouse chromosomes 16, 17 
and  4,  respectively  (Avraham  et  al  1995;  Bae  et  al  1994;  Calabi  et  al  1995; 
Levanon  et  al  1994).  The  three  mammalian  RUNX  genes  share  extensive 
homology,  which  is  also  found  in  paralogous  genes,  CLIC  and  DSCR,  that  are 
adjacent to RUNX loci (Eggers et al 2002; Levanon et al 2001; Levanon et al 
2003b)  (Figure  1.1).  All  three  mammalian  RUNX  genes  are  transcriptionally 
regulated by two independent promoter regions, P1 (distal) and P2 (proximal) 
that  encode  isoforms  with  distinct  amino terminal  sequences  (Levanon  and 
Groner 2004) (Figure 1.1).  
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Figure 1.1 Genomic organization of the human RUNX genes 
The two promoters P1 and P2 and initiator ATGs are indicated. 5’UTR are in 
yellow and orange and 3’UTR are in blue. Common exons are shown in similar 
colour and conserved neighbouring genes (CLIC and DSCR) are depicted 
The most highly conserved feature of the RUNX proteins is the 128 amino acid 
Runt  domain  that  functions  in  DNA  binding,  protein protein  interactions,  ATP 
binding  and  which  also  contributes  to  nuclear  localisation  (Crute  et  al  1996; 
Kagoshima et al 1993; Kanno et al 1998a). The runt domain lies in the N terminal 
half of the protein. Structural analysis has revealed that this domain forms an S 
type immunoglobulin fold which has also been identified in the 3 dimensional 
structure of the DNA binding domains of transcription factors such as p53, NF κB, 
NFAT, STAT, and the T box proteins (Figure 1.2) (Berardi et al 1999; Nagata et al 
1999). Outside the runt domain there is less sequence similarity between family 
members,  although  the  similarity  in  amino  acid  composition  is  evident.  The 
carboxy terminal regions of RUNX proteins tend to be rich in proline, serine and 
threonine  (PST)  and  regions  of  homology  can  be  noticed  in  the  functionally 
defined  transactivation/inhibitory  domains,  nuclear matrix attachment  signal 
and in the C terminal VWRPY motif that functions as a recruitment motif for the 
Groucho/TLE family of corepressors (Aronson et al 1997; Levanon et al 1994; 
Zeng et al 1997). The RUNX proteins bind directly to target genes and activate or 
repress  transcription  depending  on  the  context  (Otto  et  al  2003;  Speck  and 
RUNX1 
RUNX2 
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Gilliland  2002).  The  DNA binding  affinity  of  RUNX  alpha  chains  is  increased 
substantially via co interaction with the non DNA binding β chain cofactor which 
binds to the runt domain (Ogawa et al 1993a; Ogawa et al 1993b; Wang et al 
1993)  and  could  be  also  potentially  regulated  by  other  cofactors  and  by 
chromatin structure.  
 
 
 
 
 
 
 
 
 
 
Figure 1.2 Structure of the RUNX1 Runt domain-CBFβ-DNA complex 
DNA is shown in red and yellow. CBFβ is shown in magenta and the RUNX1 Runt 
domain in cyan. Runt domain loops in the major groove are coloured blue (C 
terminal  loop)  and  red  (βA’ B  loop),  whereas  the  loop  contacting  the  minor 
groove is shown in green (βE’ F loop) (Zhang et al 2003c) 
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The  RUNX  proteins  are  key  regulators  of  major  developmental  pathways  and 
their expression is tightly regulated, leading to highly specific spatio temporal 
expression  patterns  which  when  disrupted  lead  to  various  defects.  RUNX1  is 
required  for  definitive  haematopoiesis  and  is  frequently  mutated  in  human 
leukaemia (Speck and Gilliland 2002). RUNX2 is essential for osteogenesis and its 
haploinsufficiency is associated with cleidocranial dysplasia in humans (Komori 
et al 1997; Otto et al 2002). More recently, RUNX3 was shown to control some 
aspects of neurogenesis and thymopoiesis as well as play a role in the control of 
cell  proliferation  and  apoptosis  in  the  gastric  epithelium  (Inoue  et  al  2003; 
Levanon et al 2002; Levanon et al 2003a; Taniuchi et al 2002; Woolf et al 2003). 
RUNX3 is also frequently methylated in human gastric cancers (Li et al 2002). A 
growing body of evidence implicates RUNX genes as tumour suppressors in some 
cancers,  where  inactivating  mutations,  gene  deletions  or  hypermethylation 
occur. On the other hand transcriptional activation of all three RUNX genes by 
retroviral insertional mutagenesis in lymphoma prone CD2 MYC transgenic mice 
has  revealed  their  dominant  oncogenic  potential.  A  common  result  of  these 
insertions was found to be the overexpression of structurally intact RUNX gene 
products (Blyth et al 2001; Stewart et al 1996; Stewart et al 1997; Stewart et al 
2002; Wotton et al 2002).  
1.2 Nomenclature of RUNX proteins 
To avoid unnecessary confusion, an ad hoc nomenclature committee on Runt 
domain  proteins,  has  proposed  the  unified  terms  RUNX1,  RUNX2,  RUNX3  (the 
homologous genes in mouse are Runx1, Runx2, Runx3, respectively) that refer to 
transcriptional factors which had previously been described by multiple terms 
(van  Wijnen  et  al  2004).  RUNX1  has  previously  been  designated  by  different 
names:  AML1  (acute  myeloid  leukemia  1),  PEBP2αB  (polyoma  virus  enhancer 
binding protein 2αB) and CBFA2 (core binding factor α2). RUNX2 could be found 
under names such as: AML3, PEBP2αA, CBFA1. Finally RUNX3 was known in the 
literature as: AML2, PEBP2αC, CBFA3. Kamil K. Wolyniec, 2008     Chapter 1,20  
1.3 Transcriptional regulation by RUNX1 
There  are  three  major  isoforms  of  the  RUNX1  protein  that  are  produced  by 
alternative splicing: AML1c (RUNX1 P1), AML1b (RUNX1 P2) and AML1a that have 
been reported so far (Meyers et al 1993; Miyoshi et al 1991; Miyoshi et al 1995) 
(Figure 1.3). AML1b (453 amino acid) and AML1c (480 amino acid) contain the 
runt homology domain as well as a proline , serine  and threonine rich (PST) 
region which is a putative transcriptional activation domain (Bae et al 1994). The 
difference  in  length  between  AML1b  and  AML1c  arises  from  the  use  of  two 
different promoters: AML1b is transcribed from proximal P2 (MRIPV) promoter 
whereas AML1c is transcribed from distal P1 (MASDS) promoter. The shorter 250 
amino acid AML1a protein lacks the C terminus including transactivation domain 
(PST region) but has a unique nine amino  acids at its C terminal end due to 
alternative splicing and can act as a competitive inhibitor of RUNX1 (Miyoshi et 
al 1991; Niitsu et al 1997; Tanaka et al 1995). For example it was reported that 
overexpression  of  AML1a  blocks  differentiation  and  promotes  proliferation  of 
murine myeloid cell line, whereas RUNX1 has the opposite effect of promoting 
differentiation and arresting proliferation (Tanaka et al 1995). RUNX1 binds to 
consensus sequence (PyGPyGGT, where Py is a pyrimidine) termed PEBP1 site, 
that  was  originally  identified  in  polyomaviral  and  retroviral  core  enhancer 
elements (Kamachi et al 1990; Wang and Speck 1992).  
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Figure 1.3 Structure of AML1a, AML1b and AML1c 
RHD  is  the  Runt  homology  domain,  VWRPY  indicates  the  C terminal  Groucho 
binding  motif  of  RUNX1  family  members,  P1  –distal  promoter,  P2  –proximal 
promoter 
1.3.1 Transcriptional activation 
Most of the genes that have been shown to be activated by RUNX1 are involved 
in haematopoiesis i.e. T cell and B cell antigen receptor subunits (Erman et al 
1998; Prosser et al 1992; Redondo et al 1992; Wang et al 1993), interleukin 3 
(Uchida et al 1997), granulocyte macrophage colony stimulating factor (Hohaus 
et al 1995; Takahashi et al 1995), neutrophil elastase (Nuchprayoon et al 1994), 
myeloperoxidase (Britos Bray and Friedman 1997; Nuchprayoon et al 1994) and 
granzyme B (Wargnier et al 1995). Because RUNX1 binding sites are necessary 
but not sufficient for transcriptional activation, this has led to the hypothesis 
that  RUNX1  is  an  orchestrator  of  assembly  of  transcriptional  activation 
complexes  (Figure  1.4).  The  mechanism  proposed  for  activation  by  the 
RUNX1/CBFβ  complex  is  that  it  recruits  coactivators  such  as  p300/CBP 
(p300/CREB binding protein), yes associated protein (YAP) and ALY (Bruhn et al 
1997; Kitabayashi et al 1998; Yagi et al 1999). These coactivators do not bind 
DNA  directly,  but  stimulate  transcription  by  acetylating  histones  and/or 
recruiting the RNA polymerase II transcription initiating complex. However, the 
RUNX1/CBFβ  complex  is  regarded  as  a  relatively  inefficient  transcriptional 
activator and requires synergistic cooperation with other transcription factors. In 
this regard RUNX1 binding sites are frequently adjacent to binding sites of of 
Myb, Ets, AP 1 and C/EBP factors and RUNX1 cooperates with these transcription 
factors  to  activate  transcription  (Frank  et  al  1995;  Hernandez Munain  and Kamil K. Wolyniec, 2008     Chapter 1,22  
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Krangel 1994; Mao et al 1999; Petrovick et al 1998; Sun et al 1995; Zhang et al 
1996).  
 
 
 
 
 
 
 
 
Figure 1.4 RUNX1 as an organizer of trancriptional activation 
RUNX1 CBFβ  complex  binds  to  the  consensus  sequence  and  interacts  with 
coactivators  (p300,  C/EBP,  ETS,  MYB,  ALY,  AP 1)  to  initiate  transcriptional 
activation  
1.3.2 Transcriptional repression 
Paradoxically, RUNX1 can also be a context dependent transcriptional repressor, 
although  this  function  of  RUNX1  remains  largely  enigmatic.  The  CD4  gene  is 
probably  the  best  characterised  example  of  RUNX1  mediated  transcriptional 
repression  that  occurs  during  T  lymphocyte  development.  RUNX1  binds  the 
silencer and represses CD4 transcription in immature thymocytes (Taniuchi et al 
2002). The other mechanism has been recently proposed whereby RUNX1 binds 
positive transcription elongation factor b (P TEFb) and represses transcriptional 
elongation  by  RNA  polymerase  II  (Jiang  et  al  2005).  Another  example  is  the 
transcriptional repression of p21
WAF1 promoter in NIH3T3 and HEL cells (human 
erythroleukaemic  cell  line)  (Lutterbach  et  al  2000).  Interestingly,  RUNX1 
mediated repression of p21
WAF1 in these cells was independent of the Groucho 
interaction motif but required two C terminal domains of RUNX1 (amino acids 
208 237 and amino acids 290 387). One of these domains (amino acids 208 237) 
is adjacent to the runt domain and is required for interaction with the mSin3A 
and  mSin3B  corepressor  proteins.  However,  the  association  with  mSin3  was 
shown to be necessary but not sufficient for potent repression, since the other 
mutant (amino acids 290 387) that is still able to bind mSin3, was not found to 
be an efficient repressor (Lutterbach et al 2000). It is plausible that there could Kamil K. Wolyniec, 2008     Chapter 1,23  
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be several different mechanisms of gene repression by RUNX1. In general, it has 
been  proposed  that  the  repressive  property  of  RUNX1  is  attributed  to  the 
recruitment  of  transcriptional  corepressors  such  as  histone  deacetylases 
(HDACs), transducing like enhancer of split (TLE), nuclear receptor corepressor 
(nCoR), mSin3 and SUV39H1 (Figure 1.5) (Aronson et al 1997; Chakraborty et al 
2003;  Durst  and  Hiebert  2004;  Lutterbach  et  al  2000;  Reed Inderbitzin  et  al 
2006).  
 
 
   
 
 
 
 
 
Figure 1.5 RUNX1 as an organizer of transcriptional repression 
RUNX1 CBFβ  complex  binds  to  the  consensus  sequence  and  interacts  with 
corepressors  (HDACs,  nCoR,  mSin3,  SUV39H1,  TLE)  to  initiate  transcriptional 
repression  
 
If  RUNX1  is  capable  of  both  transcription  repression  and  activation  it  is  of 
particular interest to understand the mechanism that converts RUNX1 from an 
activator to a repressor of transcription. Although an extensive survey in various 
cell types has not as yet been reported there is some evidence that repression 
by RUNX1 could be cell type and tissue specific. It has been shown that although 
RUNX1 represses p21
WAF1 in NIH3T3 cells and HEL human erythroleukaemia cells 
it actually activates its promoter in K562 human myeloid cell line (Lutterbach et 
al  2000).  It  seems  that  the  factors  determining  the  outcome  of  transcription 
(repression  or  transactivation)  of  a  target  gene  involve  promoter specific 
features such as the proximity of binding sites for co activators or co repressors 
as  well  as  availability  of  such  cofactors  in  the  nucleus.  In  addition, 
postranslational modifications such as phosphorylation (Tanaka et al 1996) or 
acetylation (Yamaguchi et al 2004) may contribute to the regulation of RUNX1 
activity. The proposed model hypothesizes that binding of RUNX1 to activating 
factors such as p300 promotes expression whereas loss of p300 interaction and Kamil K. Wolyniec, 2008     Chapter 1,24  
subsequent  binding  to  mSin3  proteins  or  Groucho  family  members  leads  to 
repression. 
1.4 Role of RUNX1 in haematopoiesis 
1.4.1 Foetal haematopoiesis 
It was suggested that RUNX1 may be a master regulator of haematopoiesis when 
it  became  clear  that  there  is  a  large  number  of  chromosomal  translocations 
targeting  RUNX1  that  are  associated  with  leukaemias  (Blyth  et  al  2005). 
However, the evidence supporting the crucial role of RUNX1 in developmental 
haematopoiesis came from the analysis of the phenotype of RUNX1 null mice. 
These  animals  are  chararacterized  by  normal  morphogenesis  and  yolk sac 
derived  primitive  erythropoesis,  however  they  lack  definitive  haematopoietic 
progenitors in the yolk sac and foetal liver (Okuda et al 1996; Wang et al 1996a). 
Foetal liver cells from RUNX1 null embryo are unable to differentiate into any of 
haematopoietic lineages although this is not due to a defect in the foetal liver 
microenvironment (Okuda et al 1996; Wang et al 1996a). RUNX1 is also essential 
for the generation of functional haematopoietic stem cells (HSCs) and immature 
progenitors (Cai et al 2000). RUNX1 deficient mice die due to haemorrhaging 
(Okuda  et  al  1996;  Wang  et  al  1996a).  The  dosage  of  RUNX1  during  foetal 
haematopoiesis is critical. RUNX1 heterozygous embryos show earlier appearance 
of HSCs in the yolk sac on embryonic day 10 and a premature extinction of HSC 
in the aorta gonad mesonephros (AGM) (Cai et al 2000) while RUNX1
+/  animals 
have reduced numbers of myeloid and erythroid progenitors (Wang et al 1996a). 
Interestingly  RUNX1
 /   and  CBFβ
 /   embryos  have  significantly  overlapping 
phenotypes  implying  that  the  physiological  effects  of  these  two  proteins  are 
executed by RUNX1/CBFβ complexes, however other independent roles cannot 
be ruled out (Niki et al 1997; Sasaki et al 1996; Wang et al 1996b). 
1.4.2 Adult haematopoiesis 
The role of RUNX1 in adult haematopoiesis has been assessed in inducible gene 
targeting  systems  (conditional  KO  model,  by  f=floxed/Cre  method)  in  the 
progeny  of  RUNX1
f/   mice  crossed  to  Mx Cre  transgenic  mice  (Ichikawa  et  al 
2004).  Examination  of  bone  marrow  in  adult  animals  revealed  that  Kamil K. Wolyniec, 2008     Chapter 1,25  
haematopoietic progenitors remained intact in contrast with dramatic effects in 
the  fetus.  Moreover,  RUNX1  deletion  provides  a  proliferative  adavantage  to 
haematopoietic progenitors, as evidenced by an increased Lin
 c Kit
+Sca1
+CD34
  
population in bone marrow and increased colony formation in vitro (Ichikawa et 
al  2004).  However,  RUNX1  has  been  implicated  in  adult  megakaryocytic 
maturation  and  T lymphocyte  and  B lymphocyte  differentiation.  An  analogous 
approach  involving  thymocyte specific  deletion  of  the  RUNX1  gene  has  been 
undertaken  to  investigate  the  effects  of  RUNX1  in  T cell  development.  The 
progeny of RUNX1
fl/fl mice crossed with Lck Cre showed incomplete suppression 
of CD4 molecule in CD4
 CD8
  double negative (DN) thymocytes, and incomplete 
up regulation  of  CD8  molecule  in  CD4
+CD8
+  double  positive  (DP)  thymocytes 
(Taniuchi et al 2002). This represents a further case whereby RUNX1 is engaged 
in both gene activation (CD8) and gene repression (CD4). It was also shown in  
other studies that a hemizygous level of RUNX1 allows inefficient transition from 
DP thymocytes to more mature CD4
+CD8
  or CD4
 CD8
+ single positive thymocytes 
(SP)  (Hayashi  et  al  2000).  Conversely,  in  RUNX1  over expressing  mice,  an 
increase in the population of CD4
 CD8
+ thymocytes was observed (Hayashi et al 
2001). 
1.5 RUNX1 and leukaemia 
1.5.1 Loss-of-function 
The  first  implication  that  RUNX1  loss  of  function  may  play  important  role  in 
leukaemogenesis was provided by the discovery that RUNX1 is involved in two 
common chromosomal translocations t(8;21) in acute myeloid leukaemia (AML) 
(Erickson  et  al  1992;  Miyoshi  et  al  1991;  Nisson  et  al  1992)  and  t(12;21)  in 
pediatric B cell precursor acute lymphoblastic leukaemia (B ALL) (Golub et al 
1995; Romana et al 1995). RUNX1 chimeric proteins arising from translocations 
have been reported to have dominant negative activity with respect to the wild 
type gene product. Both RUNX1 ETO and TEL RUNX1 have been demonstrated to 
recruit  corepressors  and  actively  repress  transcription  of  RUNX1  target  genes 
(Frank et al 1995; Gelmetti et al 1998; Hiebert et al 1996; Meyers et al 1995; 
Uchida  et  al  1999).  Further  evidence  for  antagonistic  function  of  the  fusion 
proteins  was  provided  by  the  phenotype  of  RUNX1 ETO  knock in  mice  which Kamil K. Wolyniec, 2008     Chapter 1,26  
resembled RUNX1 knockouts (Okuda et al 1998; Yergeau et al 1997). Finally, in a 
retrospective study, sporadic point muations of RUNX1 were frequently found in 
myeloblastic leukaemia patients (Osato et al 1999) and subsequent studies found 
a high incidence of point mutations in the Runt domain of RUNX1 in three types 
of  leukaemia:  AML  M0  subtype,  MDS AML,  and  secondary  therapy  related 
MDS/AML.  Interestingly  AML  M0  mutations  were  predominantly  biallelic 
suggesting selection for loss of function (Osato 2004; Preudhomme et al 2000). 
Moreover,  monoallelic  mutations  underlie  the  hereditary  condition  familial 
platelet disorder (FPD), which predisposes to AML (Osato 2004; Song et al 1999). 
Despite  the  fact  that  loss  of  a  second  allele  has  not  been  observed  in  AML 
derived from FPD families so far, transdominant inhibition of the normal product 
could be considered as an alternative explanation. These observations highlight 
at least to some extent the concept of RUNX1 as a tumour suppressor where 
lower  RUNX1  activity  appears  to  correlate  with  a  higher  risk  of  developing 
leukaemia. Therefore, loss of function of RUNX1 is considered to be a common 
underlying mechanism for RUNX1 related leukaemias. However, a growing body 
of  evidence  suggests  that  RUNX1  alteration  per  se  does  not  readily  drive 
leukaemia and that additional genetic changes, ‘second hits’ are required for 
full blown  malignancy.  Activation  of  the  RAS  pathway  is  one  of  the  most 
common  cooperating  lesions  in  RUNX1  associated  leukaemias.  The  RAS  gene 
family and its upstream receptor tyrosine  kinases such as c Kit and FLT3  are 
frequently  mutated  in  these  types  of  leukaemias  (Christiansen  et  al  2005; 
Goemans  et  al  2005;  Speck  and  Gilliland  2002;  Yamashita  et  al  2005). 
Interestingly,  it  has  been  recently  shown  that  RUNX1  insufficiency  in 
hematopoetic  stem  cells  suppresses  oncogenic  N RAS induced  effects  such  as 
apoptosis,  senescence  and  differentiation  (Motoda  et  al  2007).  Therefore  it 
seems  that  in  this  context  RUNX1  is  a  part  of  a  fail safe  mechanism  that 
constrains neoplastic transformation. 
1.5.2 Gain-of-function 
On the other hand, strong evidence supporting the notion that RUNX1 act as a 
dominant  oncogene  came  from  in  vivo  mouse  model  insertional  mutagenesis 
studies. RUNX1 together with other members of the family was identified as a 
common  integration  side  in  Mo MuLV  accelerated  tumours  in  the  CD2 MYC Kamil K. Wolyniec, 2008     Chapter 1,27  
transgenic model of lymphoma susceptible mice. This viral integration resulted 
in overexpression of intact RUNX genes (Blyth et al 2001; Stewart et al 1996; 
Stewart et al 1997; Stewart et al 2002; Wotton et al 2002). In addition, more 
than a decade ago it was reported that ectopic expression of RUNX1 P2 in 3T3 
fibroblasts promotes transformation (Kurokawa et al 1996). Surprisingly, similar 
subsequent  studies  where  RUNX1  P1  was  used  instead  did  not  confirm  this 
observation (Frank et  al 1999). Recently,  however,  it has been shown  in our 
laboratory that in p53 null MEFs, RUNX1 P1 has apparent pro oncogenic effect on 
cells,  including  cytoskeletal  reorganisation,  reduced  contact  inhibition  at 
confluence  and  accelerated  tumour  expansion  in  vivo  (Wotton  et  al  2004). 
Moreover, the RUNX1 locus is also involved in genetic amplification in a number 
of  cases  in  B ALL  and  there  are  some  speculations  that  increased  dosage  of 
RUNX1 in Down’s syndrome patients predisposes them to acute megakaryocytic 
leukaemia (AMKL) (Osato and Ito 2005; Speck and Gilliland 2002). 
1.6 Chromosomal translocations that involve CBF 
CBFs  are  common  target  of  gene  rearrangements  that  are  linked  to  human 
leukaemias.  More  than  30  different  chromosomal  translocations  have  been 
described that involve either RUNX1 or CBFβ. Of these the most common are 
t(8;21),  inv(16)  and  t(12;  21).  These  translocations  generate  chimeric  fusion 
oncoproteins that share common repressive functions with respect to wild type 
RUNX1 (Figure 1.6) (Blyth et al 2005). 
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Figure  1.6  Schematic  representation  of  three  major  fusion  oncoproteins 
arising from chromosomal rearrangements targeting CBF and RUNX1 
1.6.1 RUNX1-ETO in t(8; 21) 
The t(8;21) translocation was the first to be discovered and is the most frequent 
translocation found in AML, accounting for 10 20% cases (Miyoshi et al 1991). The 
RUNX1 ETO chimeric protein (752 amino acids) is produced by the fusion of the 
N terminal portion of the RUNX1 protein, including the Runt domain, with the 
heterologous partner protein, ETO (also known as MTG8 or CBFA2T1) that lacks 
the  first  30  amino  acid  residues.  ETO  is  an  ubiquitously  expressed  nuclear 
protein  engaged  in  transcriptional  repression  through  interaction  with 
corepressors such as the N CoR complex, mSin3A and HDACs (Lutterbach et al 
1998). Two molecular characteristics of the RUNX1 ETO fusion protein provide 
clues to its leukaemogenic potential. First, RUNX1 ETO retains the DNA binding 
Runt domain and heterodimerises with CBFβ and therefore binds to specific DNA 
sequences  with  high  affinity.  In  fact,  heterodimerisation  with  CBFβ  is  more 
stable with RUNX1 ETO than with wild type RUNX1 (Tanaka et al 1998). Second, 
the adjacent ETO partner efficiently recruits multiple transcriptional repressor 
complexes (Gelmetti et al 1998). The resulting strong DNA binding constitutive Kamil K. Wolyniec, 2008     Chapter 1,29  
repressor molecule can cause perturbations in gene expression which may trigger 
the transformation of haematopoietic cells. For instance, RUNX1 ETO represses 
such  critical  transcription  factors  as  PU.1,  C/EBPα,  NF 1  (Burel  et  al  2001; 
Vangala et al 2003; Westendorf et al 1998; Yang et al 2005). Interestingly, in 
some cases RUNX1 ETO has been reported to enhance the expression of genes 
such as C/EBPε, c Jun or anti apoptotic Bcl 2 (Elsasser et al 2003; Klampfer et al 
1996; Shimizu et al 2000). The ability of RUNX1 ETO to affect normal RUNX1 
function was first shown in transient transfection assays, which demonstrated 
that  RUNX1 ETO  can  function  as  a  dominant  negative  regulator  of  RUNX1 
mediated  transcriptional  activation  (Frank  et  al  1995;  Meyers  et  al  1995). 
Consistent  with  a  negative  effect  on  RUNX1  function,  RUNX1 ETO  has  been 
shown to block the differentiation of myeloid progenitor cell lines and the ability 
of  RUNX1  to  activate  myeloid  specific  promoters  (Kitabayashi  et  al  1998; 
Westendorf et al 1998). Evidence for in vivo dominant negative activity of the 
fusion protein was provided by RUNX1 ETO knock in experiments, which showed 
that mice heterozygous for RUNX1 ETO had a similar phenotype as RUNX1 knock 
out mice (Okuda et al 1998; Yergeau et al 1997). Further attempts to express 
the  fusion  gene  in  adult  mice  using  a  tetracycline inducible  system,  a 
conditional  RUNX1 ETO  knock  in  system,  or  a  myeloid specific  promoter,  all 
failed to induce spontaneous leukaemia (Higuchi et al 2002; Rhoades et al 2000; 
Yuan  et  al  2001),  although  RUNX1 ETO  expression  consistently  enhanced  the 
proliferation  of  HSCs  and  increased  progenitor  cell  self renewal  capacity.  In 
another  study  where  stem  cells  were  transduced  with  RUNX1 ETO  and 
transplanted  into  lethally  irradiated  recipient  animals,  the  stem  cell 
compartment expanded dramatically (de Guzman et al 2002). Similarly direct 
targeting of RUNX1 ETO expression to stem cells by using the SCA 1 promoter 
enhanced myeloid progenitor expansion (Fenske et al 2004). These experiments 
suggest that AML ETO can promote the expansion of a susceptible compartment 
that ultimately would acquire additional ‘hits’ leading to disease. Therefore it 
has  become  obvious  that  the  RUNX1 ETO  fusion  protein  does  not  cause 
leukaemia  alone  and  requires  additional  cooperating  events  to  induce 
leukaemogenesis in mice. RUNX1 ETO was analysed in the context of cooperating 
mutations in animals expressing RUNX1 ETO which were mutagenised with the 
alkylating agent N ethyl N nitrosourea (ENU). In two independent systems, these Kamil K. Wolyniec, 2008     Chapter 1,30  
mice developed myeloid leukaemia at frequencies greater than ENU treated WT 
mice (Yuan et al 2001; Higuchi et al 2002). In addition, retroviral transduction 
and haematopoietic cell transplantation experiments with p21
WAF1 deficient cells 
showed that RUNX1 ETO is able to promote leukaemogenesis in the absence of 
p21
WAF1  (Peterson  et  al  2007).  Moreover,  retroviral  expression  of  a  truncated 
form of RUNX1 ETO with a deleted C terminal NcoR/SMRT interacting region in 
bone marrow cells resulted in rapid onset of leukaemia in transplant recipient 
mice  (Yan  et  al  2004)  RUNX1 ETO  was  also  shown  to  transform  NIH3T3  cells 
through activation of AP 1 (Frank et al 1999). Paradoxically, RUNX1 ETO has an 
inhibitory effect on cell proliferation (Burel et al 2001) and overexpression of 
RUNX1 ETO reduces  expression of target genes,  including cyclin D3 and CDK4 
(Bernardin Fried  et  al  2004;  Burel  et  al  2001;  Lou  et  al  2000).  The  cellular 
consequence  is  impairment  in  the  transition  from  G1  to  S  phase  and  slower 
proliferation. Therefore, the requirement for cooperating lesions that interfere 
with this block is not surprising. 
1.6.2 TEL-RUNX1 in t(12; 21) 
TEL RUNX1  is  generated  by  the  t(12;  21)  chromosomal  translocation,  which 
occurs  in  approximately  25%  of  cases  of  childhood  common  B cell  precursor 
acute  lymphoblastic  leukaemia  (Golub  et  al  1995).  In  the  TEL RUNX1  fusion 
protein  (794  amino  acids),  the  N terminus  of  TEL  (336  residues)  is  fused  to 
nearly all of the RUNX1 protein, including the Runt domain and the entire C 
terminal  portion.  TEL  (also  ETV6)  is  a  member  of  Ets  family  of  transcription 
factors that have the Ets DNA binding domain at the C terminus and a protein 
binding helix loop helix (HLH) domain at the N terminus. The Runt domain of 
TEL RUNX1 can form a heterodimer with CBFβ and specifically bind to target 
sequences but despite having the entire C terminal region of RUNX1, this fusion 
protein generally represses the reporter activities and antagonises RUNX1 driven 
transactivation (Fears et al 1997; Hiebert et al 1996; Meyers et al 1993). This 
repressor property is attributed to the recruitment of HDACs and N CoR by the 
TEL moiety and the recruitment of mSin3a by both TEL and RUNX1 (Fenrick et al 
1999;  Guidez  et  al  2000).  The  RUNX1  moiety  is  capable  of  recruiting 
transcriptional coactivators as well as repressors, however the generation of the 
fusion protein seems to increase the overall affinity towards corepressors and Kamil K. Wolyniec, 2008     Chapter 1,31  
subsequent  constitutive  repressor  complex  stability  (Guidez  et  al  2000).  TEL 
RUNX1 may also suppress not only the normal function of RUNX1 but also TEL 
through  HLH mediated  heterodimerisation  (Gunji  et  al  2004).  Wild type  TEL 
function is known to be essential for establishing  haematopoiesis in the bone 
marrow (Wang et al 1998), therefore its disruption by the chimeric protein may 
also  contribute  to  leukaemogenesis.  The  role  of  TEL RUNX1  in  inducing 
leukaemia has been assessed in mice. TEL RUNX1 expressed under the control of 
immunoglobulin  heavy  chain  enhancer/promoter  did  not  cause  leukaemia  in 
mice (Andreasson et al 2001). However, retroviral delivery of TEL RUNX1 into 
bone marrow strongly collaborated with deficiency in p16
INK4a as well as p19
ARF in 
promoting  leukaemogenic  transformation  (Bernardin  et  al  2002b).  A  detailed 
analysis using similar experimental system showed that TEL RUNX1 inhibits B cell 
differentiation,  leading  to  an  accumulation  of  early  B cell  progenitors  and  a 
corresponding deficit of mature B cells (Morrow et al 2004; Tsuzuki et al 2004). 
1.6.3 CBFβ-MYH11 in Inv(16) 
The Inv(16) does not involve the RUNX1 locus directly but instead creates the 
CBFβ MYH11  (smooth  muscle  myosin  heavy  chain)  fusion  protein  that  also 
inhibits RUNX1 dependent transactivation (Kanno et al 1998b; Lutterbach et al 
1999).  Inv(16)  is  a  common  chromosomal  inversion  event  in  myelomonocytic 
leukaemias (M4Eo). A model that has been proposed as an explanation of the 
mechanism of repression assumes that CBFβ MYH11 binds to its RUNX1 α chain 
partner with increased affinity, and might directly suppress or sequester RUNX1 
in the cytoplasm (Adya et al 1998; Kanno et al 1998b; Lutterbach et al 1999). 
Thus CBFβ MYH11 would be predicted to interfere with RUNX1 transcriptional 
activity. However, CBFβ MYH11 cooperated with RUNX1 to repress the p21
WAF1 
promoter,  suggesting  that  it  is  present  and  functional  in  the  nucleus.  A 
repression domain in the MYH11 fragment of fusion was identified and CBFβ 
MYH11 was found to interact with mSin3, but only when RUNX1 was coexpressed, 
indicating  that  RUNX1  is  bridging  the  interaction  between  CBFβ MYH11  and 
mSin3  protein  (Lutterbach  et  al  1999).  Furthermore,  a  strong  argument  for 
dominant negative function of CBFβ MYH11 was obtained from the analysis of 
the phenotype of Inv(16) knock in mice, which recapitulates RUNX1 and CBFβ 
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Inv(16)  animal  model  in  which  to  test  the  mechanism  of  pro leukaemogenic 
action of CBFβ MYH11 has been extremely difficult. Previous murine models of 
the Inv(16) have involved the expression of CBFβ MYH11 coupled with ENU (N 
ethyl N nitrosourea) mutagenesis, retroviral insertional mutagenesis (Castilla et 
al 1999; Castilla et al 2004), the removal of two tumour suppressors (Yang et al 
2002)  or  the  coexpression  of  oncogenes  (Bernardin  et  al  2002a;  Kogan  et  al 
1998). However, only the use of chimeric mice carrying a knock in Inv(16) allele 
plus  random  mutagenesis  yielded  an  AML  that  mimicked  the  human  disease 
(Castilla et al 1999, Castilla et al 2004). In a recent study it has been reported 
that Inv(16) cooperates with p19
ARF haploinsufficiency to induce AML (Moreno 
Miralles et al 2005). 
1.7 Cellular  senescence  and  its  impact  on  aging  and 
cancer 
At one time it was believed that cells could proliferate indefinitely and 
that the maintenance of a cell culture was just a question of finding the right 
conditions.  This  idea  was  radically  changed  more  than  40  years  ago  by  the 
outstanding work of Hayflick (Hayflick 1965) which demonstrated that for most 
normal cells proliferation has an end, despite optimal culturing conditions. When 
mammalian cells are isolated from tissue and cultured, they undergo a limited 
number of population doublings and then arrest (having reached the ‘Hayflick 
limit’).  The  process  underlying  this  observation  is  known  as  replicative 
senescence. The discovery of senescence led to two important hypotheses that 
were proposed to explain its physiological relevance. The first was related to the 
fact that cancer cells are immortalised and therefore proliferate indefinitely in 
culture. Hence, cellular senescence was suggested to be a tumour suppressive 
mechanism.  The  second  hypothesis  originated  from  the  fact  that  tissue 
regenerative capacity diminishes with age. In this context, cellular senescence 
was proposed to mimic aging at a single cell level (Campisi 2005). Four decades 
of subsequent intensive  research have  unravelled the primary mechanisms by 
which  cellular  senescence  occurs  and  have  shed  light  on  central  aspects  of 
organismal aging and cancer (Campisi 2005). Furthermore, it is now evident that 
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programme that can be triggered by various stimuli. Finally, it is clear that there 
are marked differences among species in the propensity of cells to spontaneously 
escape senescence and acquire an immortal replicative lifespan. In this regard 
rodent cells are much more prone to spontaneous immortalization than human 
cells (Itahana et al 2004; Sherr and DePinho 2000). 
 
1.8 The signals initiating cellular senescence 
Senescence inducing  signals  can  originate  from  telomeric  (intrinsic)  or  non 
telomeric  (extrinsic)  sources  (Figure  1.7)  (Itahana  et  al  2004).  Senescence 
mediated  by  non telomeric  signals  is  termed  “premature  senescence”, 
“accelerated senescence” or “extrinsic senescence”.  Another term: stress  or 
aberrant signalling senescence (STASIS) has been suggested to convey the notion 
that cells engage a common senescence like arrest mechanism in response to 
diverse  stimuli  (Drayton  and  Peters  2002).  Both  telomere based  and  non 
telomere based growth arrest may be due in part to repression of genes required 
for  cell  cycle  progression  and  upregulation  of  growth  inhibitory  genes.  The 
existence of non telomere induced senescence was anticipated by the behaviour 
of primary murine cells in culture. Normal mouse cells, like normal human cells, 
have  a  finite  replicative  potential.  However,  their  replicative  lifespan  is 
substantially  shorter  than  that  of  human  cells  (10 15  population  doublings 
compared to 50 70) despite murine fibroblasts having very long telomeres (~60kb 
versus ~12kb) and in some cases expressing telomerase (Itahana et al 2004; Sherr 
and  DePinho  2000).  Thus,  it  is  unlikely  that  the  replicative  senescence  of 
primary mouse fibroblasts is due to telomere shortening. It has been proposed 
that  the  senescence  phenomenon  in    primary  mouse  cells  is  due  to  a  stress 
response to culture conditions (Sherr and DePinho 2000) which can be abrogated 
by decreasing the oxygen concentration used in culturing these cells (Parrinello 
et  al  2003).  These  observations  have  led  to  the  hypothesis  that  rodent  cells 
repair DNA damage much less efficiently than human cells and are thus much 
more sensitive to a variety of agents or conditions that produce oxidative stress 
(Parinello et al 2003). It is now apparent that a diverse spectrum of stress signals 
can elicit a senescence response. Of most importance are certain types of DNA 
damage, including DNA breaks and oxidative lesions (Chen et al 1995; Robles and Kamil K. Wolyniec, 2008     Chapter 1,34  
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Adami 1998). It seems that cells may senesce when the damage is irreparable or 
is likely to impair the DNA repair machinery. Interestingly, many normal cells 
undergo senescence when they overexpress certain oncoproteins. The activated 
components of RAS RAF MEK signalling cascade (Lin et al 1998; Serrano et al 
1997; Zhu et al 1998) were the first oncogenic inducers of premature senescence 
to be identified. A common feature of these non telomeric inducers of cellular 
senescence is their potential to cause or facilitate tumourigenic transformation. 
It is not surprising, then, that overexpression of certain tumour suppressor genes 
also  causes  normal  cells  to  undergo  rapid  premature  senescence.  Tumour 
suppressors  that  strongly  induce  this  phenotype  include  p16
INK4a  cyclin 
dependent kinase inhibitor (CDKI), p21
WAF1, p27 (McConnell et al 1998), p14
ARF 
(Dimri et al 2000) and PML (Ferbeyre et al 2000). Moreover, cells can senesce in 
response  to  epigenetic  changes  to  chromatin  organisation,  for  example  those 
caused by pharmacological agents or altered expression of proteins that modify 
DNA  or  histones  (i.e.  histone  deacetylase  inhibitors)  (Neumeister  et  al  2002; 
Ogryzko et al 1996). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7 Cellular senescence is triggered by wide spectrum of stimuli 
Telomere  shortening  as  well  as  non telomeric  signals  such  as  DNA  damaging 
agents,  oncogenic  signalling,  oxidative  stress,  overexpression  of  tumour 
suppressors, cytokines, HDAC and DNMT inhibitors, and undefined stress signals 
(‘culture shock’) induce senescence Kamil K. Wolyniec, 2008     Chapter 1,35  
1.8.1 Telomere attrition 
Telomere  shortening  is  a  universal  mechanism  that  limits  the  proliferative 
potential of normal cells (lacking endogenous telomerase) following extensive 
cell  divisions.  The  role  of  telomere  exhaustion  in  the  suppression  of 
tumourigenesis in vivo by initiating cellular senescence has been demonstrated 
recently (Cosme Blanco et al 2007; Feldser and Greider 2007). It is believed that 
telomere  erosion  beyond  a  certain  limit  triggers  a  DNA  damage  response, 
thereby activating a checkpoint, resulting in growth arrest. Recent investigations 
provide some evidence that signals induced by the telomere dysfunction appear 
to be similar to those induced by double strand DNA breaks and that inactivation 
of the checkpoint kinases (CHK) can reinstate S phase progression in senescent 
cells (Gire et al 2004; d'Adda di Fagagna et al 2003). Other studies suggested 
that  telomere  shortening induced  senescence  is  a  DNA  damage  response 
mediated by the ATM/ATR p53 p21 pathway (Herbig et al 2004). Cells that fail to 
senesce  and  continue  to  proliferate  despite  dysfunctional  telomeres  develop 
chromosomal aberrations, which can result in malignant transformation (Artandi 
and DePinho 2000). 
1.8.2 DNA damage 
If  cellular  senescence  induced  by  attrition  of  telomeres  is  a  DNA  damage 
response, then the DNA damaging agents should also be able to provoke cellular 
senescence. In fact this seems to be the case since DNA damaging agents that 
influence the integrity of the genome can trigger senescence. The direct DNA 
damaging of DNA caused by sublethal doses of irradiation or by treatment with 
chemotherapeutic  drugs  (like  etoposide  or  cyclophosphamide)  can  induce 
senescence. Interestingly, such agents induce senescence in normal cells as well 
as in some tumour cells, both in culture and in vivo (Di Leonardo et al 1994; 
Roninson 2003; Schmitt et al 2002; Shay and Roninson 2004; Te Poele et al 2002; 
Wahl and Carr 2001). Such damage can either cause cell death or reversible cell 
cycle arrest, depending on the type of agent or the dose administered, and the 
type of cell treated (Wahl and Carr 2001). Disruption of DNA repair genes such as 
Brca1,  Xrcc4,  DNA  ligase  IV  and  others  in  mice  induces  the  premature 
senescence of MEFs cultured  from these animals and  symptoms of premature 
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2003). Many of these senescent phenotypes can be rescued by p53 inactivation 
indicating a pivotal role for p53 in DNA damage induced senescence (Frank et al 
2000; Gao et al 2000; Ongusaha et al 2003). Moreover, cancer cells that retain 
intact  p53  are  much  more  susceptible  to  senescence  in  response  to 
chemotherapy at least in cell culture and mouse models (Roberson et al 2005; 
Roninson  2003;  Schmitt  et  al  2002;  Shay  and  Roninson  2004;  Te  Poele  et  al 
2002). 
1.8.3 Oxidative stress 
Oxidative stress and the accumulation of intracellular reactive oxygen species 
(ROS)  play  crucial  roles  in  the  induction  of  senescence.  Human  fibroblasts 
undergo premature senescence when grown in high ambient oxygen conditions, 
but their proliferative lifespan can be substantially extended when cultured in 
low ambient oxygen (2 3%) which more closely resembles physiological oxygen 
levels (Chen et al 1995). The senescence of MEFs has also been linked oxidative 
stress  in  culture.  When  these  cells  are  grown  in  3%  oxygen  instead  of  20%, 
senescence is greatly delayed or prevented altogether (Parrinello et al 2003). 
Moreover, MEFs that are propagated in 20% oxygen suffer from a high level of 
DNA damage that is much more apparent than in human cells grown in the same 
conditions (Busuttil et al 2003; Parrinello et al 2003). This indicates that human 
cells  cope  with  the  oxidative  stress  much  more  efficiently  than  murine  cells 
either  due  to  ability  to  neutralize  ROS  or  to  detect  and  repair  DNA  lesions. 
Increase  of  intracellular  ROS  levels  through  hydrogen  peroxide  treatment  or 
through the inhibition of ROS  scavenging enzymes (e.g. superoxide dismutase 
Sod1)  causes  premature  senescence  (Blander  et  al  2003;  Chen  et  al  1998). 
Internal ROS can not only damage cellular components through the oxidation of 
DNA, proteins and lipids but can also act as second messengers in specific signal 
transduction pathways (Halliwell 2007). There is some evidence that oxidative 
stress induced senescence, like telomere dysfunction operates through the p53 
p21 Rb axis. This idea is supported by the observation that a reduced ambient 
oxygen  level  reduces  the  proportion  of  pre senescent  p21 expressing  cells 
without any effect on p16 expressing cells (Itahana et al 2003). However, other 
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of p38 MAPK, a member of the stress activated protein kinase family (Iwasa et al 
2003). 
1.8.4 Oncogene activation 
Proto oncogenes  are  genes  that  have  the  potential  to  transform  cells  when 
mutated  or  overexpressed  usually  in  cooperation  with  other  accompanying 
mutations.  The  expression  of  oncogenes  in  primary  cells  triggers  defence 
responses that prevent their uncontrolled proliferation. Some oncogenes such as 
c Myc or adenovirus E1A induce apoptosis whereas others such as activated Ras 
(H Ras
V12)  trigger  a  permanent  arrest  that  is  reminiscent  of  replicative 
senescence  (de  Stanchina  et  al  1998;  Serrano  et  al  1997;  Zindy  et  al  1998). 
Prototypical Ras driven senescence has been extensively studied over the last 
decade in various human and mouse cell systems and has been shown to occur in 
epithelial cells of human and mouse origin as well as fibroblasts (Jones et al 
2000;  Lin  and  Lowe  2001;  Serrano  et  al  1997).  These  studies  have  yielded  a 
wealth of information about the molecular pathways relevant to oncogenesis. 
The  tumour  suppressor  p16INK4a  which  inactivates  D type  cyclins  and  p19
ARF 
(p19
ARF(mouse) = p14
ARF(human)) which activates p53  together with general cell 
cycle regulators pRb, p107 and p130, play  key roles in Ras induced senescence 
(Dannenberg et al 2000; Jones et al 2000; Lin et al 1998; Palmero et al 1998; 
Sage et al 2000; Serrano et al 1997). In mouse cells, induction of senescence by 
RAS occurs through the p19
ARF p53 pathway. Targeted mutations that exclusively 
disrupt p16
INK4a but not p19
ARF have revealed that p16
INK4a is a less potent tumour 
suppressor  in  the  mouse  and  that  p16
INK4a  null  MEFs  are  susceptible  to  Ras 
induced senescence whereas p19
ARF null cells are not (Krimpenfort et al 2001; 
Sharpless et al 2001). In contrast to MEFs, in human fibroblasts p16
INK4a seems to 
have a more prominent role than p14
ARF. It has been reported that Ras mediated 
senescence in human diploid fibroblasts occurs independently of p14
ARF (Wei et 
al 2001) and human fibroblasts with biallelic mutation in p16
INK4a (Leiden cells) 
are resistant to RAS induced senescence (Brookes et al 2002). Other members of 
the RAS signalling pathway (for example, RAF, MEK, MOS and BRAF) as well as 
other  oncoproteins  such  as  nuclear  protein  E2F  or  tyrosine  kinase  receptor 
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various pathways (Bartkova et al 2006; Dimri et al 2000; Lazzerini et al 2005; Lin 
et al 1998; Michaloglou et al 2005; Trost et al 2005; Zhu et al 1998). 
1.8.5 Other inducers of cellular senescence 
There are also other less well understood cellular senescence initiating signals. 
Chemical  histone  deacetylase  inhibition,  which  involves  decondensation  of 
chromatin  and  formation  of  euchromatin  was  found  to  induce  senescence  in 
primary fibroblasts of murine and human origin (Munro et al 2004; Ogryzko et al 
1996). Interestingly, whereas in human cells the p16
INK4a pRb pathway is critical 
for this response, in murine cells p53 pathway is more important (Munro et al 
2004).  Inhibition  of  DNA  methyl  transferase  (DNMT)  with  5 azacytidine  also 
results  in  senescence like  growth  arrest  (Weller  et  al  1993).  Intriguingly, 
prolonged signalling by the anti proliferative cytokine, interferon β can induce 
ROS  accumulation,  DNA  damage  response  and  p53 dependent  senescence 
(Moiseeva  et  al  2006).  Likewise,  chronic  signalling  by  TGF β  promotes 
senescence in normal and cancer cells (Katakura et al 1999; Vijayachandra et al 
2003; Zhang and Cohen 2004). Finally, a phenomenon known as ‘culture shock’ 
can  induce  senescence  by  a  p16 dependent  but  telomere independent  route. 
Human keratinocytes and mammary epithelial cells spontaneously express p16 
and enter premature senescence with long telomeres  under standard  in vitro 
culture  conditions.  These  effects  can  be  reversed  by  culturing  cells  on 
fibroblastic  feeder  layers  suggesting  that  inadequate  growth  conditions  also 
causes senescence and supporting the notion that senescence is a cellular stress 
response programme (Ramirez et al 2001). 
1.9 Characteristics of senescent cells 
Cellular  senescence,  originally  defined  as  proliferative  arrest  that  occurs  in 
normal  cells  after  a  limited  number  of  cell  divisions  (cell  aging,  replicative 
senescence),  has  now  become  regarded  more  generally  as  a  biological 
programme of signal transduction leading to terminal, irreversible growth arrest, 
accompanied by a distinct set of alterations in the cellular phenotype (Dimri 
2005).  Cells  that  undergo  senescence  cannot  divide  even  if  stimulated  by 
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dramatic  changes  in  chromatin  structure  and  gene  expression.  This  is 
accompanied by characteristic and easily observed changes in morphology such 
as an enlarged and flattened cell shape with increased granularity and formation 
of intracellular vacuoles (Campisi 2001; Dimri et al 1995). Senescence has been 
most  widely  studied  in  fibroblasts  in  vitro  but  is  also  well defined  in 
melanocytes and epithelial cells as well as cancer cells (Jones et al 2000; Lin 
and Lowe 2001; Michaloglou et al 2005, Olsen et al 2002; Serrano et al 1997; 
Shay  and  Roninson,  2004).  Other  cell  types  suggested  to  undergo  senescence 
include  haematopoetic  and  neural  progenitors  (Geiger  and  Van  Zant  2002; 
Palmer  et  al  2001).  The  most  widely  used  marker  for  senescent  cells  is 
senescence associated β galactosidase  (Dimri  et  al  1995).  The  senescent 
phenotype also entails type specific changes. Some senescent cells, for example 
human  fibroblasts  but  not  endothelial  cells,  become  resistant  to  apoptosis 
(Hampel et al 2004). In addition, senescent fibroblasts secrete proteins that can 
influence  the  tissue  microenvironment  (Chang  et  al  2002;  Mason  et  al  2004; 
Shelton  et  al  1999;  Trougakos  et  al  2006;  Zhang  et  al  2003a)  as  well  as 
inflammatory  cytokines  such  as  IL 6  (Kuilman  et  al  2008).  Interestingly, 
paracrine factors produced by senescent cells have major effects on the growth 
and survival of tumour cells (Krtolica et al 2001). Hence, senescence should not 
be  viewed  as  merely  the  end  point  in  a  cell’s  life  cycle  but  rather  as  a 
physiological state determined by the homeostatic programmes of an organism. 
1.9.1 Growth arrest 
Somatic  cell  cycles  consist  of  alternating  DNA  synthetic  (S)  and  mitotic  (M) 
phases, separated by gap phases (G1 and G2) (Figure 1.8). Senescent cells are 
unable to progress through the cell cycle and usually arrest growth with G1 DNA 
content. Once arrested they cannot be stimulated to resume proliferation by 
physiological  mitogens.  This  is  primarily  caused  by  upregulation  of  cell  cycle 
inhibitors and chromatin condensation (Campisi 2005; Narita et al 2003). The 
preferred  theories  emphasising  G1  arrest  have  been  overthrown  by  several 
reports that have shown that cellular senescence can be also associated with 
G2M arrest. For example, a defect in the stress signalling kinase MKK7 caused 
G2M arrest (Wada et al 2004) and also overexpression of oncogenic RAF results in 
a preferential accumulation in the G2M phase of the cell cycle (Zhu et al 1998). Kamil K. Wolyniec, 2008     Chapter 1,40  
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Although  earlier  studies  of  H RAS
V12  induced  senescence  have  described 
predominant G1 arrest, recent work from our laboratory has revealed a stronger 
block in G2M, and an increased number of cells with a 4N DNA content (Kilbey et 
al 2007). 
 
 
 
 
 
 
 
 
 
Figure 1.8 Schematic diagram of checkpoints in the eukaryotic cell cycle 
The  cell  cycle  consists  of  alternating  S  phase  (DNA  synthesis)  and  M  phase 
(mitosis), separated by two gap phases G1 and G2. Cyclin D dependent kinases 
(CDKs)  accumulate  in  response  to  mitogenic  signals  and  initiate  the 
phosphorylation of pRb, a process that is completed by cyclin E cdk2. Once cells 
enter  S  phase,  cyclin  E  is  degraded  and  cyclin  A  enters  into  complexes  with 
cdk2.  Cyclin  B Cdc2  mediates  G2/M  transition.  INK4  proteins  (p16INK4a, 
p15INK4b,  p18INK4c,  p19INK4d)  oppose  the  activities  of  the  various  cyclin  D 
dependent  kinases,  whereas  Cip/Kip  proteins  (p21Cip1,  p27Kip1,  p57Kip2) 
specifically inhibit cyclin E cdk2 and cyclin A cdk2. Gadd45, 14 3 3σ and p21Cip1 
interefere with cyclin B Cdc2. 
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1.9.2 Altered gene expression 
Cells  that  undergo  senescence  show  dramatic  changes  in  gene  expression 
patterns,  especially  cell cycle  inhibitors  which  are  activated  and  cell  cycle 
progression genes that are downregulated (Trougakos et al 2006; Zhang et al 
2003a). p16
INK4a and p21
WAF1, which are governed by two tumour suppressors, p53 
and  pRb  respectively,  are  the  most  common  cell  cycle  inhibitors  that  are 
expressed in senescent cells (Campisi 2005). P53 and pRb are often dysfunctional 
in cancer (Sherr and McCormick 2002). p21
WAF1 is a direct downstream target of 
p53,  whereas  induction  of  p16
INK4a  remains  poorly  understood,  although 
transcription  factors  of  the  Jun,  Ets  and  Id  families  together  with  polycomb 
group proteins, Bmi, have been implicated in the regulation of INK4a expression, 
thereby  governing  cellular  senescence  (Lowe  and  Sherr  2003;  Gil  and  Peters 
2006). Ultimately, p16
INK4a and p21
WAF1 maintain pRb in a hypophosphorylated, 
active state (Lowe and Sherr 2003). Repressed genes during senescence include 
replication dependent histones, c FOS, cyclin A, cyclin B and PCNA (proliferating 
cell nuclear antigen) (Narita et al 2003; Pang and Chen 1994; Serrano et al 1997; 
Seshadri and Campisi 1990). The repression of some of these genes is believed to 
reflect  pRb  mediated  inactivation  of  E2F  target  genes  and  pRb dependent 
epigenetic  chromatin  reorganisation  and  formation  of  discrete  foci  termed 
senescence associated heterochromatin foci (SAHF) within the nucleus (Narita et 
al 2005). 
1.9.3 Senescence markers 
The extensive study of senescence has yielded several markers that are useful 
for the detection of this phenotype not only in vitro but more importantly in 
vivo. Senescent cells do not replicate their DNA, which can be detected by the 
lack of incorporation of 3H thymidine or BrdU. Alternatively, immunostaining for 
PCNA  or  Ki 67  can  be  performed.  SA β gal  staining  serves  as  a  reliable  and 
extensively  used  marker.  In  addition,  components  of  two  main  pathways 
involved  in  senescence:  ARF p53  and  p16
INK4a pRb  are  now  used  to  identify 
senescent cells (Campisi 2005). Recently, the Serrano group has reported new 
markers that could help to describe senescence in vivo e.g. p15
INK4b, DCR2 and 
DEC1  (Collado  and  Serrano  2006).  Senescent  cells  can  also  be  detected  by 
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foci) and senescence associated DNA damage foci (SDFs) (Bartkova et al 2006; 
DiMicco et al 2006; Mallette et al 2007; Narita et al 2003) 
1.9.3.1  Senescence-associated β-galactosidase 
The most widely used assay for senescence cells is the cytochemical detection of 
β galactosidase activity at pH 6, termed senescence associated β galactosidase 
(SA β Gal)  (Dimri  at  al  1995).  Most  cells  express  a  lysosomal  β-Gal  that  is 
optimally active at about pH 4 and either pre senescent or senescent cells stain 
equally when assayed at pH 4, but only senescent cells stain for β Gal activity at 
pH 6. Neither pre senescent nor senescent cells stain at pH 7.5 which is the 
optimum for bacterial β Gal enzyme (Dimri at al 1995). β-galactosidase activity 
reflects increased lysosomal biogenesis (Kurz et al 2000). It has been recently 
reported that SA β–Gal is expressed from  GLB1, the gene encoding lysosomal 
beta D galactosidase  and  that  downregulation  of  this  gene  by  RNAi  did  not 
prevent cellular senescence indicating that SA β–Gal is not required for cells to 
undergo senescence (Lee et al 2006). There is also evidence for a positive SA β–
Gal reaction in settings of cellular stress that are unrelated to senescence such 
as serum withdrawal or high confluency in culture dish (Severino et al 2000). 
Although  SA β–Gal  is  not  necessary  for  senescence  it  is  still  a  useful  and 
extensively used assay for detection of senescent phenotypes. 
1.9.3.2  Senescence-associated heterochromatin foci (SAHF) 
When stained with DAPI (4’ 6 Diamidino 2 phenylindole) or PI (propidium iodide) 
normal human cells exhibit a relatively even distribution of DNA across the cell 
nucleus.  However  most  of  the  senescent  cells  undergo  dramatic  chromatin 
condensation which can be visualised by staining with DAPI as bright, punctate 
DNA foci (Narita et al 2003). SAHF are characterised by the presence of certain 
heterochromatin asscociated  histone  modifications  (for  example, 
hypoacetylation of histones or methylation of Lys9 of histone H3   H3K9Me) and 
bound heterochromatin proteins (e.g. HP1, heterochromatin protein 1) (Narita et 
al 2003) as well as loss of the linker histone H1 and enrichment in histone variant 
macroH2A and HMGA proteins (Funayama et al 2006; Narita et al 2006; Zhang et 
al 2005). The molecular mechanism of SAHF assembly is very complex and still 
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bodies play a critical role in this process (Figure 1.9) (Adams 2007). SAHF are 
believed to reflect p16 pRB mediated silencing of E2F target genes involved in 
cell cycling (Narita et al 2003). In mice, pericentric heterochromatin is much 
more prominent than in human cells and therefore it can be mistaken for SAHF 
(Adams 2007). Whether SAHF always occur in response to various stimuli and 
how exactly they are formed are questions that remain to be answered. It seems 
that not all cells have equal propensity to form SAHF. For instance WI 38 and 
IMR90  lung  embryonic  fibroblasts  and  primary  melanocytes  accumulate 
pronounced SAHF, whereas BJ foreskin fibroblasts form less marked SAHF (Adams 
2007). It is very possible that the nature of pro senescent stimuli may account 
for the SAHF occurrence, for example, STAT5A does not promote obvious SAHF 
formation (Hemann and Narita 2007). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.9 A model of SAHF formation in senescent human cells 
The  HIRA/ASF1a  complex  cooperates  with  p16INK4a/pRB  pathway  to  drive 
chromatin condensation. HP1 and macroH2A are deposited into SAHF. HIRA and 
HP1  transiently  localise  to  PML  bodies  where  are  activated  through 
phosphorylation (adapted from Adams 2007) Kamil K. Wolyniec, 2008     Chapter 1,44  
1.9.3.3  Senescence-associated DNA-damage foci (SDF) 
As  discussed  before,  telomere  uncapping  can  trigger  a  DNA  damage  response 
that  results  in  senescence like  growth  arrest  (d’Adda  di  Fagagna  et  al  2003; 
Herbig et al 2004). In addition γ irradiation and genotoxic drugs can also drive 
cellular senescence through DNA damage response pathways (Schmitt et al 2002; 
Wahl and Carr 2001). Interestingly, oncogenes such as H RAS
V12. MOS, Cdc6 or 
STAT5a induce DNA double strand breaks (DSBs) and a DNA damage response due 
to  replication  stress  that  engages  activation  of  ATM/ATR,  CHK2  and  CHK1 
(Bartkova et al 2006; Di Micco et al 2006; Mallette et al 2007). SDFs can be 
detected in senescent cells from mice and humans and contain proteins that are 
involved in DNA damage such as γ H2AX, 53BP1, MDC1 and NBS1 (Bartkova et al 
2006; d’Adda di Fagagna et  al 2003; DiMicco et al 2006; Herbig et al 2004). 
Importantly,  it  seems  that  not  all  oncogenes  effectively  induce  DNA  damage 
(Hemann and Narita 2007) and the role of SDF as a general marker of senescence 
remains to be investigated further. 
1.10 Signalling pathways in cellular senescence 
1.10.1  p53 and pRb, two master regulators of senescence 
Regardless of the senescence initiating signals, tumour suppressor pathways are 
critical for initiation and maintenance of the senescent phenotype in human and 
mouse cells. These pathways are controlled by the tumour suppressor proteins 
p53 and pRB with a wide range of upstream regulators and downstream effectors 
(Figure 1.10). It was in the early 90s when Shay and colleagues identified p53 
and pRB as two principal regulators of senescence (Shay et al 1991) and since 
then the molecular networks regulated by these proteins have become a subject 
of extensive research. Various studies have examined the relative functions of 
p53 and pRB in the initiation of senescence by assessing the outcomes of their 
inactivation.  Numerous  methods  have  been  used  to  this  end,  for  example: 
ectopic expression of SV40 large T antigen and the human papilloma virus E6 and 
E7 oncoproteins (Shay et al 1991), germline homologous recombination in the 
mouse  (Dannenberg  et  al  2000;  Sage  et  al  2000],  somatic  homologous 
recombinations in human cells (Brown et al 1997) or RNAi knock down models 
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sufficient  to  prevent  senescence  (Dirac  and  Bernards  2003).  Likewise, 
inactivation of pRb gene together with other members of Rb family such as p107 
and p130, but not pRb alone, is sufficient to escape senescence (Dannenberg et 
al 2000; Sage et al 2003). This implies that both p53 and the Rb family are 
required for the induction of senescence. P53 and pRb were also found to be 
necessary for the maintenance of the senescent state because inactivation of 
either of these genes in senescent MEFs was enough for proliferation to resume 
(Dirac  and  Bernards,  2003;  Sage  et  al  2003).  These  observations  suggested  a 
model of linear signalling, whereby a stress signal activates p53 which in turn 
activates  pRb.  The  p21
WAF1  protein,  an  inhibitor  of  cyclin  E/Cdk2  complexes 
which is a direct transcriptional target of p53 was proposed to act as a linking 
chain  between  these  two  pathways.  However,  p21  null  MEFs  undergo  RAS 
induced  senescence  (Pantoja  and  Serrano  1999),  therefore  exactly  how  the 
signal is transduced remains elusive. Unlike the behaviour of mouse cells, the 
inactivation of both p53 and pRb is essential to prevent the onset of replicative 
senescence  in  human  cells  (Smogorzewska  and  de  Lange  2002),  whereas 
disruption of only one of these proteins only delays the onset of senescence. This 
indicates that in human cells, p53 and pRb operate in two parallel pathways. A 
degree of complexity arises from other studies where it has been demonstrated 
that inactivation of either p53 or pRb by somatic homologous recombination in 
human  lung  fibroblasts  allows  bypass  of  senescence,  suggesting  that  a  linear 
model could be also applicable to human cells in some contexts (Wei et al 2003). 
This  idea  is  supported  by  the  fact  that  abrogation  of  p21
WAF1  by  homologous 
recombination  is  sufficient  to  prevent  replicative  senescence  in  human 
fibroblasts (Brown et al 1997). 
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Figure 1.10 Control of cellular senescence by p53 and pRB pathway   
Shown here are pathways that are activated by senescence inducing signals. The 
model  assumes  linear  crosstalk  between  the  p53  pathway  (red)  and  the  pRB 
pathway (green). Positive and negative regulators of these two pathways are 
indicated and the effects of their action illustrated by arrows(          positive 
effect;         negative effect) 
1.10.1.1  pRb 
It is well established that pRb is constitutively hypophosphorylated (in its active 
state) in senescent cells and there is a growing body of evidence that this is 
achieved  at  least  to  some  extent  by  p16
INK4a.  The  p16
INK4a,  an  inhibitor  of 
CDK4/CDK6/Cyclin D complex activity, is upregulated during either replicative 
senescence or premature senescence in human fibroblasts (Alcorta et al 1996; 
Serrano  et  al  1997;  Stein  et  al  1999).  Therefore,  it  has  been  proposed  that 
p16
INK4a prevents phosphorylation of pRb resulting in its activation. Consistent 
with this hypothesis, p16
INK4a and its upstream regulators such as Bmi 1, CBX7, 
JunB, ID1 and Ets 1 regulate senescence in a pRb dependent fashion (Gil et al 
2004;  Itahana  et  al  2003;  Ohtani  et  al  2001;  Passegue  and  Wagner  2000). 
Moreover, inactivation of p16
INK4a in human cells causes a delay in the onset of 
replicative senescence, quite significantly in some cases (Brookes et al 2004) and 
p16  deficient  human  fibroblasts  are  resistant  to  RAS  induced  senescence 
(Brookes et al 2002). However, whereas in certain fibroblastic strains such as the Kamil K. Wolyniec, 2008     Chapter 1,47  
frequently used WI 38 strain, p16
INK4a is clearly upregulated, in the other strains 
such as BJ fibroblasts, p16
INK4a is only minimally expressed (Itahana et al 2003). 
Intriguingly,  fibroblasts  with  low  or  undetectable  p16
INK4a  levels,  in  contrast 
those with high p16
INK4a expression levels, can be induced to re enter cell cycle 
by  inactivation  of  p53  (Beausejour  et  al  2003).  Interestingly  SAHF  which  are 
known to be responsible for the irreversibility of senescence are present only in 
human fibroblasts that contain high levels of p16
INK4a (Narita et al 2003). In view 
of recent studies, it is plausible that there might be CDK inhibitors other than 
p16
INK4a, playing a surrogate role in the regulation of pRb. Using a p16
INK4a knock 
down  strategy,  it  was  shown  that  p16
INK4a  inactivation  is  not  functionally 
equivalent  to  pRb  inactivation  (Wei  et  al  2003).  Given  that  p21
WAF1 
overexpression in human fibroblasts results in premature senescence (McConnel 
et  al  1998)  and  its  induction  can  also  lead  to  the  inhibition  of  pRb 
phosphorylation by suppressing CDK2/Cyclin E activity, p16
INK4a and p21
WAF1 may 
cooperate in maintaining pRb in the active state during cellular senescence. 
1.10.1.2  p53 
p53 is considered to be a guardian of the genome and depending on the severity 
of the damage it can activate genetic programmes that stop cell proliferation 
transiently (G1 and G2 arrest) or permanently (senescence), or eliminate the 
cell (apoptosis). The signals that induce a DNA damage response such as ionizing 
radiation  or  telomere  dysfunction  induce  senescence  primarily  via  the  p53 
pathway. p53 activity, and in some cases  protein level, increases when cells 
undergo senescence (Itahana et al 2001). The mechanisms responsible for this 
are  incompletely  understood,  but  some  molecular  details  are  emerging.  One 
cause  of  p53  activation  appears  to  be  an  increase  in  the  expression  of  ARF 
(p14ARF  in  human;  p19ARF  in  mouse),  a  tumour  suppressor  encoded  by  the 
INK4a-ARF locus. It stimulates p53 activity due to sequestration of HMDM2 (MDM2 
in  mice),  an  E3  ubiquitin  ligase  that  targets  p53  for  proteosome mediated 
degradation. Thus, ARF prevents negative feedback regulation of p53 by MDM2 
(Bringold and Serrano 2000; Gil and Peters 2006). ARF is upregulated in cultured 
senescent murine cells as well as during premature senescence induced by H 
RAS
V12 and has been reported to be absolutely required for telomeric and non 
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al 2004). In human cells the role of ARF is more complicated. For example it has 
been proven to be a critical regulator of E2F induced senescence (Dimri et al 
2000; Wei et al 2001) but not H RAS
V12 induced senescence in human primary 
fibroblasts (Wei et al 2001). ARF can be transcriptionally activated by DMP1, a 
transcription factor that was found to be essential in RAS RAF ARF signalling in 
murine  cells  (Inoue  et  al  2000;  Sreeramaneni  et  al  2005).  ARF  can  be  also 
negatively regulated by TBX2 and Pokemon that can bind to the ARF promoter 
and  repress  its  transcription  (Jacobs  et  al  2000;  Maeda  et  al  2005).  Another 
cause  for  the  increase  in  p53  activity  is  reported  to  be  the  promyelocytic 
leukaemia  (PML)  tumour  suppressor.  PML  is  upregulated  in  replicatively 
senescent cells and mediates premature senescence in response to oncogenic H 
RAS
V12 by interaction with CBP/p300 acetyltransferase  and acetylation of p53 
and its stimulation (Ferbeyre et al 2000; Pearson et al 2000). PML was also found 
to bind to MDM2 and sequester it into the nucleolus (Bernardi et al 2004). 
1.10.2  Reactive  oxygen  species  as  signal  transducer  in 
cellular senescence 
The  results  discussed  earlier  in  this  chapter  in  the  section  ‘oxidative  stress’ 
(1.8.3)  suggest  that  oxygen  concentration  limits  cellular  lifespan  in  vitro  by 
induction of cellular senescence. The relationship between intracellular oxidants 
and the senescent programme has been strengthened by the observation that 
treatment  with  sub lethal  doses  of  hydrogen  peroxide  can  trigger  certain 
primary cells to rapidly enter senescence (Chen and  Ames 1994; Chen  et al 
1998; Frippiat et al 2002). Molecular analysis of these hydrogen peroxide treated 
cells revealed a predominant G1 arrest with an increase in p53 protein levels 
and increased p53 activity, accompanied by subsequent upregulation of p21
WAF1 
(Chen et al 1998). Interestingly, an increase in the expression of a subset of p38 
MAPK dependent  genes  in  H202 induced  premature  senescence  was  identified 
suggesting  a  link  between  reactive  oxygen  species  (ROS)  and  p38  activation 
(Zdanov et al 2006). A strong argument supporting the role of ROS in mediating 
senescence  stems  from  the  fact  that  overexpression  of  H RAS
V12  induces 
senescence and increases ROS levels (Lee et al 1999). Interestingly, Seladin-1, 
which  encodes  an  oxidoreductase  enzyme  involved  in  cholesterol  synthesis 
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Alzheimer’s disease (Greeve et al 2000) has been identified as a crucial mediator 
of  H RAS
V12  induced  senescence  and  has  been  linked  to  RAS induced  reactive 
oxygen  species  signalling  (Wu  et  al  2004).  Moreover,  the  p53  transcriptional 
target p21
WAF1, when ectopically expressed induces the hallmarks of senescence 
with an accompanying rise in intracellular ROS (Macip et al 2002). Treatment 
with antioxidant NAC (N acetyl cysteine) has been shown to prevent both RAS 
induced  senescence  and  p21 induced  senescence  (Lee  at  1999;  Macip  et  al 
2002). Recently, Takahashi and coworkers have demonstrated that p16
INK4a/pRb 
pathway can also induce a rise in intracellular ROS levels through activation of 
PKCδ (Protein Kinase C δ), which, in turn seems to lead to further production of 
ROS  by  activating  NADPH  oxidase,  thus  establishing  a  self sustained  positive 
feedback loop. In addition, the activation of PKCδ results in dramatic depletion 
of WARTS protein (WTS/large tumour suppressor 1 mitotic kinase) expression, 
the  kinase  essential  in  cytokinesis,  and  G2M  cell  cycle  arrest  which  act  as  a 
second barrier ensuring irreversibility of senescence (Takahashi et al 2006). 
1.10.3  p38  Mitogen-acivated  protein  kinase  represents  a 
common senescence pathway 
The  p38  kinase  belongs  to  the  family  of  mitogen activated  protein  kinases 
(together with extracellular regulated kinase, ERK and c Jun N terminal kinase, 
JNK)  and  is  also  known  as  stress activated  protein  kinase  (SAPK).  The 
mammalian genome encodes four isoforms of p38 (α, β, γ, δ). P38 plays a crucial 
role  in  various  processes  such  as  inflammation,  cellular  responses  to  micro 
organisms and other environmental stresses (Bulavin and Fornace 2004; Nebreda 
and  Porras  2000)  and  has  aslo  been  also  been  strongly  linked  to  cellular 
senescence in mouse and human cells. It has emerged as a common signalling 
pathway  that  is  required  by  various  stimuli  to  cause  senescence  including 
replicative  stress,  oncogene  overexpression,  hydrogen  peroxide  and  culture 
shock  (Iwasa  et  al  2003;  Trost  et  al  2005;  Wang  et  al  2002).  The  mitogen 
activated protein kinase (MAPK) signalling cascade is the principal Ras effector 
pathway responsible for premature senescence (Lin et al 1998). Remarkably, this 
is  the  same  pathway  whereby  Ras  induces  mitogenesis  in  immortal  cells 
suggesting the existence within the RAS signalling cascade of a signalling branch 
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been shown that activation of MEK ERK pathway by RAS in primary fibroblasts 
leads to activation of p38 MAPK, which in turn induces accumulation of cell cycle 
inhibitors  and  senescence.  RAS induced  p38  activation  is  achieved  by  its 
upstream kinases MKK3 and MKK6 (Wang et al 2002). Constitutive activation of 
p38 signalling by overexpression of active mutants of MKK3 or MKK6 results in 
premature senescence. Conversly, suppression of p38 by the inhibitor SB203580 
or  by  dominant  negative  mutants  of  MKK3/MKK6,  substantially  rescues 
senescence induced by RAS (Wang et al 2002; Iwasa et al 2003). In addition, 
expression of Wip1 (a p38 phosphatase) which inactivates p38, renders primary 
human fibroblasts refractory to RAS induced senescence (Bulavin et al 2002), 
whereas inactivation of Wip1 causes p38 activation and premature senescence in 
MEFs (Bulavin et al 2004). Furthermore, MEFs that are deficient in Gadd45a, a 
DNA damage and stress induced protein that binds and activates p38, are unable 
to  undergo  senescence  induced  by  RAS  (Bulavin  et  al  2003).  Interestingly, 
expression  of  RAS  oncogene  in  human  osteosarcoma  U2OS  results  in  a 
p16
INK4a/ARF independent senescence like growth arrest that can be rescued by 
the inhibition of p38 MAPK (Bihani et al 2004). Another oncogene, erbB2, the 
tyrosine kinase receptor that is frequently overexpressed in breast carcinomas 
and other human cancers induces premature senescence that requires intact p38 
MAPK (Trost et al 2005). These studies strongly implicate p38 MAPK in oncogene 
induced  senescence.  Currently,  it  remains  largely  unknown  what  are  the 
downstream effectors of p38 in the context of senescence. However, the p16
INK4a 
and p53 are believed to be two major downstream targets of p38 in RAS induced 
senescence. It has been suggested that p38 activation stabilises p16
INK4a and p53 
mRNA by as yet elusive mechanisms (Wang et al 2002). Other studies identified 
PRAK (p38 regulated/activated protein kinase), a downstream regulator of p38 
MAPK  to  be  essential  for  RAS  induced  transcriptional  activity  of  p53.  PRAK 
directly phosphorylates p53 at Ser37, a residue required for p53 to drive RAS 
induced  senescence.  In  addition  to  PRAK,  p38  directly  phosphorylates  p53  at 
Ser33 and Ser46 during RAS induced senescence (Sun et al 2007). It is also not 
very clear what is the mechanism by which MKK3/6 p38 is activated since there 
is a profound delay in the transduction of signal from MEK ERK to MKK3/6 and 
p38, indicating that it occurs via an indirect and slow route (Wang et al 2002). 
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induced  by  RAS  and  mediate  both  p38  activation  and  oncogene induced 
senescence (Colavitti and Finkel 2005); Iwasa et al 2003; Lee et al 1999). In 
support  of  this  hypothesis,  recent  studies  demonstrated  that  MINK  kinase  is 
activated  by  RAS  induced  ROS  and  subsequent  activation  of  p38  by  MINK  (a 
Ste20/germinal  center  kinase  family  MAP  kinase  kinase  kinase)    results  in 
premature  senescence  (Nicke et  al 2005).  Moreover,  p38 itself has also been 
shown  to  restrict  RAS induced  tumourigenesis  by  acting  as  a  sensor  of  ROS 
(Dolado et al 2007). 
1.11 Oncogene induced senescence as a cancer fail-safe 
mechanism 
In  principle,  cellular  senescence  is  thought  to  be  an  important,  evolutionary 
conserved fail safe mechanism, a natural barrier that cells must overcome in 
order to become immortal and induce tumourigenesis. Apoptosis has been a well 
established mechanism of tumour suppression for a long time (Brown and Attardi 
2005; Kim et al 2006) but to what extent the observed cellular senescence in 
vitro reflects a relevant anti cancer mechanism in vivo has been controversial. It 
was important to address this issue especially in view of some studies showing 
that not all primary fibroblasts undergo H Ras induced senescence. Galloway and 
collegues reported that ectopic expression of Ras in human foreskin fibroblasts 
(HFFs) freshly established from the primary tissue does not result in premature 
senescence but instead causes mild transformation of these cells (Benanti and 
Galloway 2004). Interestingly freshly established HFFs were found to differ from 
routinely used strain of IMR90 fibroblasts in the basal levels of p16 (undetectable 
in HFFs, detectable in IMR90s) and the relative extent of p16 upregulation by H 
Ras.  The  authors  suggested  that  passaging  of  cells  leads  to  culture imposed 
stress causing accumulation of p16 allowing for Ras induced arrest. Hence HFFs 
used directly after isolation from the tissue had been exposed to considerably 
less environmental stress, did not express any detectable p16 and were resistant 
to  senescence.  In  support  of  this  hypothesis  it  has  been  demonstrated  that 
extended  passaging  of  HFFs  may  render  them  sensitive  to  H Ras  induced 
senescence.  Several  recent  studies,  however,  have  reported  that  oncogene 
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models,  and  indeed  provides  a  vital  mechanism  that  constrains  neoplastic 
transformation (Figure 1.11). Abnormal activation of oncogenic Ras, BRAF, E2F 
or loss of PTEN tumour suppressor can promote aberrant cell proliferation, which 
eventually provokes activation of a cellular senescence programme in vivo. If 
the programme remains  intact, the neoplastic growth may remain benign  for 
many years. However, mutations that disrupt p53, p16
INK4a or Suv39H1 which are 
sustaining cellular senescence cooperate with tumour progression (Braig et al 
2005; Chen et al 2005; Collado et al 2005; Lazzerini et al 2005; Michaloglou et al 
2005). Probably the most spectacular example of oncogene induced senescence 
in vivo is the appearance of naevi or moles on human skin, which are benign 
tumours of cutaneous melanocytes containing senescent cells (Michaloglou et al 
2005).  In  addition  several  studies  have  demonstrated  that  re expression  of 
endogenous  p53  rapidly  induces  senescence  and  curtails  oncogenesis  in 
genetically engineered mouse models of sarcoma and hepatocellular carcinoma 
(Ventura et al 2007; Xue et al 2007). Xue and coworkers showed that even brief 
reactivation  of  p53  in  p53 deficient  tumours  can  result  in  complete  tumour 
regression.  This  response  also  triggered  an  innate  immune  response  that  was 
associated  with  tumour  clearance  (Xue  et  al  2007).  Importantly  cellular 
senescence has also been found to be involved in the tumour regression related 
to  the  inactivation  of  the  c Myc  oncogene  in  diverse  tumour  types  including 
lymphoma, osteosarcoma, hepatocellular carcinoma (Wu et al 2007). 
 
 
 
 
 
 
 
 
 
 
Figure  1.11  Oncogene  induced  senescence  as  an  anti-cancer  fail-safe 
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Activating  mutations  of  RAS  or  BRAF  or  inactivation  of  PTEN  resulting  in 
hypermitogenic  signalling  produce  premalignant  lesions.  Disruption  of  tumour 
suppressors p53 and p16/pRb allows escape from senescence and progression to 
malignant tumours 
1.12 RUNX genes and senescence 
It has been reported by our laboratory that all three RUNX proteins are capable 
of inducing senescence like growth arrest in primary MEFs (Kilbey et al 2007; 
Wotton et al 2004). RUNX1 induced senescence in MEFs was found to be p53 
dependent and pro oncogenic activity of RUNX1 could be revealed in p53 null 
MEFs  (Wotton  et  al  2004).  RUNX  expressing  MEFs  were  found  to  undergo 
profound  growth  arrest  without  the  initial  burst  of  proliferation  which 
characterizes oncogenic RAS induced senescence (Kilbey et al 2007, Wotton et al 
2004). However, issues such as whether RUNX1 can also induce senescence in 
primary human fibroblasts or which structural domains of RUNX1 are required for 
the senescence induction have  not been previously investigated. Furthermore 
the mechanism by which RUNX1 expressing cells acquire a senescent phenotype 
and the potential of RUNX1 fusion oncoproteins to cause senescence  had not 
been addressed at the outset of my studies. 
1.13 Aims of the project 
1. To investigate the mechanism and structural requirements for senescence like 
growth arrest induced by RUNX1.  
2. To test the effect of ectopic RUNX1 expression in human primary fibroblasts 
as well as characterise a system to study oncogene induced senescence. 
3. To compare the effects of RUNX1 and its derivatives to Ras
V12, a prototypic 
inducer of oncogene induced senescence in human fibroblasts. 54 
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2  Materials and methods 
2.1 Materials 
2.1.1 Antibodies 
Antibodies were used for Western blotting or immunolocalisation in microscopy. 
The dilution used for each antibody is provided in brackets. 
Active Motif Europe (Belgium) 
Anti AML1/Runx1 (39000), (1:1000) 
Cell Signalling Technology (New England Biolabs, UK) 
Anti p38 (9212), (1:1000) 
Anti phospho p38 (9211), (1:1000) 
DAKO Ltd, UK 
Polyclonal rabbit Anti mouse immunoglobulins/HRP, (1:1000) 
Polyclonal swine Anti rabbit immunoglobulins/HRP, (1:3000) 
Polyclonal rabbit Anti goat immunoglobulins/HRP, (1:2000) 
Dr.  Nancy  Speck  (Department  of  Biochemistry,  Dartmouth  Medical  School, 
Hanover, USA) 
Monoclonal supernatant recognising CBFβ (peptide 42 214 amino acids) 
Dr. Scott Hiebert (Vanderbilt Cancer Center, USA) 
Anti Runx1 ETO polyclonal rabbit antibody that recognising ETO zinc finger motif 
was a kind gift from Dr. Scott Hiebert, (1:500) Kamil K. Wolyniec, 2008     Chapter 2,56  
Dr. Tina Rich (University of Glasgow, UK) 
Anti PML  (N19,  Santa  Cruz)  (1:200)  and  Alexa  Fluor conjugated  secondary 
antibody (Molecular Probes) (1:100) 
Jackson Immuno Reasearch Laboratories, Inc (Stratech Scientific Ltd., UK) 
Fluorescein (FITC) conjugated Affinity Purified Sheep Anti Mouse IgG, (1:100) 
Medical and Biological Laboratories Co., Ltd (MBL) (Stratech Scientific Ltd, 
UK) 
Anti Runx (D207 3), (1:1000) 
NeoMarkers (Lab Vision Products Thermo Fisher Scientific, UK) 
Anti p14ARF (Ab 2), (1:500) 
Positive control for anti p14 (MS 850 PCL) 
Oncogene Research Products (Merck, UK) 
Anti H ras (Ab 1), (1:200) 
Roche Diagnostics Ltd, UK (In situ Cell Proliferation Kit, FLUOS) 
Monoclonal anti BrdU conjugated with fluorescein  
Santa Cruz Biotechnology Inc (Insight Biotechnology, UK) 
Anti p16 (sc 468), (1:1000) 
Anti p21 (sc 397), (1:250) 
Anti p53 (sc 126), (1:1000) 
Anti actin (sc 1616), (1:1000) Kamil K. Wolyniec, 2008     Chapter 2,57  
Upstate Cell Signalling Solutions (Millipore, UK) 
Anti phospho Histone H2A.X (Ser139) (05 636), (1:200) 
2.1.2 Cell culture 
2.1.2.1  Cell lines 
Wild  type  and  p53
 /   mouse  embryo  fibroblasts  (MEFs)  were  prepared  from 
E13.5 day embryos of wild type (C57B16/CBA) and p53 null mice as described 
before (Wotton et al 2004). Briefly, the head and red organs were removed and 
the body minced and treated with 0.5% trypsin for 15 min to disperse the cells. 
The cells were expanded in culture and frozen at passage two in 60% FCS, 10% 
DMSO 
Hs68  strain  of  human  neonatal  foreskin  fibroblasts  (passage  30;  ATCC:  CRL 
1635). These were rendered sensitive to ecotropic retroviruses by expression of 
murine leukaemia virus receptor have been previously described (Brookes et al 
2004) and kindly provided by Prof. Gordon Peters (CR UK, London). 
Leiden  cells  (passage  29).  These  are  a  p16
INK4a  deficient  human  diploid 
fibroblasts that were originally isolated from a male patient who from the age of 
6 developed multiple prominent naevi which by puberty had become atypical. 
Dermal fibroblasts were isolated from a region of normal epidermis adjacent to 
one  of  the  dysplastic  naevi  removed  when  the  patient  was  24  years  of  age. 
Leiden cells expressing mouse ecotropic receptor were kindly provided by Prof. 
Gordon Peters (CR UK, London) (Brookes et al 2002) 
Phoenix ecotropic packaging cell line is a second generation retrovirus producer 
lines for the generation of helper free ecotropic retroviruses. The line is based 
on  the  293T  cell  line  (a  human  embryonic  kidney  line  transformed  with 
adenovirus E1a and carrying a temperature sensitive T antigen co selected with 
neomycin). The unique feature of this cell line is that it is highly transfectable 
with either calcium phosphate mediated transfection or lipid based transfection 
protocols. The lines were created by placing into 293T cells constructs capable 
of  producing  gag pol,  and  envelope  protein  for  ecotropic  and  amphotropic Kamil K. Wolyniec, 2008     Chapter 2,58  
viruses. Phoenix cell line was obtained from G. Nolan, Stanford University, Palto 
Alto, CA, USA. 
2.1.2.2  Media and supplements 
All  supplements  and  media  for  cell  culture  were  supplied  by  Invitrogen  Life 
Technologies 
Media 
The media was delivered as sterile 1x solution and stored at 4°C. 
Dulbecco’s  Minimum  Essential  Medium  (DMEM)  with  4500  mg/L  glucose,  L 
Glutamine and pyruvate. 
Supplements 
Foetal Bovine Serum (FBS), HyClone, Perbio: virus and mycoplasma screened. 
FBS was heat inactivated at 56 °C for 30 minutes by the supplier and routinely 
used at a concentration of 10%. 
L glutamine: supplied as  a 200 mM  (100x)  stock solution.  This was routinely 
added to culture media prior to use to a final concentration of 2mM. 
Penicillin/streptomycin (P/S): supplied as a 100x stock solution of 10,000 units 
penicillin  and  10,000  units  streptomycin  per  millilitre.  This  was  used  to 
supplement media to a final concentration of 100 units penicillin/100 units of 
streptomycin. 
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2.1.2.3  Solutions, reagents and antibiotics 
Antibiotics 
Puromycin  (Sigma),  solid  was  dissolved  in  water,  aliquotted  and  stored  as 
5mg/ml stock solution in –20 °C 
Transfection Reagent 
Superfect transfection Reagent (Qiagen) stored in –4 °C 
SA β galactosidase staining 
25% glutaraldehyde stock solution stored in –4 °C (5% PBS pH 7.2) solution freshly 
prepared prior to use) 
0.12 M stock solution of K3Fe[CN]6 and K4[Fe]CN6 stored in –4 °C 
1M stock solution of MgCl2  stored in –4 °C 
Ultra pure
TM X Gal (Invitrogen) stored as solid in –4 °C 
Fresh SA β gal staining solution in PBS (pH 6) prepared immediately prior to use 
consisted of: X gal (1mg/ml), 0.12 mM  K3Fe[CN]6 and K4[Fe]CN6 and 1mM MgCl2 
Inhibitors 
SB203580, a highly specific p38 kinase inhibitor (Calbiochem) was dissolved in 
DMSO,  aliquoted and stored in –20 °C as 8mM stock solutions  
Other 
Trypsin EDTA (Invitrogen): supplied as 0.5% 1x liquid, stored at –20 °C 
DCF  (2’,  7’ dichlorofluorescein  diacetate,  Calbiochem),  cell permeable 
fluorogenic probe that is used for the detection of reactive oxygen species was 
stored in –20 °C as a powder and diluted in DMSO prior to use Kamil K. Wolyniec, 2008     Chapter 2,60  
2.1.2.4  Plasticware 
Tissue culture flasks, pipettes (5, 10, and 25 ml), 100 mm cell culture dish, 12 
well plates were supplied by Costar (Corning Incorporated, Netherlands) 
Cryotubes 1.8 ml were supplied by Nunc (DK 400, Roskilde, Denmark) 
Falcon  conical  centrifuge  tubes  (15  and  50  ml)  were  supplied  by  Becton 
Dickinson Labware Europe 
Syringe  filters  (0.2   m  and  0.45   m)  were  supplied  by  Sartorius  (Hannover, 
Germany); used for sterilising of filtering small volumes of solutions 
Syringes (2, 5, 10, 20, 50) ml were supplied by Becton Dickinson 
Chamber Slide System 2 well glass slide was supplied by Lab Tek (Nalge Nunc 
International, Rochester, New York). Chamber slides were coated with poly L 
lysine (13.3  g/ml) prior to use 
2.1.3 Bacteriology 
2.1.3.1  Bacterial strain 
E. coli One shot 
® TOP10: One Shot Chemically Competent E.coli cells (~1 x 10
9 
colony  forming  units/ g)  (Invitrogen).  Genotype:  F
   mcrA   (mrr-hsdRMS 
mcrBC)Φ80 lacZ M15  lacX74 deoR recA1 araD139  (ara-leu)7697 galU galK rpsL 
(Str
R) endA1 nupG.  
2.1.3.2  Antibiotics 
Ampicillin  (Sigma):  100  mg/ml  in  ddH2O.    Filtered  through  a  0.22   m  filter, 
aliquotted and stored at –20°C until use 
2.1.3.3  Bacteriological media 
Media were sterilised by autoclaving at 121 °C for 15 minutes, unless otherwise 
stated. Kamil K. Wolyniec, 2008     Chapter 2,61  
LB  (Luria  Bertani)  medium:  1%  (w/v)  Tryptone,  0.5%  (w/v)  Yeast  extract,  1% 
(w/v) NaCl in dH20.  pH then adjusted to 7.0 with NaOH. 
LB agar: as for LB medium but also containing 1.5% (w/v) agar. 
SOC medium: 2% Tryptone, 0.5% Yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM 
MgCl2, 10 mM MgSO4, and 20 mM Glucose. (Invitrogen, UK). 
2.1.3.4  LB agar plates supplemented with ampicillin  
Plates  were  prepared  (Sterilin,  Staffordshire,  UK)  with  LB  agar  which  was 
supplemented with 100  g/ml ampicillin. Plates were stored in  4°C for no more 
than two weeks. 
2.1.4 Complete kits 
Big Dye
® Terminator Version 1.1 Cycle Sequencing Kit (Applied Biosystems) 
ECL
TM Western Blotting Detection Reagents (Amersham Biosciences) 
EndoFree
® Plasmid Maxi Kit (Qiagen) 
QIAquick
® PCR Purification Kit (Qiagen) 
QIAquick
® Gel Extraction Kit (Qiagen) 
Klenow Fill In Kit (Stratagene) 
Quick Ligation
TM Kit (New England Biolabs) 
In Situ Cell Proliferation Kit, FLUOS (Roche) 
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2.1.5 DNA 
Plasmid,  molecular  weight  markers  and  oligonucleotide  DNAs  were  stored  at       
–20 °C. 
2.1.5.1  Retroviral vectors 
pBabe puro  
The pBabe puro retroviral vector facilitates the transmission of inserted
 genes at 
high viral titres and their expression them from the Long
 Terminal Repeat (LTR) 
of  the  Moloney  murine  leukaemia  virus  (Mo  MuLV).  This  vector  includes  a 
dominantly  acting  selectable  marker,  conferring  resistance  to  puromycin  to 
infected  mammalian  cells  during  selection  with  puromycin  (Figure  2.1) 
(Morgenstern  and  Land  1990).  pBabe  puro  also  contains  an  ORI  origin  of 
replication  and  the  AmpR  gene  for  propagation  and  antibiotic  selection  in 
bacteria. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 Structure of pBabe puro retroviral vector 
LTR long  terminal  repeats;  MCS multiple  cloning  sites;  SV40 simian  virus 
promoter; Puro puromycin resistance gene; ORI origin of replication; ;  AmpR 
ampicillin resistance gene Kamil K. Wolyniec, 2008     Chapter 2,63  
pBabe  puro  plasmids  containing  human  RUNX1  P1,  RUNX1 ETO  and  RUNX1 
ETO 469 were kindly provided by Dr. Scott Hiebert (USA) (Linggi et al 2002). The 
pBabe puro plasmids containing H RAS
V12 was a kind gift from Dr. Scott Lowe 
(USA)  and  the  plasmid  encoding  p53  was  supplied  by  Prof.  Gordon  Peters 
(London).  The  other  pBabe  puro  vectors  including  AML1a  and  TEL RUNX1  or 
RUNX1  mutants:  K83N  and  T161A  were  constructed  as  described  in  Section 
2.2.2.7. All of the constructs were sequenced as described in Section 2.2.3. 
pLXSN 
pLXSN  contains  elements  derived  from  Moloney  murine  leukaemia  virus 
(MoMuLV)  and  Moloney  murine  sarcoma  virus  (MoMuSV)  and  is  designed  for 
retroviral gene delivery and expression. Upon transfection into packaging cell 
line, pLXSN can transiently express or integrate and stably express the gene of 
interest. The 5’ viral LTR in this vector contains promoter/enhancer sequences 
that control expression of the gene in the multiple cloning site. The SV40 early 
promoter  (PSV40)  controls  expression  of  the  neomycin  resistance  gene  which 
allows  antibiotic  selection  in  eukaryotic  cells.  pLXSN  also  includes  the  ColE1 
origin of replication and Amp
r gene for propagation and antibiotic selection in 
bacteria (Figure 2.2). 
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Figure 2.2 Structure of pLXSN retroviral vector 
LTR long  terminal  repeats;  MCS multiple  cloning  sites;  PSV40 simian  virus 
promoter;  Neo puromycin  resistance  gene;  ColE1 origin  of  replication;  Amp 
ampicilllin resistance gene 
Empty  vector  (pLXSN)  and  vector  containing  Human  papilloma  virus  16  E6 
oncoprotein (pLXNS E6) were kindly provided by Prof. Saveria Campo (University 
of Glasgow) 
2.1.5.2  Molecular size standards 
Molecular size standards used include fX174 RF DNA/HaeIII fragments (size range 
72 bp to 1,353 bp), l DNA/HindIII fragments (size range 125 bp to 23,130 bp), 
and Low DNA Mass™ Ladder (size range: 100 2000 bp) all supplied by Invitrogen 
Life Technologies. 
2.1.5.3  Oligonucleotide primers 
Oligonucleotides  for  sequencing  were  synthesised  by  MWG  Biotech,  and 
delivered as high purity salt free lyophilised DNA.  Primers were reconstituted at 
100 pmol/ l in distilled water (dH20) and stored at –20 °C. Kamil K. Wolyniec, 2008     Chapter 2,65  
2.1.6 Enzymes 
All enzymes were stored at –20 °C and were removed from storage immediately 
before use. 
2.1.6.1  Restriction enzymes 
All  enzymes  and  their  associated  buffers  were  supplied  by  Invitrogen  Life 
Technologies (UK) except for SnaBI which was supplied by Promega (UK). 
Details of restriction enzymes, their restriction sites and reaction conditions are 
shown in Table 2.1. 
Table 2.1 Restriction enzymes. 
Restriction 
enzyme 
Restriction site  Buffer  Temperature  of 
incubation (°C) 
EcoR I  [5´ G↓AATTC 3´]  REACT
® 3  37 
Sna BI  [5´ TAC↓GTA 3´]  Buffer B  37 
Not I  [5´ GC↓GGCCGC 3´]  REACT
® 3  37 
Hind III  [5' A^A G C T T 3']  REACT
® 3  37 
Sal I  [5´ G↓TCGAC 3´]  REACT
® 10  37 
 
2.1.6.2  Antarctic phosphatase 
Recombinant  Antarctic  phosphatase  (New  England  Biolabs)  supplied  with  10x 
buffer 
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2.1.7 Protein SDS-PAGE standards 
Prestained  SDS PAGE  (Sodium  Dodecyl  Sulphate     Polyacrylamide  Gel 
Electrophoresis) standard was the Precision Plus Protein
TM Standards, supplied by 
Biorad. This standard contains ten highly purified recombinant proteins ranging 
from 10 kDa to 250 kDa.  The stock was aliquoted and stored at –20 °C.  Each 
aliquot  was  heated  to  95  °C  for  3  minutes  prior  to  use  to  dissolve  any 
precipitated solids. 
2.1.8 General chemicals 
Chemicals used were of analytic, ultrapure or molecular grade quality and were 
supplied  by  Sigma  Aldrich,  Fisher  Scientific  UK  Limited,  Invitrogen  Life 
Technologies, unless stated otherwise. 
Acetic acid sodium salt (Sodium acetate) 
Agarose  
Albumin from bovine serum (BSA) 
Butanol 
β Mercaptoethanol 
Crude ethanol (University of Glasgow Stores) 
Crystal Violet 
Dimethyl sulfoxide (DMSO) 
D (+) Glucose 
Ethanol 
Ethidium Bromide Kamil K. Wolyniec, 2008     Chapter 2,67  
Ethylene diamine tetra acetate (EDTA) disodium salt 
Glycerol 
Glycine 
Hi Di™ Formamide (Applied Biosystems) 
4 (2 Hydroxyethyl) piperazine 1 ethanesulfonic acid (HEPES) 
Hydrochloric acid 
Magnesium Chloride  
Methanol 
Nonident P 40 (NP40) 
16% paraformaldehyde (Science Services Ltd) 
Propan 2 ol (Isopropanol) Molecular Biology Grade 
Potassium Chloride 
Potassium hexacyanoferrate(III) (K3Fe[CN] 6) 
Potassium hexacyanoferrate(IV) (K4[Fe]CN6) 
Sodium Acetate 
Sodium Chloride 
Sodium dodecyl sulphate (SDS) 
3′,5′,5′′ Tetrabromophenolsulfophethalein (Bromphenol Blue) 
Tris Base (2 Amino 2 (hydroxymethyl) 1, 3 propanediol) Kamil K. Wolyniec, 2008     Chapter 2,68  
Triton X 100 
Tween 20 (Polyoxethylene sorbitan nonolaurate) 
2.1.9 Equipment 
2.1.9.1  Major Equipment 
Automated  Processor:  SRX 101A  Compact  X4  (Xograph  Imaging  Systems, 
Gloucestershire, UK) 
Automatic  Sequencing  Apparatus:  ABI  Prism  3100  Genetic  Analyzer  (Applied 
Biosystems, Foster City, USA) 
Benchtop centrifuge:  Legend
TM Sorvall (Kendro Laboratory Products, Germany), 
Avanti
®  J E  Centrifuge  (Beckman  Coulter,  USA),  Centrifuge  5810,  5810R 
(Eppendorf,  Cambridge,  UK),  EBA 12R  (Hettich  Zentrifugen,  Tuttlingen, 
Germany), Biofuge 13 (Heraeus, Germany) 
Bench top microprocessor pH meter: pH 213 Microprocessor pH  Meter (Hanna 
Instruments, Sarmeola di Rubano, Italy) 
Biological  safety  cabinet:  Fume  Cupboard  (Premier  Laboratory  Systems, 
Scotland),  and  TriMAT
2,  Class  II  Microbiological  Safety  Cabinet  (Medical  Air 
Technology Ltd, Oldham, UK) 
Flow cytometer: Coulter Epics XL MCL (Beckman Coulter Company, Florida, USA) 
Gel cast: AE 6210 Slab Gel Cast (Atto Incorporation, Japan); casting stand and 
casting frames from Mini Protean 3 Cell and Systems, and gel caster from Sub 
Cell Systems (Bio Rad Hertfordshire, UK) 
Gel electrophoresis systems: Biomax QS710 Horizontal Unit (Scientific Imaging 
Systems  –  Eastman  Kodak  Company,  New York,  USA);  Sub Cell  GT  Submerged 
Horizontal  Agarose  Gel  Electrophoresis  System,  and  MiniProteanII
TM  (Bio Rad, Kamil K. Wolyniec, 2008     Chapter 2,69  
Hertfordshire, UK); AE 6200 Slab EP Chamber, and AE 6220 Slab EP Chamber, for 
two gels (Atto Incorporation, Japan) 
Hemocytometer (Bright Line Sigma), cell counting chamber 
Horizontal orbital shaker: Orbital Incubator (Gallenkamp, Leicester, UK) 
Incubator: MIR 262 (Sanyo Electric Biomedical Co. Ltd., Japan) 
Incubators for tissue culture: Hera cell 150 (Heraeus, Surrey, UK) 
Microcentrifuges:  Minispin  (Eppendorf,  Cambridge  UK),  Mikroliter  (Hettich 
Zentrifugen, Tuttlingen, Germany) 
Microscopes:  Laser  Confocal  Scanning  Microscope  (Leica  DM  IRE2),  Inverted 
Microscope (Leica DM IL) 
Microwave Micro chef St44 (Proline, UK) 
Oven Maxi 14 (Hybaid Limited, Middlesex, UK) 
PCR  Machine:  PTC 220  DNA  Engine  Dyad
®  Cycler  (MJ  Research  Incorporated, 
Massachusetts, USA) 
PCR workstation: PCR 6 Vertical Laminar Airflow Cabinet with UV Sterilisation 
(Labcaire Systems Ltd, North Somerset, UK) 
Pipettes:  Pipetman  (P10,  P20,  P200,  and  P1000)  supplied  by  Gilson  Medical 
Electronics (Villiers le Bel, France) 
Power  packs:  Electrophoresis  Power  Supply  EPS  500/400  (Pharmacia  Fine 
Chemicals, Uppsala, Sweden), and Power PAC 300 (Bio Rad, Hertfordshire, UK)  
Rotator: Spiramix 5 (Denley Instruments Ltd, England) Kamil K. Wolyniec, 2008     Chapter 2,70  
Semi dry electrophoretic transfer: Trans blot
® SD Semi Dry Transfer Cell (Bio 
Rad Hertfordshire, UK) 
Shaker:  Model  R100  Rotatest  Shaker  (Luckham,  England),  Stuart  SSL1  Orbital 
Shaker  (Bibby  Sterilin  Ltd,  Staffordshire,  UK),  and  Orbital  Shaker  (Bellco 
Biotechnology, New Jersey, USA) 
Spectrophotometer:  DU
®  640  Spectrophotometer  (Beckman,  California,  USA), 
Agilent 2100 Bioanalyzer (Agilent Technologies, Germany) 
Stirrer:  Magnetic  Stirrer  Hotplate  B212  (J.  Bibby  Science  Products  Limited, 
Staffordshire, England), and Stir SB161 (Stuart Scientific Laboratory, Surrey, UK) 
Thermo Block: Dri block
® DB 2A (Techne, Cambridge, UK) 
Ultraviolet trans illuminator: High Performance Ultraviolet Transluminator (UVP 
Ultra  Violet  Products,  San  Gabriel,  CA),  and  Geneflash  Syngene  Bio  Imaging 
(Fisher Scientific  Synoptics Ltd, UK) 
Vortex: WhirliMixer
TM (Fisons Scientific Equipment, Leicestershire, UK) 
Water baths: Grant, SBB6, and Y14 (Grant Instruments Ltd, Cambridge, England)  
2.1.9.2  Consumables 
Caterers foil (Morrisons, Anniesland, Glasgow) 
Eppendorf  tubes:  Flip top  0.5  ml  and  1.5  ml,  and  screw top  1.5  ml  (Elbkay 
Laboratory Products, Hampshire, UK), and Rnase free Microfuge Tubes (Ambion, 
Cambridgeshire, UK) 
Filter paper: Qualitative Circles 185 mm Ø (Whatman
®, Kent, England) 
Filter tip pipette tips: A range of capacities (10, 20, 200, 1000)  l supplied by 
Rainin Instrument Co (Woburn, MA); for use in setting up PCR reactions 
Fine Tip Pastette Sterile were supplied by Alpha Laboratories (Hampshire, UK) Kamil K. Wolyniec, 2008     Chapter 2,71  
Hybond
TM ECL  nitrocellulose  membrane  (Amersham  Biosciences, 
Buckingshamshire, UK) 
Hyperfilm ECL (Amersham Biosciences, Buckingshamshire, UK) 
Marvel Dried Skimmed Milk (Premier Beverages, Stafford, UK) 
Parafilm was supplied by Pechiney Plastic Packaging (Menasha WI) 
Petri dishes were supplied by Sterilin (Staffordshire, UK) 
Pipette tips were supplied by Sarstedt (Nümbrecht, Germany) 
Pipette tips RNAse  free: 1000  l and 200   l supplied by Starlab (Ahrensburg, 
Germany),  and  1   l  to  20   l  supplied  by  Elkay  Laboratory  Products  Ltd 
(Hampshire, England) 
Saran barrier food wrap (Morrisons, Anniesland, Glasgow) 
Scalpel blades: Sterile disposable scalpels (Schwann Morton , Sheffield, UK) 
Spreaders, L shaped were supplied by VWR International (Lutterworth, UK) 
Sterile  plastic  containers:  Bijoux  and  Universals  (Greiner  Bio One, 
Gloucestershire, UK) 
Syringes (2, 5, 10, 20, 50) ml were supplied by Becton Dickinson 
Syringe  filters  (0.2   m  and  0.45   m)  were  supplied  by  Sartorius  (Hannover, 
Germany); used for sterilising of filtering small volumes of solutions 
Vectashield Mounting Medium with DAPI (Vector Laboratories, Ltd) 
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2.1.10  Buffers and solutions  
Water 
Diethylpyrocarbonate (DEPC) treated RNAse free water was supplied by Ambion, 
Cambridgeshire,  UK.  Tissue  culture  grade  distilled  water  was  supplied  by 
Invitrogen  Life  Technologies.  Ultrapure  water  (for  procedures  involving 
recombinant  DNA,  PCR  etc.)  was  provided  by  a  Milli  Q
®  ultrapure  water 
purification system (Millipore Ltd., Watford, UK). An Elix
® purification system 
(Millipore Ltd., Watford, UK) was used to supply water for preparation of general 
solutions and media. 
Buffers and solutions 
10x Dry Blot Buffer: 0.5 M Tris base, 0.4 M Glycine, 12.8 mM Sodium Dodecyl 
Sulfate (SDS). Working stock was prepared prior to use at a 1:10 dilution with 
20% (v/v) Methanol. 
10x SDS-PAGE Running Buffer: 0.25 M Tris base, 1.92 M Glycine, 34.7 mM SDS 
10x TBE (Tris-borate-EDTA) Buffer Solution: 0.9 M Tris base, 0.9 M Boric acid,   
23 mM Na2EDTA.  pH 8.2/8.3.  Stored at room temperature. 
10x TBST (Tris-buffered-saline-tween) Buffer Solution: 0.1 M Tris base, 1.5 M 
NaCl, 0.5% Tween 20, adjusted to pH 8.0. 
10x Tris-glycine buffer for electrotransfer of proteins onto membranes (transfer 
buffer): 0.25 M Tris base, 1.92 M Glycine.  Working stock was prepared prior to 
use at a 1:10 dilution with 15% (v/v) Methanol. 
1M  Tris  HCl:  121  g  Tris  base,  800  ml  dH2O.    Adjusted  to  desired  pH  with 
concentrated HCl and made up to 1 L. 
1x Phosphate buffered saline (PBS): 140 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 
1.8 mM KH2PO4 (pH 7.3)  Kamil K. Wolyniec, 2008     Chapter 2,73  
20x Propidium iodide (PI) stock solution:  made to a working solution of 1 mg/ml 
with ddH2O in a fume cupboard.  This was filtered through a 0.22 mm syringe 
filter, and stored at 4 °C in the dark. 
50x TAE (Tris-acetate-EDTA) Buffer Solution: 2 M Tris base, 50 mM Na2EDTA,    1 
M glacial acetic acid. 
Ammonium persulphate: 10% (w/v) stock solution in ddH2O, freshly made. 
Ethidium bromide: made to a working solution of 3 mg/ml with ddH2O in a fume 
cupboard.  Stored at room temperature in the dark. 
Gel loading buffers: 
1.  DNA   30%  Glycerol,  0.25%  (w/v)  Bromophenol  blue,  0.25%  (w/v)  Xylene 
cyanol, in ddH2O.  Stored at room temperature and used at a 1:5 dilution. 
2. Protein  SDS PAGE Protein 2x Sample Loading Buffer: 120 mM Tris HCl, pH 6.8, 
20% (v/v) Glycerol, 5% SDS, 7.4% b mercaptoethanol, 0.5% (w/v) Bromophenol 
blue in ddH2O. Stored in aliquots at –20 °C. Sample diluted at least 1:2 with 
buffer and heated at 100 °C for 5 minutes prior to loading gel. 
PI Staining solution: 50  g/ml 20x PI stock solution, 100 U/ml Rnase A in sample 
buffer (1 g/l Glucose in PBS.  This was filtered through a 0.22 mm syringe filter, 
and stored at 4 °C) 
TE Buffer: 10 mM Tris HCl, 1 mM Na2EDTA adjusted to pH 8.0.  Autoclaved and 
stored at room temperature. 
Whole Cell Lysis Buffer (Marais et al  1993): 20 mM Hepes pH 7.0, 5 mM EDTA, 
10 mM EGTA, 5 mM NaF, 1 mM DTT, 0.4 M KCl, 0.4% (v/v) Triton X 100, 10% (v/v) 
Glycerol.  Stored in aliquots at –20 °C.  Working Whole Cell Extract buffer was 
prepared  prior  to  use  by  addition  of  0.1   g/ml  Okadaic  acid,  and  protease 
inhibitors as follows: 5  g/ml Aprotinin, 5  g/ml Leupeptin, 5  g/ml Pepstatin A, 
1 mM Benzamidine, 50  g/ml PMSF. Kamil K. Wolyniec, 2008     Chapter 2,74  
Mild stripping solution: prepared fresh by adding 20 ml 2M glycine pH 2.5, 20 ml 
10% SDS to 160 ml dH20  
Sringent sripping solution: 100mM 2 Mercaptoethanol, 2% SDS, and 62.5mM Tris 
HCl pH 6.7 
3.7% paraformaldehyde in PBS: prepared fresh from 16% solution obtained from 
Science Services Ltd) 
0.1 % Triton X-100 in PBS 
10% FBS (Fetal Bovine Serum), 0.5% BSA(Bovine Serum Albumin/) in PBS Kamil K. Wolyniec, 2008     Chapter 2,75  
2.2 Methods 
Many of the methods described here are based on standard protocols, which are 
found in several laboratory manuals (Sambrook et al 1989). 
2.2.1 Growth, manipulation of mammalian cells and cell assays 
All  procedures  involving  mammalian  cells were  carried  out  in  a  laminar  flow 
hood using standard aseptic procedures. 
2.2.1.1  Cryopreservation of cells 
Stocks of cells for long term storage were preserved over liquid nitrogen. Cells 
to  be  frozen  were  grown  to  confluence  and  removed  into  a  sterile  50  ml 
centrifuge tube (using 1x trypsin EDTA solution).  Cells were centrifuged at 1000 
rpm  for  5  minutes  and  the  supernatant  discarded.    The  cells  were  then  re 
suspended in freezing medium at a concentration of 2 4 x 10
6 cells/ml. Freezing 
medium consisted of the DMEM culture medium supplemented with FBS to 50% 
for MEFs, 20% for Hs68 cells and Leiden cells and 10% dimethylsulphoxide (DMSO, 
Sigma Aldrich) as a cryoprotectant. Phoenix cell were frozen down as advised in 
90% FBS and 10% DMSO. The cell suspension was transferred in one millilitre 
aliquots,  to  labelled  cryovials  (Nunc  cryotubes)  and  brought  to  –70  °C  at  a 
controlled  rate  of  –1  °C  per  minute  using  a  NALGENE™  Cryo  1  °C  Freezing 
container  (NALGENE,  USA).    The  vials  were  transferred  to  a  liquid  nitrogen 
freezer  for  long term  storage  after  24hs.  Cell  stocks  were  revived  by  rapid 
thawing in a 37 °C water bath and maintained following standard techniques 
(described below). 
2.2.1.2  Cell counting 
Cells were counted in a haemocytometer (Bright Line Hemacytometer, Sigma) as 
follows. Cell pellets were suspended in an appropriate volume of media to allow 
ease of counting in the haemocytometer chamber. A 10  l volume of the cell 
suspension  was  then  diluted  1:1  in  trypan  blue  stain  0.4%  (Invitrogen  Life 
Technologies) and incubated at room temperature for 1 minute. The suspension 
was  then  introduced  to  the  haemocytometer  chamber  and  cell  counts  made Kamil K. Wolyniec, 2008     Chapter 2,76  
using an inverted microscope with a 4x or 10x objective. Cells lying on the top 
and right hand perimeter of each large square (1 mm) were included; those on 
the  bottom  or  left  hand  perimeters  were  excluded.  Cell  concentrations 
(cells/ml) were calculated by multiplying the mean numbers of cells per large 
marked square by 2 x 10
4 to account for the volume of the haemocytometer 
chamber and to correct for the dilution factor. Dead cells were differentiated by 
uptake of the trypan blue stain. 
2.2.1.3  Maintenance of mammalian adherent cell lines 
All cell lines (MEF, Hs68, Leiden, Phoenix) form adherent monolayers in culture, 
and were cultured in 75 cm
2, 162 cm
2 tissue culture flasks or 100mm cell culture 
dishes kept at 37 °C in a humidified incubator containing 5% (v/v) CO2.  Cells 
were cultured in 20 ml, 50 ml or 10 ml DMEM (Section 2.1.2.2) supplemented 
with 10% FBS, 100 international units (IU)/ml penicillin, 100  g/ml streptomycin, 
and 2 mM glutamine. Cultures were passaged, every 3 4 days, when they have 
reached  approximately  80%  of  confluence.  To  split  cultures  the  medium  was 
decanted from the cell monolayer and cells washed with 10 ml of warm PBS.  
Then, 3 ml to 5 ml of 1x trypsin EDTA solution was added, cells were incubated 
at  37 °C for 5 to 15 minutes and observed by microscopy to ensure cell layer 
dispersal. The detached cells were then washed in fresh medium, pelleted by 
centrifugation at 1000 rpm for 5 minutes, prior to resuspending in fresh medium 
and seeding new tissue culture flasks. 
2.2.1.4  Retroviral transduction 
Phoenix cells were plated at 5 x 10
6 in 10 cm dishes and incubated overnight at 
37°C.  Transfections  of  Phoenix  cells  with  relevant  retroviral  plasmids  were 
performed  using  Superfect  Transfection  Reagent  (Qiagen)  according  to  the 
manufacturer's  protocol  for  transient  transfection  of  adherent  cells.  Viral 
supernatants were harvested after 48 h incubation at 37°C and filtered through 
0.45 mm filters (Sartorius). The media was replaced and the cells incubated for a 
further  24  h  before  retrieval  of  a  second  viral  supernatant.  Each  10  ml  of 
supernatant was supplemented with 4mg/ml polybrene and split between two 10 
mm plates of target cells plated at 8 x 10
5 per dish 24 h earlier. Cells were 
incubated with the appropriate first harvested supernatant overnight and with Kamil K. Wolyniec, 2008     Chapter 2,77  
the second harvested supernatant during the day for 8 h. Infected cells were 
then incubated overnight in normal growth medium after which selection was 
applied  using  puromycin  (Sigma)  at  2ug/ml  for  4  days.  The  efficacy  of  the 
selection protocol was confirmed using untransduced cells which all died under 
these selection conditions. Following selection (designated day 0), transduced 
cells  were  replated  for  experimental  purposes.  Puromycin  selection  was 
maintained throughout. 
2.2.1.5  Growth curves 
MEFs were plated at day 0 (day following 4 days of puromycin selection) at 2.5 x 
10
4/well  in  12  well  plates  in  selection  DMEM  medium  containing  2mg/ml 
puromycin  (2ml/well).  Live  cell  counts  were  carried  out  in  triplicate  using  a 
haemocytometer and trypan blue exclusion to assess  viability. Media changes 
were  carried  out  every  3 4  days.  Graphs  were  plotted  using  Sigma  plot  and 
significance values determined by Student’s t test. Error bars relate to standard 
deviations. 
2.2.1.6  Senescence-Associated-β-galactosidase 
SA β gal activity was detected as previously described (Serrano et al., 1997). 
Cells were washed once with PBS (pH 7.2), fixed with 0.5% glutaraldehyde (PBS 
pH 7.2) and washed in PBS (pH 7.2) supplemented with 1mM MgCl2. Cells were 
stained in X Gal solution (1mg/ml [Invitrogen], 0.12 mM  K3Fe[CN]6 and K4[Fe]CN6 
and 1mM MgCl2 in PBS at ph 6.0) overnight at 37°C. 
2.2.1.7  Cell cycle analysis 
Hs68s plated at 1 x 10
6 cells/10cm dish were sampled for flow cytometry on day 
7  post selection.  The  protocol  for  cell  cycle  analysis  has  been  described 
previously (Blyth et al 2006). For simultaneous labelling with bromodeoxyuridine 
(BrdUrd), cells were incubated at 37
oC for 3 hours with 10 M BrdUrd (Sigma) 
then  rinsed  three  times  in  warmed  PBS.  After  harvesting,  cells  (10
6  )  were 
washed in 2ml cold PBS, resuspended in 0.2ml cold PBS and fixed for at least 30 
minutes in 2mls 70% ethanol at 4
oC.  BrdUrd incorporation was identified using 
FITC conjugated  anti BrdUrd  antibody  (In  situ  Cell  Proliferation  Kit,  Roche) 
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containing 10 g/ml PI and analysed on a Beckman Coulter Epics XL.  The analysis 
was performed using EXPO32 software 
2.2.1.8  Analysis of intracellular ROS 
To  assess  the  generation  of  intracellular  ROS  levels  at  day  7  of  cell  culture 
period, cells were incubated for 20 min in the dark at 37
oC with 15 m DCF DA 
(Calbiochem). Then cells were washed in PBS, trypsinised and DCF fluorescence 
was measured using a flow cytometer (Beckman Coulter Epics XL) with excitation 
at 488 nm and emission at 530 nm 
2.2.1.9  Visulisation of ROS by confocal laser microscopy 
Cell were grown on plated on poly L lysine coated glass chamber slides (Section 
2.1.2.4) and at day 7 of cell culture period were incubated for 20 min in the 
dark at 37
oC with 15 m DCF DA (Calbiochem). Then cell were washed in PBS and 
fixed with freshly prepared 4% paraformaldehyde (in PBS) for 10 minutes and 
subsequently coverslips were mounted in glycerol mixed with water (1:1). DCF 
fluorescence  was  detected  using  a  FITC  filter  and  fluorescent  images  were 
captured using a confocal microscope (Leica DM IRE2) (Section 2.1.9.1) 
2.2.2 Recombinant DNA techniques 
2.2.2.1  Storage and growth of bacteria 
Plasmid DNA was maintained and stored in the E.coli strain One Shot Chemically 
Competent cells
®. Glycerol stocks were prepared from transformed bacteria and 
their long term storage as outlined below. 
The desired bacterial culture was streaked onto a LB agar plate (Section 2.1.3.4) 
as the plasmid conferred ampicillin resistance the medium was supplemented 
with 100  g/ml ampicillin. The plate was then incubated overnight at 37 °C and 
the following day single colonies were picked using a sterile pipette tip into a 
sterile  universal  containing  5  ml  LB  medium  supplemented  with  100   g/ml 
ampicillin. Cultures were incubated at 37 °C overnight in a horizontal orbital 
incubator at 220 rpm. Confirmation that overnight cultures were derived from 
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restriction digestion.  Glycerol stocks were prepared by addition of 150  l of 
glycerol to 850  l of culture broth to produce a 15% glycerol mixture. Glycerol 
stocks were then stored at –70 °C.  Bacterial stocks were revived for subsequent 
work by using a sterile platinum loop dipped into the glycerol stock and streaked 
onto an agar plate as outlined above. 
2.2.2.2  Extraction and purification of plasmid DNA 
Small scale plasmid preparation 
Plasmid DNA was isolated using a modification of the alkaline lysis technique 
described by Birnboim and Doly (Birnboim and Doly 1979). 
Large scale plasmid preparation 
Large quantities of highly pure, endotoxin free plasmid were prepared using the 
EndoFree
® Plasmid Maxi Kit (Qiagen,UK). 50  l of glycerol stock from the desired 
transformant was used to seed an overnight multiplier culture in 100 ml of LB 
medium incubated at 37°C with shaking at 220 rpm. These exponentially growing 
bacteria  were  harvested  by  centrifugation  of  the  culture  in  50  ml  sterile 
centrifuge tubes at 4000 g for 20 minutes at 4°C. The remainder of the protocol 
was performed according to the manufacturers instructions. DNA was stored at –
20°C. 
2.2.2.3  Determination  of  nucleic  acid  concentration  and 
quality 
Determination by spectrophotometry 
Nucleic  acid  samples  were  diluted  either  at  1:20  by  addition  of  25   l  of 
resuspended nucleic acid in 475  l of dH2O, or 1:100 by addition of 5  l of the 
resuspended nucleic acid in 495  l of dH2O. Optical density readings were taken 
at 260 nm and 280 nm, using dH2O as a blank. An optical density reading of 1.0 
at 260 nm corresponds to an approximate nucleic acid concentration of 50  g/ml 
for double stranded (ds) DNA and 40  g/ml for single stranded (ss) RNA. The 
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an estimate of the purity of the nucleic acid. Pure preparations of DNA and RNA 
have  an  OD260/OD280  of  1.8  and  2.0  respectively;  a  lower  value  suggests 
contamination, typically with protein or phenol. 
Estimation of double stranded DNA concentration and quality by agarose gel 
electrophoresis. 
This  method  was  used  when  there  were  insufficient  amounts  of  dsDNA  for 
spectrophotometry, or when purity of a particular DNA fragment needed to be 
investigated. The concentration of dsDNA was determined by running the sample 
on  an  agarose  gel  electrophoresis  (Section  2.2.3.5),  and  the  intensity  of  the 
fluorescence of the unknown DNA was compared to that of a known quantity of 
the appropriate size marker (fX174 RF DNA/HaeIII fragments or Low DNA Mass™ 
Ladder)  following  staining  with  ethidium  bromide  and  visualisation  by  UV 
transillumination. Smearing of a DNA band indicated degradation of the sample 
and resulted in exclusion of that DNA from further analysis. 
2.2.2.4  Restriction endonuclease digestion 
Typically,  1  mg  of  DNA  was  digested  in  a  20  ml  reaction  mix  containing  the 
appropriate buffer for the restriction endonuclease(s) and 10 units of the desired 
restriction enzyme. The reactions were incubated at 37 °C for a minimum of 1 
hour.  Where  the  isolation  of  restriction  fragments  was  required,  larger 
quantities of DNA, generally 10 mg, were digested with 50 units of enzyme, and 
the  reaction  volume  and  others  components  increased  proportionally.  In  this 
case, reactions were incubated at 37 °C overnight. 
2.2.2.5  Electrophoresis of DNA 
Agarose gel electrophoresis 
DNA fragments of 1.0 kb to 10 kb were separated by agarose gel electrophoresis 
using  a  Biomax  QS710  Horizontal  Unit  (Scientific  Imaging  Systems  –  Eastman 
Kodak Company, New York, USA) or Sub Cell GT Submerged Horizontal Agarose 
Gel Electrophoresis Systems (Bio Rad, Hertfordshire, UK).  Typically, 0.6 g to 0.9 
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melted in a microwave for 1 minute to 2 minutes and mixed to produce a 1% to 
1.5% gel (w/v).  Once the gel mix had cooled to 55 °C, the gel was poured into a 
100 mm x 65 mm or 150 mm x 200 mm gel support in its casting tray and an 
appropriate  gel  comb  (eight,  twelve  or  twenty  well)  inserted.  The  gel  was 
allowed to solidify before transferring to an electrophoresis tank; the gel was 
immersed  in  1x  TBE  or  1x  TAE  buffer  and  the  comb  carefully  removed.  Gel 
loading buffer (Section 2.1.1) was added to DNA samples and samples loaded 
into the wells using a micropipette. Known concentrations of DNA size markers 
were prepared similarly and run alongside the samples in order to gauge both 
product size and yield.  Gels were run at 100 volts for 60 to 120 minutes, then 
removed from the gel apparatus and stained in buffer solution containing 0.5 
mg/ml ethidium bromide for 20 minutes. Following destaining for 20 minutes in 
dH2O, gels were visualised on a medium wave UV transilluminator (UVP Inc. and 
Geneflash Syngene Bio Imaging) and photographed using black and white Video 
Graphic Printer Sony UP 895MD (Fisher Scientific  Synoptics Ltd, UK). 
2.2.2.6  Purification of restriction enzyme fragments 
Purification  of  the  DNA  fragments  required  for  construction  of  recombinant 
plasmids was purified from agarose gels using the QIAquick
® Gel Extraction Kit 
(Qiagen). The DNA fragments of interest were cut from an agarose gel using a 
clean scalpel blade and extracted according to the manufacturers instructions. 
2.2.2.7  Subcloning  the  cDNAs  of  RUNX1  mutants  (K83N, 
T161A), TEL-RUNX1 and AML1a 
Preperation of relevant inserts 
Inserts containing cDNAs of RUNX1 mutants (K83N and T161A) were excised from 
the  pGFP  retroviral  vectors  (kind  gift  from  Dr.  Carol  Stocking,  Hamburg)  by 
digestion  with  NotI.  After  fragment  separation  and  purification  by 
electrophoresis  on  1%  Agarose  TBE  gel,  the  NotI  restriction  fragments  were 
extracted using the QIAquick Gel Extraction Kit (Qiagen) (Section 1.2.2.6) and 
suspended in 30 l of TE buffer. The overhanging 5’ ends (NotI) of the obtained 
fragments  were  blunt  ended  using  a  Klenow  Fill in  Kit  (Klenow)  according  to 
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The cDNA insert of TEL RUNX1 was excised from pcDNA3 vector (kindly provided 
by Dr. Olivier Bernard, Paris), by digestion with EcoRI. After fragment separation 
and purification by electrophoresis on 1% Agarose TBE gel, the EcoRI restriction 
fragments  were  extracted  using  the  QIAquick  Gel  Extraction  Kit  (Qiagen) 
(Section 1.2.2.6) and suspended in 30 l of TE buffer 
The  cDNA  insert  of  AML1a  was  excised  from  pCR
®II TOPO
®  by  digestion  with 
EcoRI  (The  AML1a  DNA  had  been  previously  PCR  amplified  from  thymus  and 
cloned  into  EcoRI  site  using  Invitrogen  TOPO  TA  Cloning
®  kit  by  Dr.  Monica 
Stewart  from  this  laboratory).  After  fragment  separation  and  purification  by 
electrophoresis  on  1%  Agarose  TBE  gel,  the  EcoRI  restriction  fragments  were 
extracted using the QIAquick Gel Extraction Kit (Qiagen) (2.1.4) and suspended 
in 30 l of TE buffer 
Ligation of vector and insert DNA 
The  quantity  of  vector  and  insert  DNA  used  in  ligations  was  calculated  to 
produce a molar ratio between 1:3 using the equation: 
X ng of vector x Y kb of insert x insert : vector ratio = ng of insert required Z kb 
of vector 
Vector DNA (pBabe puro) was linearised using appropriate restriction enzyme(s). 
For the blunt end cloning of K83N and T161A RUNX1 mutants pBabe puro was cut 
with SnaBI whereas for cloning of AML1a and TEL RUNX1 pBabe puro was cut 
with EcoRI. To prevent re circularisation of the vector DNA following digestion 
with a single enzyme, both 5’ phosphate groups were dephosporylated with  5 
units  of  antarctic  phosphatase  according  to  the  manufacturer  protocol  (New 
England Biolabs) at 37 °C for 15 minutes. Generally, 50 ng of vector DNA and a 
three fold molar excess of insert DNA were ligated, using Quick Ligation
TM Kit 
(New England Biolabs) according to manufacturer protocol. A control ligation, 
omitting insert DNA was set up in parallel to the above, in order to check for 
‘background’ when performing subsequent bacterial transformations. 
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Transformation of bacteria with plasmid DNA 
All transformations included a positive control using supercoiled plasmid DNA (eg 
pUC19 10 pg/ml) to monitor the efficiency of the transforming bacteria and a 
ligation  control  (vector  DNA,  no  insert)  to  monitor  the  background  rate  of 
transformation due to recircularisation of vector DNA. 
2  l of a 1:5 dilution of ligation mix, 2  l of neat ligation mix or 2  l of TA 
ligation mix were added to 50  l of One Shot
ÒTOP10 Chemically Competent E. 
coli  cells  (Invitrogen).  Cells  and  DNA  were  mixed  by  gentle  tapping  to  avoid 
damage to the bacterial cells. In all cases the reactions were then incubated on 
ice for 30 minutes. Cells transformed with ligation mix were subsequently heat 
shocked at 42 °C for exactly 40 seconds and 30 seconds respectively, and then 
returned  to  ice.  250   l  of  SOC  medium  (Invitrogen)  was  then  added  and 
incubated at 37 °C for 1 hour with shaking at 220 rpm. Cells (50 ml and 200 ml) 
were  plated  onto  LB  plates  containing  100   g/ml  ampicillin.  Plates  were 
incubated overnight at 37 °C. 
Screening for transformants with the right orientation of insert 
All plasmid strains used in this project conferred ampicillin resistance, allowing 
selection  and  maintenance  of  transformed  bacteria  with  ampicillin 
supplemented media. 
The  DNA  from  10 20  clones  was  prepared  and  used  for  restriction  fragment 
length polymorphism analysis to find clones with the appropriate orientation of 
insert. SalI restriction analysis were performed for K83N and T161A mutants of 
RUNX1 and HindIII restriction analysis for TEL RUNX1 and AML1a.  
2.2.3 DNA sequence analysis (automated sequencing) 
2.2.3.1  Sample preparation 
DNA sequencing was carried out using the Big Dye
® Terminator Version 1.1 Cycle 
Sequencing  Kit  (Applied  Biosystems).  Generally,  200  ng  to  500  ng  of  highly 
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3.2 pmol of sequencing primers (Table 2), 0.5x sequencing buffer (80 mM Tris 
HCl, 2 mM MgCl2) and 4  l of cycle sequencing mix (Big Dye
® Terminator Version 
1.1 Cycle Sequencing Kit, Applied Biosystems). Samples were prepared in the 
PTC 220  DNA  Engine  Dyad
®  Cycler  (MJ  Research  Incorporated)  employing  25 
cycles of amplification, each cycle consisting of a denaturing step at 96 °C for 30 
seconds  followed  by  an  annealing  step  at  50  °C  for  15  seconds,  and  an 
elongation phase at 60 °C for 4 minutes. Sequencing products were purified by 
precipitation using ethanol (80%) at room temperature for 15 minutes. Pelleted 
DNA (14000 rpm for 20 minutes) was washed in ethanol (70%) and repelleted 
(14000 rpm for 10 minutes). After all the ethanol was removed, the pellet was 
dried at 90 °C for 1 minute, and was subsequently resuspended in 25  l of Hi Di 
Formamide (Applied Biosystems). 
2.2.3.2  Sample sequencing and evaluation 
Samples were loaded into 96 well plates and run on the ABI PRISM
® 3100 Genetic 
Analyzer (PE Applied Biosystems, UK) under standard sequencing conditions for 
generation of automated sequence data. Electrophoresis on the ABI PRISM
® 3100 
Genetic Analyzer was performed using 36 cm and 80 cm capillaries which read 
up to 500 nucleotides and 950 nucleotides respectively, with a 98.5% base calling 
accuracy and less than 2% ambiguity. A computational software ClustalW was 
used for sequence alignments (http://www.ncbi.nlm.nih.gov/) 
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Table 2. Sequencing primers. 
Primer 
name 
Primer sequence  Description 
pBabe 5’  5’d[CTTTATCCAGCCCTCAC]3’  Forward sequencing 
primer  from  pBabe 
puro vector 
pBabe 3’  5’d[ACCCTAACTGACACACATTCC]3’  Reverse  sequencing 
primer  from  pBabe 
puro vector 
Runx1 xd5  5’d[GCAGAAACTAGATGATCAGACC]3’  Forward sequencing 
primer from exon 5 
of Runx1 
Runx1 xd3  5’d[CCTCAAAGTCAGATGCAG]3’  Reverse  sequencing 
primer from exon 5 
of Runx1 
2.2.4 Protein analysis 
2.2.4.1  Protein extraction 
Whole  cell  extracts,  from  cells  grown  in  tissue  culture  were  prepared  for 
western blot analysis according to the method of Marais et al (Marais et al 1993).  
All procedures were performed at 4 °C. Typically, cells were washed twice with 
ice cold PBS, drained thoroughly, lysed in 100  l working whole cell lysis buffer 
(Section 2.1.10) per 10
6 cells or 60 mm dish and rotated for 10 minutes.  The 
crude extract was cleared in a bench top centrifuge at 14000 rpm for 30 minutes 
and the supernatant transferred to a fresh pre cooled eppendorf.  Extracts were 
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2.2.4.2  Estimation of protein concentration 
In order to estimate protein yields, a Bio Rad Protein Assay (Bio Rad), based on 
the method of Bradford was used, in which a differential colour change of a dye 
occurs in response to various concentrations of protein (Bradford 1976). 
A  protein  standard  (bovine  serum  albumin,  BSA)  was  diluted  with  dH2O  to 
concentrations ranging from 0.025 to 0.8 mg/ml to allow the production of a 
standard  curve  each  time  the  assay  was  performed.    Aliquots  of  protein  for 
quantification were diluted in order to give a concentration in the above range.  
The dye reagent was prepared by addition of 4 volumes of ddH2O to 1 volume of 
Dye  Reagent  Concentrate  (Bio Rad)  and  filtration  through  a  Whatman  #1  to 
remove particulates. Samples were diluted 1/500 in diluted dye reagent, and 
incubated in sterile polystyrene cuvettes at room temperature for 5 minutes to 1 
hour. OD595 was determined against the reagent blank. The absorbance of the 
protein  standards  was  used  to  construct  a  standard  curve  from  which  an 
approximate concentration of the unknown samples could be read. 
2.2.4.3  SDS - PAGE of proteins 
The  separation  and  analysis  of  proteins  was  facilitated  by  one  dimensional 
denaturing discontinuous gel electrophoresis, as originally described by Laemmli 
(Laemmli, 1970). 
Standard SDS PAGE gels (13.8 cm x 13 cm) were formed and run using the AE 
6200  Slab  EP  Chamber,  and  AE 6220  Slab  EP  Chamber,  for  two  gels  (Atto 
Incorporation). The separating gel was poured to a depth of approximately 10 
cm; consisting of 16.7 ml 30%: 0.8% w/v acrylamide/bisacrylamide (giving a 10% 
gel), 13.4 ml dH2O, 18.75 ml 1 M Tris HCl (pH 8.8), 500  l 10% SDS, 375  l 10% 
APS  and  20  ml  TEMED.  This  was  overlain  with  ddH2O saturated  butanol  and 
allowed to polymerise.  The butanol was then poured off and the surface of the 
separating gel rinsed with ddH2O. Excess water was removed with a sheet of 
3mm Whatman filter paper, and the stacking gel poured; consisting of 3.4 ml 
30%: 0.8% w/v acrylamide/bisacrylamide, 13.6 ml dH2O, 2.5 ml 1 M Tris HCl (pH 
6.8), 200  l 10% SDS, 200  l 10% APS and 20 ml TEMED. A 14 well comb was 
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and samples were treated as for mini SDS PAGE gels (see above). Moreover, 14 ml 
of a protein molecular weight standard (Precision Plus Protein
TM Standards, Bio 
Rad) was loaded in one or both outer wells to allow estimation of the size of 
sample proteins. 
Standard SDS PAGE gels were electrophoresed 230 volts to 250 volts for 2 3 hours 
until the bromophenol blue dye reached the bottom of the separating gel. The 
gel was then removed from the glass plates, the stacking gel discarded, and the 
protein bands detected by immunodetection (Section 2.2.4.5). 
2.2.4.4  Electroblotting 
After polyacrylamide resolving gel electrophoresis proteins were transferred to a 
nitrocellulose membrane by electroblotting: 
Standard SDS PAGE gels were removed from the glass plates, and the resolving 
gel equilibrated in 1x dry blot buffer with 20% methanol (Section 2.1.10) for 15 
minutes at room temperature.  The gel was covered in pre wetted nitrocellulose 
membrane (1x dry blot buffer) and sandwiched between 12 pieces of Whatman 
3MM rinsed in 1x dry blot buffer.  The sandwich was turned over and placed on 
the  semi  dry  blotter  (Trans blot
®  SD  Semi Dry  Transfer  Cell,  Bio Rad).  Air 
bubbles were removed and transfer effected at 20 volts for 2 hours.  Molecular 
weight marker positions were highlighted and the membrane stored at 4 °C. 
2.2.4.5  ECL detection 
The detection of proteins by immunoblotting (Western Blotting) is a rapid and 
sensitive technique that exploits the inherent specificity of antigen recognition 
by antibodies (Towbin et al 1979):  
Hybond ECL nitrocellulose membrane (Amersham Biosciences) was immersed in 
1x  TBST  buffer  (Section  2.1.10)  containing  5%  low  fat  dried  milk  (Marvel    
Premier  Beverages,  Stafford,  UK)  and  left  overnight  at  4  °C,  to  block  non 
specific binding sites. The membrane was rinsed briefly with 1x TBST buffer, 
washed once for 15 minutes, and then twice for 10 minutes, with shaking at 
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antibody, at a pre determined dilution in blocking buffer (either 5% low fat dried 
milk TBST or, 5%BSA TBST), with shaking. This was followed by washing three 
times in 1x TBST buffer for 10 minutes, with shaking at room temperature, prior 
to incubating with secondary antibody (HRP labelled), appropriately diluted in 
5% low fat dried milk TBST, for 1 hour, at room temperature, with shaking. The 
membrane  was  washed  as  above  before  detection  using  the  ECL
TM  Western 
Blotting  Detection  Reagents  (Amersham  Biosciences).  The  Enhanced 
Chemiluminescence system (ECL) is a light emitting non radioactive method for 
detecting  immobilized  specific  primary  antibodies  using  secondary  antibodies 
conjugated with horseradish peroxidase (HPR linked secondary antibodies). Light 
emission is generated by the HPR/hydrogen peroxide catalysis of luminal to an 
excited oxidated state, and it is dramatically enhanced in the ECL system by 
chemical enhancers such as phenol (Durrant et al 1990). Briefly, an equal volume 
of detection reagent A was mixed with reagent B (typically 4 ml each). Excess 
buffer was drained from the membrane and the detection solution was pipetted 
onto the surface of the membrane to which the protein are bound. After 2 5 
minutes incubation at room temperature, excess reagent was drained from the 
membrane, which was then wrapped in plastic film. The membrane was exposed 
to  blue light  sensitive  autoradiography  film  (Hyperfilm  ECL,  Amersham 
Biosciences) for seconds or minutes, before developing the film in an automated 
processor (SRX 101A Compact X4, Xograph Imaging Systems). 
2.2.4.6  Stripping membranes 
Antibodies  and  substrate  complexes  could  be  removed  from  the  membranes 
allowing  for  reprobing  of  the  same  blot  with  different  antibodies.  The 
membranes  were  stripped  by  submerging  in  either  mild  stripping  buffer  or 
stringent stripping buffer (Section 2.1.10), and incubating at room temperature 
for 1h or at 50˚C for 30 minutes with agitation. Following this incubation the 
membranes  were  washed  three  times  for  10  minutes  with  PBS  at  room 
temperature, and blocked overnight in 5% milk TBST, before adding the desired 
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2.2.5 Confocal laser scanning microscopy 
Cells were plated on poly L lysine coated glass chamber slides (Section 2.1.2.4) 
and fixed for 15 min with freshly prepared 4% paraformaldehyde (in PBS). After 
washing with PBS, cells were permeabilized for 15 min with PBST (PBS with 0.1% 
Triton X 100). The specimens were blocked with 10% FCS, 0.5% BSA in PBS for 30 
min and incubated overnight in 4°C with a relevant primary antibody diluted in 
blocking buffer. After washing x3 in 10% FCS, 0.5% BSA in PBS, cells were stained 
with  FITC conjugated  secondary  antibody  (1:100,  Jackson  Immuno  Research 
Laboratories) (Section 2.1.1) for 45 min at room temperature. Finally, cells were 
washed 3x in PBS and coverslips were mounted in VectaShield containing DAPI 
(4’,  6’ diamidino 2 phenylindole)  (Vector  Laboratories)  (Section  2.1.9.2). 
Fluorescent images were captured using a confocal microscope (Leica DM IRE2) 
(Section 2.1.9.1) 
2.2.6 Statistical significance  
Statistical  significance  for  the  data  presented  in  this  thesis  was  typically 
calculated  using  a  Students T test  to  give  a  significance  value  (p).  This  was 
carried  out  using  Sigma  Plot  Software  (T test  function).  The  cut  off  for  all 
experiments was taken as 0.05, therefore if two sets of data return a p value of 
<0.05 there is a less than 5% chance that the result observed is due to chance, 
and the two groups are therefore statistically significantly different 90 
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3  Structural  requirements  for  RUNX1  induced 
senescence 
3.1 Introduction 
Previous work in this laboratory established that RUNX1 induces senescence in 
primary  murine  embryonic  fibroblasts  (MEFs)  (Wotton  et  al  2004),  but  the 
structural components of RUNX1 necessary to effect this cellular response have 
not  been  examined.  To  investigate  this  question  various  mutated  or  deleted 
forms  of  RUNX1  were  used  to  dissect  out  which  functional  domains  were 
required  for  the  induction  of  premature  senescence  by  RUNX1.  It  was  also 
important to investigate whether RUNX1 retains potential to induce premature 
senescence in human primary fibroblasts and hence if it can be regarded as a 
universal phenomenon caused by ectopic expression of RUNX1. 
3.2 RUNX1 requires DNA binding and CBFβ interaction to 
induce senescence in murine embryonic fibroblasts 
To test whether RUNX1 binding to DNA and heterodimerisation with CBFβ are 
required  for  the  induction  of  premature  senescence,  two  mutated  forms  of 
RUNX1 were used in the MEF system. The DNA binding mutant of RUNX1 (K83N), 
which  was  identified  in  a  retrospective  genetic  study  of  patients  with 
myeloblastic  leukaemias  (Matheny  et  al  2007;  Osato  et  al  1999)  and  another 
point mutant, T161A, which was reported to be defective in  heterodimerization 
with CBFβ (Matheny et al 2007; Zhang et al 2003b), MEFs were transduced with 
these mutants of RUNX1 (K83N and T161A), wild type RUNX1 or the empty vector 
(here also referred to as pBabe) via retroviral mediated gene transfer. Following 
infection, cells were kept under puromycin selection for 4 days from which point 
(day 0) monitoring of their proliferative properties using viable cell counts was 
started.  All  the  proteins  were  expressed  at  similar  levels  as  determined  by 
Western  blot  (Figure  3.1a).  As  previously  reported  MEFs  expressing  RUNX1 
displayed  obvious  growth  suppression  immediately  after  selection  (pBabe  vs 
RUNX1  day  10  p≤0.00005)  (Figure  3.1b).  RUNX1  mediated  growth  arrest  was Kamil K. Wolyniec, 2008     Chapter 3,92  
accompanied  by  morphological  alterations  indicative  of  cellular  senescence 
whereby most cells carrying RUNX1 became flat and enlarged between day 2 and 
4 of the culture period. Senescence associated b galactosidase (SA b Gal) was 
detected  at  day  7  in  virtually  every  cell  (Figure  3.1c).  By  contrast,  cells 
expressing  the  mutants  of  RUNX1  continued  to  proliferate  although  not  as 
rapidly as empty vector control cells (K83N vs RUNX1 day 10 p≤0.00005; T161A vs 
RUNX1  day  10  p≤0.005)  (Figure  3.1b).  Furthermore,  they  displayed  no 
morphological  changes  and  expressed  no  SA b Gal  (Figure  3.1c).  The  puro 
controls  and  cultures  expressing  the  mutants  of  RUNX1  reached  high  cell 
densities  and  showed  some  background  SA b Gal  staining  but  this  was  not 
associated with single cells and was not as intense as the specific intracellular 
staining seen in large, flattened senescent cells. Indeed it has been previously 
reported  that  cellular  stress,  unrelated  to  senescence  such  as  high  levels  of 
confluency in culture can cause positive SA b Gal reaction (Severino et al 2000). Kamil K. Wolyniec, 2008     Chapter 3,93  
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Figure 3.1 DNA (K83N) and CBFβ (T161A) binding mutants of RUNX1 fail to 
induce senescence-like growth arrest in murine embryonic fibroblasts 
Cells were transduced with retroviral vectors expressing RUNX1, K83N, T161A or 
control vector (pBabe) and selected for 4 days in puromycin. (a) The expression 
of  RUNX1  was  measured  by  immunoblotting  lysates  from  MEFs  containing  an 
empty vector (pB), RUNX1 (RX) or RUNX1 mutants (K83N and T161A) on day 7 
post selection  using  anti AML1/Runx1  (3900,  Active  Motif)  (b)  Representative 
growth  curves  showing  viable  cell  numbers  corresponding  to  cell  populations 
containing control vector (pBabe), RUNX1, K83N or T161A. Each experiment was 
performed three times and each time point was determined in triplicate 
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Figure 3.1 continued 
(c) SA-β-Gal staining of cells containing control vector (pBabe), RUNX1, K83N or 
T161A (day 7 post-selection) 
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3.3 RUNX1 requires DNA binding and CBFβ interaction to 
induce senescence in human primary fibroblasts 
Fundamental differences in the requirements for the senescence phenotype in 
mouse and human cells have been reported (Itahana et al 2004; Campisi, 2005), 
therefore  it was important to address the  question  of whether the ability of 
RUNX1 to induce premature senescence could be recapitulated in human cells, 
indicating  a  general  feature  of  RUNX1  overexpression.  To  address  this  issue, 
Hs68  human  neonatal  foreskin  fibroblasts  expressing  the  ecotropic  murine 
leukaemia virus receptor were employed (Brookes et al 2002). This enabled the 
same retroviral system as for murine cells to be used. Hs68 cells were infected 
with retroviruses containing RUNX1, the mutants (K83N and T161A) or control 
vector (pBabe) and selected with puromycin. Western blotting confirmed that all 
the  introduced  constructs  were  expressed  at  similar  levels  (Figure  3.2a). 
Interestingly, it also revealed that the endogenous RUNX1 levels in these cells 
were quite high and could be readily detected in control vector expressing cells 
(Figure  3.2a).  Ectopic  expression  of  RUNX1  in  human  neonatal  foreskin 
fibroblasts resulted in a growth arrest as determined by analysis of growth curve 
data (pBabe vs RUNX1 day 9 p≤0.0001) (Figure 3.2b) and SA b Gal staining was 
detected  by  day  7  (Figure  3.2c).  These  cells  were  enlarged  and  flattened, 
although  not  to  the  same  extent  as  was  observed  in  murine  cells.  The  two 
mutants of RUNX1 failed to cause a proliferative arrest (K83N vs RUNX1 day 9 
p≤0.0005; T161A vs RUNX1 day 9 p≤ 0.005) (Figure 2b) and did not induce SA b 
Gal activity nor any change to the enlarged and flattened cellular morphology 
characteristic  of  senescence  (Figure  3.2c).  These  results  indicate  that  high 
affinity binding to DNA is absolutely critical for RUNX1 to elicit the senescence 
response  in  human  cells.  However  unlike  in  the  primary  mouse  cells,  Hs68 
expressing T161A mutant did not proliferate as well as K83N mutant (K83N vs 
T161A day 9 p≤0.005) (Figure 3.2b) despite similar levels of expression (Figure 
3.2a) 
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Figure 3.2 The ability of RUNX1 to induce senescence-like growth arrest in 
human neonatal foreskin fibroblasts is impaired in K83N and T161A mutants 
Cells were transduced with retroviral vectors expressing RUNX1, K83N, T161A or 
control vector (pBabe) and selected for 4 days in puromycin. (a) The expression 
of RUNX1 was measured by immunoblotting lysates from Hs68 cells containing 
empty vector (pB), RUNX1 (RX) or RUNX1 mutants (K83N and T161A) on day 7 
post selection  using  anti AML1/Runx1  (3900,  Active  Motif)  (b)  Representative 
growth  curves  showing  viable  cell  numbers  corresponding  to  cell  populations 
containing control vector (pBabe), RUNX1, K83N or T161A. Each experiment was 
performed three times and each time point was determined in triplicate 
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Figure 3.2 continued 
 (c) SA-β-Gal staining of cells containing control vector (pBabe), RUNX1, K83N or 
T161A (day 7 post-selection) 
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3.4 The  C-terminal  transcriptional  activation/repression 
domain  of  RUNX1  is  essential  for  induction  of 
senescence in human primary fibroblasts 
AML1a is a short isoform of RUNX1 (250 amino acids), with a large deletion that 
includes the C terminal transactivation domain (Miyoshi et al 1991, Miyoshi et al 
1995). It has been shown to antagonise wt RUNX1 in vitro and may be important 
for  leukaemogenesis  and/or  myeloid  cell  differentiation  (Tanaka  et  al  1995). 
AML1a has no transactivational function by itself, but inhibits the transcriptional 
activity of wt RUNX1 by competing for the DNA sequence of target genes with a 
higher affinity (Tanaka et al 1995). Overexpression of AML1a inhibits the myeloid 
terminal  differentiation  of  the  myeloid  precursor  lineage  32Dcl3  induced  by 
granulocyte colony stimulating factor (G CSF) and importantly levels of AML1a 
are commonly elevated in AML patients (Tanaka et al 1995).  
The  RUNX1  protein  has  a  number  of  transcriptional  activation  and  repression 
domains in the C terminal region (Aronson et al 1997; Kanno et al1998a). The 
effect  of  overexpressing  the  C terminal  truncation  isoform,  AML1a,  in  human 
fibroblasts was examined. Retroviral mediated gene transfer was employed to 
introduce control vector (pBabe) or AML1a into Hs68 cells. The AML1a expressing 
cells proliferated almost as well as control cells (pBabe vs AML1a day 6 p≥0.05) 
and displayed no features of senescence as determined by lack of staining for 
SA b Gal and lack of characteristic alterations to the cellular morphology (Figure 
3.3).  These  data  demonstrate  the  requirement  for  C terminal  transactivation 
and/ or repressor domains in senescence induction by RUNX1 in Hs68 cells.  
 
 
 
 Kamil K. Wolyniec, 2008     Chapter 3,99  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  3.3  C-terminal  transactivation/repression  domain  of  RUNX1  is 
required to induce senescence in Hs68 cells 
Cells were transduced with retroviral vectors expressing AML1a or control vector 
(pBabe) and selected for 4 days in puromycin. (a) Representative growth curves 
showing viable cell numbers corresponding to cell populations containing control 
vector (pBabe) or AML1a. Each experiment was performed three times and each 
time  point  was  determined  in  triplicate.  (b)  The  expression  of  AML1a  was 
measured by immunoblotting lysates from Hs68 cells containing empty vector (pB) 
or AML1a on day 7 post-selection using anti-Runx (D207-3, MBL) (c) Lack of SA-
β-Gal staining of cells containing control vector (pBabe), or AML1a (day 7 post-
selection) 
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3.5 Discussion 
In this study RUNX1 was clearly demonstrated to require both intact DNA binding 
activity and CBFβ interaction, allowing high affinity binding to the target DNA 
sequences  to  drive  premature  senescence.  Moreover  the  ability  of  RUNX1  to 
induce senescence seems to be a general feature as it is observed in both human 
primary  fibroblasts  and  murine  primary  fibroblasts.  Furthermore,  neither  the 
K83N DNA binding mutant nor the T161A CBFβ interaction mutant was able to 
induce senescence in Hs68 cells or MEFs, although in the  higher proliferating 
human cells, the T161A CBFβ mutant produced more dramatic reduction in the 
rate of proliferation than in the MEFs. Could this represent a difference between 
the human and mouse system? Does this demonstrate a greater dependence on 
CBFβ  heterodimerisation  to  drive  senescence  by  RUNX1  in  the  murine  cells? 
Perhaps this observation reflects higher affinity of CBFβ for binding to RUNX1 in 
MEFs compared to Hs68 fibroblasts or relative abundance of CBFβ in murine cells  
compared to human cells. This could be addressed by performing electrophoretic 
mobility shift assays and examining endogenous levels of CBFβ in murine and 
human fibroblasts. Importantly, the AML1a isoform of RUNX1 has been found to 
fail  to  induce  senescence  in  Hs68  cells  indicating  that  the  C terminal 
transactivation/repression portion of RUNX1 is critical in this response. These 
results are consistent with the well established role of AML1a as an antagonist of 
wild type RUNX1 in the context of myeloid and erythroid cell culture models of 
differentiation (Tanaka et al 1995; Nitsu et al 1997) and with the report that 
overexpression of RUNX1 but not AML1a can transform NIH3T3 cells (Kurokawa et 
al 1996) suggesting that AML1a does not act as an oncogene per se. Given that 
senescence is recognised as an anti cancer barrier in primary cells it is perhaps 
not  surprising  that  AML1a  did  not  trigger  senescence  in  Hs68  cells.  Taken 
together, these data confirm that RUNX1 transcriptional regulatory activity is 
required to drive premature senescence in primary  fibroblasts of murine  and 
human origin.  101 
 
 
 
 
 
Chapter 4 Kamil K. Wolyniec, 2008     Chapter 4,102  
4  Induction  of  premature  cellular  senescence  by 
RUNX1 fusion oncoproteins  
4.1 Introduction 
The existence of naturally occurring RUNX1 fusion oncoproteins associated with 
various  leukaemias  not  only  makes  the  investigation  into  RUNX1  function 
clinically relevant but provides useful tools to carry out that investigation. The 
accepted  hypothesis  has  been  that  these  oncoproteins  interfere  with  RUNX1 
function by acting in a dominant negative  fashion or acting  as a constitutive 
repressors  of  RUNX1  target  genes.  Hence  it  was  of  considerable  interest  to 
address the question as to whether leukaemia related fusion oncoproteins would 
antagonise senescence induction. 
4.2 RUNX1-ETO  is  a  potent  inducer  of  senescence  in 
murine embryonic fibroblasts 
The  RUNX1 ETO  fusion  oncoprotein  arises  as  a  consequence  of  the  t(8;21) 
chromosomal translocation and is a frequent feature of acute myeloid leukaemia 
(AML). RUNX1 ETO is a chimeric protein that lacks the transactivation domain of 
RUNX1 but is fused to a putative transcriptional repressor, ETO, and likewise 
AML1a has been shown to have dominant negative activity with respect to wild 
type RUNX1. RUNX1 ETO blocks transactivation of the GM CSF promoter and the 
T cell receptor beta enhancer by RUNX1 (Frank et al 1995; Meyers et al 1995). 
Consistent  with  a  negative  effect  on  RUNX1  function,  RUNX1 ETO  has  been 
shown to inhibit differentiation of myeloid progenitor cells (Kitabayashi et  al 
1998;  Westendorf  at  al  1998).  RUNX1 ETO  was  found  to  repress  p19
ARF,  the 
upstream effector of p53 which is required for RUNX1 induced senescence in 
murine  embryonic  fibroblasts  (Linggi  et  al  2002)  and  was  also  reported  to 
transform NIH3T3 cells (Frank et al 1999).  
It  was  therefore  of  particular  interest  to  test  the  effects  of  ectopically 
expressing  RUNX1 ETO  in  primary  murine  embryonic  fibroblasts.  To  this  end Kamil K. Wolyniec, 2008     Chapter 4,103  
RUNX1 ETO and RUNX1 were overexpressed in MEFs (Figure 4.1a) and cell growth 
assayed and SA β Gal staining carried out to test for senescence, as described in 
Chapter 2 and 3. Again, RUNX1 proved to be an inducer of senescence as these 
cells  ceased  proliferation  (pBabe  vs  RUNX1  day  9  p≤0.005)  (Figure  4.1b)  and 
approximately  70%  of  total  cell  population  were  stained  for  SA b Gal  (Figure 
4.1c). A more unexpected finding was that the fusion derivative seemed to be at 
least as potent inducer of senescence as RUNX1 itself. The population of RUNX1 
ETO expressing cells underwent a profound proliferative block (pBabe vs RUNX1 
ETO  day  9  p≤0.005)  (Figure  4.1b)    and  approximately  80%  of  the  total  cell 
population  displayed  more  intense  staining  for  SA b Gal  activity  compared  to 
RUNX1 expressing cells (Figure 4.1c,d). 
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Figure 4.1 RUNX1-ETO induces senescence-like growth arrest in MEFs 
Cells were transduced with retroviral vectors expressing RUNX1, RUNX1-ETO or 
control  vector  (pBabe)  and  selected  for  4  days  in  puromycin.  (a) Western  Blot 
analysis of RUNX1 (using anti-AML1/Runx1, 3900, Active Motif) and RUNX1-ETO 
(using  anti-RUNX1-ETO  from  Dr.  Scott  Hiebert)  expression  in  cells  containing 
empty vector (pB), RUNX1 (RX) or RUNX1-ETO (RX-E) on day 7 post-selection;   
* indicates non-specific bands (b) Representative growth curves of cells containing 
control vector (pBabe), RUNX1 or RUNX1-ETO. Each experiment was performed 
three times and each time point was determined in triplicate 
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Figure 4.1 continued 
(c)  SA-β-Gal  staining  of  cells  containing  control  vector  (pBabe),  RUNX1  or 
RUNX1-ETO (day 7 post-selection) (d) Quantitation of data in (c), showing the 
percentage  of  SA-β-Gal  positive  cells.  The  data  represent  the  mean  of  three 
independent counts of 200 cells (error bars relate to standard deviation) 
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4.3 RUNX1-ETO  induces  profound  premature 
senescence-like  growth  arrest  in  human  primary 
fibroblasts 
Again  the  question  arose  as  to  whether  RUNX1 ETO  retains  the  capacity  to 
induce senescence in human cells and if so whether the phenomenon is as potent 
as in murine cells. Human neonatal foreskin fibroblasts were transduced with 
retroviral  constructs  encoding  RUNX1 ETO,  RUNX1,  H RAS
V12  or  control  vector 
(pBabe) and following puromycin selection were analysed as previously described 
for  proliferative  properties  and  SA β Gal  activity.  In  this  experiment  the 
prototypic inducer of premature senescence, oncogenic H RAS
V12 (Lin and Lowe, 
2001;  Serrano  et  al  1997),  was  also  expressed  to  compare  the  senescent 
phenotypes of RUNX1, H RAS
V12 and potentially RUNX1 ETO. All the introduced 
constructs  were  expressed  at  readily  detectable  levels  (Figure  4.2a). 
Interestingly, it was noticeable that H RAS
V12 clearly downregulated endogenous 
RUNX1 (Figure 4.2a). Ectopic expression of both RUNX1 and RUNX1 ETO resulted 
in  a  growth  arrest  that  was  more  pronounced  than  that  of  the  H RAS
V12 
expressing cells (RUNX1 vs H RAS
V12 day 9 p≤0.05; RUNX1 ETO vs H RAS
V12 day 9 
p≤0.005) (Figure 4.2a) with RUNX1 ETO expressing cells showing an even more 
profound proliferative arrest than RUNX1 (RUNX1 ETO vs RUNX1 day 9 p≤0.05). In 
addition, in contrast to H RAS
V12, which initially stimulated growth as previously 
reported by others  (Kilbey et al 2007; Lin et al 1998), RUNX1 and especially 
RUNX1 ETO  were  potent  growth  suppressors  immediately  after  puromycin 
selection. This was reflected in the growth rates over first 3 days during which 
period  H RAS
V12  was  not  significantly  different  from  the  puro  control  (day  3 
p≥0.1) (Figure 4.2b). Interestingly, RUNX1 ETO expressing cells displayed more 
profound morphological changes (very flat and enlarged) than RUNX1 expressing 
cells and stained more intensly for SA b Gal (Figure 4.2c). This more pronounced 
senescent  phenotype  of  RUNX1 ETO  expressing  cells  was  also  reflected  by 
significant quantitative changes in SA b Gal staining where as many as 80% of 
RUNX1 ETO  cells  were  positively  stained  compared  to  40%  of  the  RUNX1 
expressing  cells  (RUNX1 ETO  vs  RUNX1  p=0.01)  (Figure  4.2d).  Therefore  it Kamil K. Wolyniec, 2008     Chapter 4,107  
appears that RUNX1 ETO can induce an even stronger senescence response than 
RUNX1 or even H RAS
V12 in human cells. 
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Figure 4.2 RUNX1-ETO induces more profound senescence than RUNX1 in 
human neonatal foreskin fibroblasts 
Cells were transduced with retroviral vectors expressing  RUNX1-ETO, RUNX1, 
H-RAS
V12  or  control  vector  (pBabe)  and  selected  for  4  days  in  puromycin.  (a) 
Western Blot analysis of RUNX1-ETO (anti-RUNX1-ETO from Dr. Scott.Hiebert), 
RUNX1 (anti-AML1/Runx1, 3900, Active Motif) and H-RAS
V12 (Anti H ras, Ab 1, 
Oncogene  Research)  expression  in  cells  containing  empty  vector  (pB),  RUNX1 
(RX),  RUNX1-ETO  (RX-E)  or  H-RAS
V12  (R)  on  day  7  post-selection  (b) 
Representative growth curves of cells containing control vector (pBabe), RUNX1-
ETO, RUNX1 or H-RAS
V12. Each experiment was performed three times and each 
time point was determined in triplicate 
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Figure 4.2 continued 
(c)  SA-β-Gal  staining  of  cells  containing  control  vector  (pBabe),  RUNX1  or 
RUNX1-ETO  (day  7  post-selection)  (d)  Quantitation  of  data  in  (c)  showing  the 
percentage  of  SA-β-Gal  positive  cells.  The  data  represent  the  mean  of  three 
independent counts of 200 cells (error bars relate to standard deviation) 
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4.4 RUNX1-ETO  requires  transcriptional  repressor 
activity  to  drive  senescence  in  human  primary 
fibroblasts 
To gain more insight into the premature senescence triggered by RUNX1 ETO the 
ability  to  induce  senescence  by  RUNX1 ETO  mutant  (RUNX1 ETO∆469)  was 
examined. In contrast to RUNX1 ETO this mutant lacks corepressor binding sites 
and fails to repress transactivation of RUNX1 target genes (Lenny et al 1995). In 
addition RUNX1 ETO∆469, as opposed to full length RUNX1 ETO, was reported to 
be  unable  to  transform  NIH3T3  (Frank  et  al  1999).  Retroviral  mediated  gene 
transfer was employed to overexpress mutant RUNX1 ETO∆469 and RUNX1 ETO 
in human neonatal foreskin fibroblasts. In contrast to RUNX1 ETO cells, RUNX1 
ETO∆469  expressing  cells  continued  to  proliferate  after  puromycin  selection 
(RUNX1 ETO∆469  vs  RUNX1 ETO  day  10,  p≤0.05),  although  growth  rates  were 
reduced  compared  to  empty  vector  control  cells  (Figure  4.3a).  The  RUNX1 
ETO 469 protein was expressed at an equivalent level to that of RUNX1 ETO 
(Figure 4.3b). Furthermore, RUNX1 ETO 469 expressing cells did not stain with 
SA b Gal,  nor  did  they  display  the  characteristic  senescence associated 
morphology  (Figure  4.3c)  indicating  that  RUNX1 ETO∆469  does  not  induce 
premature  senescence  in  Hs68  cells.  These  data  identify  the  importance  of 
repressor domains of ETO fusion partner in RUNX1 ETO induced senescence in 
Hs68 cells.  
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Figure  4.3  RUNX1-ETO  requires  ETO  transcriptional  repressor domains to 
induce senescence in human neonatal foreskin fibroblasts 
Cells  were  transduced  with  retroviral  vectors  expressing  RUNX1-ETO∆469, 
RUNX1-ETO or control vector (pBabe) and selected for 4 days in puromycin. (a) 
Representative growth curves showing viable cell numbers corresponding to cell 
populations containing control vector (pBabe), RUNX1-ETO∆469 or RUNX1-ETO. 
Each experiment was performed three times and each time point was determined 
in  triplicate.  (b)  Western  Blot  analysis  of  RUNX1-ETO∆469  and  RUNX1-ETO 
expression in cells containing empty vector (pB), RUNX1-ETO∆469 (RX1-E∆469) 
or RUNX1-ETO (RX-E) on day 7 post-selection using Anti-Runx (D207-3, MBL) 
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Figure 4.3 continued 
(c) SA-β-Gal staining of cells containing control vector (pBabe), RUNX1-ETO∆469 
or RUNX1-ETO (day 7 post-selection) 
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4.5 CBFβ-MYH11  oncoprotein  but  not  TEL-RUNX1 
induces a moderate senescence-like growth arrest in 
human primary fibroblasts 
Since RUNX1 ETO proved to be a very potent inducer of premature senescence it 
was  tempting  to  speculate  that  other  fusion  oncoproteins  e.g.  TEL RUNX1  or 
CBFb MYH11 which target RUNX1 and CBFb, respectively, and would share the 
same  property  of  being  able  to  execute  a  senescence  programme  in  human 
primary fibroblasts. TEL RUNX1 is generated through the t(12;21) chromosomal 
translocation, which occurs in approximately 25% cases of B cell origin pediatric 
acute lymphoblastic leukaemias. CBFb MYH11, is a consequence of a common 
chromosomal  inversion  event  (INV16)  which  occurs  in  myelomonocytic 
leukaemias and results in fusion of the CBFb gene with a smooth muscle myosin 
heavy chain  gene  (MYH11).  Both  are  thought  to  act  as  dominant  negative 
regulators  of  RUNX1  function  (Speck  and  Gilliland  2002).  To  investigate  the 
effects  of  TEL RUNX1  and  CBFb MYH11  overexpression,  Hs68  cells  were 
transduced with either construct and monitored for their growth characteristics, 
morphological changes and SA b Gal staining. Interestingly, western blot analysis 
of expression of transgenes revealed that whereas CBFb MYH11 seemed to be 
stably expressed over the course of time, TEL RUNX1 protein levels gradually 
declined  over  the  same  period  (Figure  4.4a).  Intriguingly,  overexpression  of 
CBFb MYH11 fusion protein but not TEL RUNX1 partially repressed cell growth 
(Figure 4.4b). The proportion of CBFb MYH11 expressing cells which acquired flat 
and  enlarged  morphology  and  displayed  positive  staining  for  SA b Gal  (Figure 
4.4b)  was  significantly  higher  than  TEL RUNX1  or  vector  control  cells  and 
accounted for approximately 25% of the total cell population (CBFb MYH11 vs 
pBabe, p≤0.05; CBFb MYH11 vs TEL RUNX1, p≤0.05) (Figure 4.4c) indicating that 
CBFb MYH11 unlike TEL RUNX1 can induce senescence like growth arrest. 
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Figure  4.4  CBFβ-MYH11  but  not  TEL-RUNX1  induces  a  moderate 
senescence-like growth arrest in human neonatal foreskin fibroblasts 
Cells  were  transduced  with  retroviral  vectors  expressing  TEL-RUNX1,  CBFβ-
MYH11  or  control  vector  (pBabe)  and  selected  for  4  days  in  puromycin.  (a) 
Western Blot analysis of TEL-RUNX1 (Anti Runx, D207 3, MBL) and CBFβ-MYH11 
(anti-CBFβ  from  Dr.  Nancy  Speck)  expression  in  cells  containing  empty  vector 
(pB), TEL-RUNX1 (T-R), CBFβ-MYH11 (C-M) on day 0 and day 7 post-selection 
(b) Representative growth curves showing viable cell numbers corresponding to 
cell populations containing control vector (pBabe), TEL-RUNX1 or CBFβ-MYH11. 
Each experiment was performed three times and each time point was determined 
in triplicate 
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Figure 4.4 continued 
(c) SA β Gal staining of cells containing control vector (pBabe), TEL RUNX1 or 
CBFβ MYH11 (day 7 post selection) (d) Quantitation of data in (c) showing the 
percentage  of  SA β Gal  positive  cells.  The  data  represent  the  mean  of  three 
independent counts of 200 cells (error bars relate to standard deviation) 
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4.6 Discussion 
The discovery that the RUNX1 ETO oncoprotein is capable of inducing profound 
senescence like growth arrest both  in  MEFs and Hs68 cells more dramatically 
than the archetypal RAS inuced senescence was both novel and surprising. Its 
established role as a dominant negative inhibitor of RUNX1 would lead to the 
prediction  that,  contrary  to  the  senescence  phenotype  resulting  from  RUNX1 
expression, RUNX1 ETO would fail to induce senescence, although this assumes 
that  RUNX1  induces  senescence  via  its  gene  activation  potential.  However, 
unlike  AML1a  which  also  lacks  the  C terminal  domain  of  wild  type  RUNX1, 
RUNX1 ETO  proved  to  drive  premature  senescence,  that  was  even  more 
pronounced  that  of  RUNX1  itself.  This  suggests  that  it  has  unique  features 
independent  of  RUNX1  function  that  are  likely  to  be  conferred  by  its  fusion 
partner protein, ETO. Indeed, ETO itself is known to be a strong transcriptional 
repressor (Lutterbach et al 1998; Wang et al 1998) and and the results reported 
here show that the mutant of RUNX1 ETO containing the deletion of corepressor 
binding  sites  of  ETO  (RUNX1 ETO∆469)  is  unable  to  promote  senescence. 
Therefore it is likely that RUNX1 ETO mediated senescence engages a repression 
of important target genes whereas it is not clear from the data presented here 
whether RUNX1 induced senescence relies on transcriptional activation and/or 
repression, although previous work in our laboratory showed a requirement for 
p53 while Linggi et al reported that p19
ARF was required and induced by RUNX1 
but repressed by RUNX1 ETO (Linggi et al 2002). This may imply that RUNX1 ETO 
induced senescence occurs independently of p19
ARF in MEFs and it is possible that 
RUNX1 and RUNX1 ETO employ distinct signalling pathways for the induction of 
premature senescence or that both can induce a senescence response based on 
gene  repression.  Given  that  RUNX1 ETO  has  oncogenic  properties,  the 
senescence  response  may  act  as  an  initial  barrier  that  restricts  a  full  blown 
transformation by RUNX1 ETO. 
Interestingly, overexpression of two other leukaemia related oncoproteins TEL 
AML and CBFβ-MYH11 that target RUNX1 or CBFβ, respectively, revealed that 
only the latter displayed a limited activity to induce premature senescence in 
Hs68  human  fibroblasts.  Only  25%  CBFβ-MYH11  expressing  cells  displayed Kamil K. Wolyniec, 2008     Chapter 4,117  
hallmarks of senescence (compare with approximately 40% for RUNX1, 80% for 
RUNX1 ETO or 75% for RAS as shown in Figure 2d of this chapter). It could be 
possible that CBFB MYH11 requires more time for manisfestation of the complete 
senescent phenotype and therefore by day 7, when the analysis was performed, 
only 25% of cells displayed SA β gal activity. The other explanation could be that 
CBFB MYH11  requires  endogenous  RUNX,  which  would  be  rate  limiting,  for 
induction  of  senescence.  TEL RUNX1  failed  to  induce  senescence  at  all  but 
western blot analysis revealed that whereas CBFb MYH11 was stably expressed 
over  the  course  of  time,  TEL RUNX1  protein  levels  rapidly  declined  making 
interpretation of this result difficult. It is possible that TEL RUNX1 fails to induce 
senescence due to relatively low levels of expression and that a threshold of 
signal potency may be required to elicit a senescence response that could not be 
achieved by TEL RUNX1. It is also possible that cells with low expression may 
have a selective advantage in the population if the cells were unable to tolerate 
high  levels  of  TEL RUNX1  expression.  Alternatively  since  some  level  of  TEL 
RUNX1  did  remain  throughout  the  time  course  the  result  may  be  a  true 
reflection  of  TEL RUNX1  expression  conferring  a  specific  advantage  to  this 
oncoprotein in its target cell and may suggest that TEL RUNX1 exerts its effect 
by a different mechanism to the other fusion oncoproteins used. 
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5  Characterisation  of  RUNX1  and  RUNX1-ETO 
induced  senescence  in  human  primary 
fibroblasts 
5.1 Introduction 
The  exciting  finding  that  RUNX1 ETO  induces  a  more  profound  senescent 
phenotype  than  H RAS
V12  in  human  fibroblasts  clearly  warranted  further 
investigation. The pathways underlying H RAS
V12 induced senescence have been 
largely elucidated, hence I decided to examine RUNX1 ETO and RUNX1 induced 
senescent phenotypes by comparing and contrasting them with H RAS
V12. Human 
primary  fibroblasts  overexpressing  H RAS
V12  are  predominantly  arrested  in  G1 
phase of the cell cycle (Serrano et al 1997). This senescence like growth arrest 
induced by H RAS
V12 is associated with accumulation of growth inhibitors such as 
p21
WAF1,  p53  and  p16
INK4a  (Serrano  et  al  1997).  Oncogenic  RAS  induced 
senescence  is  also  characterised  by  accumulation  of  PML  nuclear  bodies 
(Ferbeyre et al., 2000), high levels of reactive oxygen species (ROS) (Lee at al  
1999) and activation of p38 MAPK (Wang et al 2002). Furthermore, formation of 
specific  chromatin  condensations  described  as  senescence associated 
heterochromatin  foci  (SAHF)  has  been  linked  recently  to  H RAS
V12  induced 
senescence (Narita et al 2003). Ras also triggers the accumulation of DNA double 
strand breaks (DSBs) following a pre eliminary burst of proliferation (DiMicco et 
al 2006). 
5.2 RUNX1 and RUNX1-ETO cell cycle arrest 
Since both RUNX1 and RUNX1 ETO have been found to cause growth arrest in 
human neonatal foreskin fibroblasts it was important to define where in the cell 
cycle RUNX1 and RUNX1 ETO expressing cells are arrested. The cell cycle profile 
of RUNX1 and RUNX1 ETO expressing Hs68 cells was analysed at day 7 of growth 
curve,  by  employing  bromodeoxyuridine  (BrdU)  incorporation  combined  with 
propidium  iodide  staining  (PI)  followed  by  flow  cytometry  analysis.  H RAS
V12 
expressing  cells  were  used  as  a  positive  control.  In  accord  with  previously Kamil K. Wolyniec, 2008     Chapter 5,120  
published  data  (Serrano  et  al  1997,  Ferbeyre  et  al  2000),  oncogenic  RAS 
expressing cells were arrested in G1 and G2M with a preference to accumulate in 
G1.  RUNX1  and  RUNX1 ETO  expressing  cells  had  slightly  different  cell cycle 
profiles to that of H RAS
V12 with a prominent G1/G2M arrest and loss of S phase 
DNA content, an effect that was more pronounced in RUNX1 ETO cells (Figure 
5.1 and Table 5.1). RUNX1 ETO containing cells in particular displayed a skew 
towards  the  G2M  phase  of  the  cell  cycle  (Table  5.1)  (pBabe  vs  RUNX1 ETO, 
p=0.01). In this respect it was interesting to note that this finding corresponded 
to  a  relatively  high  proportion  of  binucleate  and  multinucleate  RUNX1 ETO 
expressing cells observed under the light microscope (Figure 5.2) suggesting a 
defect in cytokinesis. It may also be the case that the arrested cells are G1 
tetraploid binucleates and further analysis of cell cycle arrest will be useful. 
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Figure 5.1 RUNX1 and RUNX1-ETO causes G1/G2M arrest in Hs68 cells 
Representative  cell  cycle  profiles  of  cells  transduced  with  retroviral  vectors 
expressing  RUNX1 ETO, RUNX1, H RAS
V12 or control vector (pBabe). The cells at 
day 7 post selection were pulsed with BrdU for 3 hours and analyzed for BrdU 
uptake and DNA content by two colour flow cytometry using a FITC conjugated 
anti BrdU antibody and propidium iodide. The experiment was performed twice 
and yielded similar results 
 
 
 
 
 
 
 
 
Table 5.1 RUNX1-ETO growth arrested Hs68 cells display a greater tendency 
to accumulate in the G2/M phase of the cell cycle 
pBabe  H-RAS
V12 
RUNX1  RUNX1-ETO 
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Figure  5.2  Phase-contrast  photomicrograph  illustrating  binucleate  (right 
upper corner) and multinucleate (left bottom corner) RUNX1-ETO expressing 
Hs68 cells (day 8 post-selection) 
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5.3 RUNX1-ETO and RUNX1 induced senescence display 
distinct pattern of induction of p16
INK4a, p21
WAF1 and 
p53 
P16
INK4a, p14
ARF, p21
WAF1 and p53 are well established negative growth regulators 
that are upregulated in senescent cells (Collado and Serrano 2006). P16
INK4a and 
p21
WAF1 act as inhibitors of cyclin dependent kinases (CDK) and interfere with G1 
to S progression during the cell cycle. P21
WAF1 is induced by p53 and inhibits 
CDK2/Cyclin E activity whereas p16
INK4a inhibits CDK4 and CDK6 activity (Sherr 
2000). This in turn results in hypophosphorylation of pRb and cell cycle arrest 
during senescence. P14
ARF has been shown to neutralise the ability of Mdm2 to 
promote p53 degradation leading to the stabilisation and accumulation of p53 
(Weber et al 1999; Zhang et  al 1998). Overexpression of p16
INK4a, p14
ARF and 
p21
WAF1  in  human  primary  fibroblasts  induces  the  hallmarks  of  premature 
senescence (Dimri et al 2000; McConnell et al 1998; Wei et al 2001).  
To further explore the nature of the senescence programmes elicited by RUNX1 
and RUNX1 ETO in human primary fibroblasts the levels of expression of p16
INK4a, 
p14
ARF, p21
WAF1 and p53 were analysed in Hs68 cells. The H RAS
V12 oncogene has 
been reported to upregulate all of these effectors except for p14
ARF (Serrano et 
al  1997;  Wei  at  al  2001].  In  the  work  reported  here  a  similar  pattern  of 
regulation was seen in human neonatal foreskin fibroblasts expressing H RAS
V12 
(Figure 5.3a). It was of particular interest to determine whether p14
ARF status is 
affected either by RUNX1 or RUNX1 ETO expression in Hs68 cells since RUNX1 
and RUNX1 ETO have been reported to have opposing effects on this gene locus 
(Linggi et al 2002). Analysis of d7 post selection Hs68 fibroblasts gave contrasting 
results with levels of p14
ARF appearing refractory to RUNX1 or RUNX1 ETO status 
(Figure 5.3b). Further western blot analysis revealed interesting differences in 
p16
INK4a, p21
WAF1 and p53 expression between RUNX1 and RUNX1 ETO expressing 
cells suggestive of distinct senescence execution pathways. Notably RUNX1 ETO 
and RUNX1 induced p53, with RUNX1 ETO the more potent agonist (Figure 5.3a). 
Intriguingly, the levels of p53 did not correlate with the potency of induction of 
p21
WAF1,  the  downstream  target  of  p53  (Figure  5.3b).  In  this  respect  p21
WAF1 Kamil K. Wolyniec, 2008     Chapter 5,124  
expression levels were dramatically induced by RUNX1 but not by RUNX1 ETO 
suggesting  possible  opposing  transcriptional  effects  on  the  p21
WAF1  promoter. 
Even  more  surprisingly,  especially  in  comparison  to  H RAS
V12,  RUNX1  but  not 
RUNX1 ETO upregulated p16
INK4a (Figure 5.3a). 
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Figure 5.3 RUNX1-ETO and RUNX1 induced senescence display distinct 
patterns of induction of p16
INK4a, p21
WAF1 and p53 in Hs68 cells 
(a) Western blot analysis of expression of p16
INK4a (anti p16, sc 468, Santa Cruz) 
p21
WAF1 (anti p21, sc 397, Santa Cruz) and p53 (anti p53, sc 126, Santa Cruz) in 
cells containing control vector (pB), RUNX1 (RX), RUNX1 ETO (RX E) and or H 
RasV12  (R)  (day  7  post selection)  (b)  Western  blot  analysis  of  expression  of 
p14
ARF (anti p14ARF, Ab 2, Neomarkers) in Hs68 cells containing control vector 
(pB),  RUNX1  (RX),  RUNX1 ETO  (RX1 E)  or  H Ras
V12  (R)  (day  7  post selection). 
Human cells 13 lysate (MS 850 PCL, neomarkers) was used as a positive control 
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5.4 Activation of p38 MAPK in RUNX1 and RUNX1-ETO 
induced senescence 
The p38 MAPK pathway mediates responses to environmental stresses, including 
DNA damaging agents such as UV and γ irradiation [Bulavin and Fornance, 2004]. 
Interestingly, the mitogen activated protein kinase p38 plays a pivotal role in 
mediating cellular senescence caused by a broad spectrum of stimuli, including 
oxidative stress, dysfunctional telomeres, culture shock and the proto oncogene 
erbB2 (Iwasa et al 2003, Trost et al 2005]. Therefore it has been suggested that 
p38 kinase links pro oncogenic signals to tumour suppressors. P38 MAPK has been 
also implicated in H RAS
V12 induced senescence where p38 is phosphorylated by 
two upstream kinases, MKK3 and MKK6 (Wang et al 2002) and was shown to be 
responsible for H RAS
V12 induced transcriptional activity of p53 (Sun et al 2007) 
and to contribute to the upregulation of p16
INK4a and p53 (Wang et al 2002).  
Therefore, I considered that the p38 MAPK pathway may also mediate RUNX1 
and RUNX1 ETO induced senescence. To investigate this hypothesis, the abilities 
of RUNX1 and RUNX1 ETO to activate p38 MAPK were examined using a specific 
antibody  that  recognises  two  phosphorylation  sites  responsible  for  p38  MAPK 
activation (Thr180 and Tyr182) (Wang et al 2002). Indeed, western blot analysis 
on day 7 of culture period revealed that both RUNX1 and RUNX1 ETO elevated 
levels of phospho p38 while RUNX1 ETO was more potent agonist and induced 
phospho p38 to a similar degree as H RAS
V12 (Figure 5.4). Notably, the levels of 
total p38 MAPK remained unaffected (Figure 5.4). These results suggest that the 
p38  MAPK  is  involved  in  RUNX1  and  RUNX1 ETO  induced  senescence. 
Furthermore,  the  upregulation  of  phospho p38  by  RUNX1  and  RUNX1 ETO 
reflected  the  p53  levels  (Section  5.3,  Chapter  5)  suggestive  of  a  common 
signalling pathway. 
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Figure  5.4  RUNX1-ETO  and  RUNX1  induce  phospho-p38  with  differing 
potencies in Hs68 cells 
Western blot analysis of phospho p38 (anti phospho p38, 9211, Cell signalling) 
and p38 (anti p38, 9212, Cell signalling) expression in cells containing control 
vector  (pB),  RUNX1  (RX),  RUNX1 ETO  (RX E)  or  H RasV12  (R)  (day  8  post 
selection). 
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5.5 Activation of p38 MAPK correlates with induction of 
intracellular reactive oxygen species 
There is a significant body of experimental evidence supporting the idea that a 
rise  in  intracellular  reactive  oxygen  species  (ROS)  contributes  to  cellular 
senescence  (Colavitti  and  Finkel,  2005;  Passos  and  Zglinicki,  2006).  Various 
extrinsic or intrinsic manipulations changing the intracellular antioxidant status, 
raising the ambient oxygen concentration, direct exposure of cells to hydrogen 
peroxide  or  the  expression  of  certain  oncogenes  like  H RAS
V12,  all  appear  to 
produce  a  rise  in  intracellular  ROS  levels  (Lee  et  al  1999;  Chen  et  al  1998; 
Frippiat et al 2000). This rise in ROS within cells accompanies and potentially 
triggers senescence entry (Passos and Zglinicki, 2006). It has been reported that 
ROS induction leads to activation of p38 kinase (Iwasa et al 2003; Guyton et al 
1996) and upregulation of a subset of p38 target genes (Zdanov et al 2006) in 
cells treated with hydrogen peroxide. It was also demonstrated that MINK kinase 
is  activated  by  RAS  induced  ROS  and  subsequent  activation  of  p38  by  MINK 
results in premature senescence (Nicke et al 2005).  
To investigate whether ROS levels are altered in prematurely senescent cells 
expressing RUNX1 and RUNX1 ETO and could therefore cause the activation of 
p38 MAPK in these cells, the levels of ROS in human neonatal foreskin fibroblasts 
were  examined  at  day  7  post selection  by  using  FACS  based  detection  of 
fluorescence emitted by the peroxide sensitive fluorophore DCF. As expected H 
RAS
V12 cells displayed high levels of intracellular ROS consistent with published 
data  (H RASV12  vs  pBabe,  p≤0.005)  (Figure  5.5a,  b)  (Lee  et  al  1999). 
Interestingly, both RUNX1 and RUNX1 ETO expressing cells were found to have 
elevated  intracellular  ROS  levels  compared  to  empty  vector  control  cells  
(RUNX1 vs pBabe, p≤0.05; RUNX1 ETO vs pBabe, p≤0.0001) (Figure 5.5a, b) but 
only RUNX1 ETO expressing cells showed as profound or even greater induction 
than H RAS
V12 expressing cells (Figure 5.5a, b). Furthermore, the intracellular 
ROS levels appeared to correlate well with the degree of phospho p38 activation 
by  RUNX1  and  RUNX1 ETO  as  found  in  previous  experiments.  The  DCF 
fluorescence was also imaged with a laser scanning confocal microscope visually 
confirming the quantitative analysis of ROS levels (Figure 5.5c) Kamil K. Wolyniec, 2008     Chapter 5,129  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5 Activation of p38 MAPK correlates with induction of intracellular 
ROS in Hs68 cells 
Cells  were  infected  with  retrovirus  encoding  RUNX1,  RUNX1 ETO,  H RAS
V12  or 
control retrovirus (pBabe) and analysed with DCF for intracellular ROS levels 7 
days  after  puromycin  selection  (a)  Intracellular  ROS  was  monitored  by  FACS 
analysis of DCF fluorescence (b) Quantitation of DCF fluorescence 
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Figure 5.5 continued 
 
(c) Visualisation of DCF fluorescence by confocal laser scanning microscopy (day 
7 post selection) 
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5.6 DNA  damage  and  senescence  associated 
heterochromatin  foci  in  RUNX1  and  RUNX1-ETO 
induced senescence 
Severe DNA damage, especially damage that involves DNA double strand breaks, 
(DSBs) causes many cell types to undergo senescence (DiLeonardo et al 1994). 
Critically short, dysfunctional telomeres can also trigger a classical DNA damage 
response  (DDR)  (Herbig  et  al.,  2004).  Moreover,  oncogenic  RAS  induced 
senescence has been linked to the accumulation of DNA damage. It has been 
suggested that DNA damage is caused by oncogene driven increases in cellular 
levels of  reactive oxygen species which can result  in DNA single and double 
strand breaks (Lee et al 1999). Other possible mechanisms have been proposed 
whereby oncogenes such as H RAS
V12 induce a robust DDR owing to prematurely 
terminated  DNA  replication  forks  and  DSBs  that  are  caused  by  DNA  hyper 
replication stress (DiMicco et al 2006; Bartkova et al 2006).  
To  determine  whether  DNA  damage  signalling  is  associated  with  RUNX1  and 
RUNX1 ETO  induced  senescence  in  Hs68  cells,  confocal  laser  scanning 
immunofluorescence  microscopy  was  performed  on  Hs68  fibroblasts  on  day  7 
post selection following retroviral transduction with RUNX1, RUNX1 ETO and H 
RAS
V12. The cells were fixed and dual labelled with a monoclonal antibody that 
recognises  phosphorylated  histone  H2AX  (γ H2AX),  a  marker  of  DNA  double 
strand  breaks  and  DAPI  to  visualise  nuclear  DNA.  As  shown  in  Figure  5.6, 
overexpression of H RAS
V12 resulted in accumulation of multiple γ H2AX positive 
nuclear foci on day 7 of culture. These correspond to DSBs and have previously 
been reported in H RAS
V12 induced senescence. In contrast, RUNX1 and RUNX1 
ETO expressing populations of cells exhibited only one or two fluorescent dots 
and more closely resembled vector control cells than H RAS
V12 expressing ones 
(Figure  5.6)  DAPI  staining  of  the  nuclear  content  revealed  that  RUNX1  and 
RUNX1 ETO,  in  contrast  to  oncogenic  RAS,  did  not  cause  specific  chromatin 
condensations or senescence associated heterochromatin foci (SAHF) that have 
previously been observed during cellular senescence (Figure 5.6). 
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Figure 5.6 Ras but not RUNX1 or RUNX1-ETO induces DNA damage foci and 
SAHF in Hs68 human fibroblasts 
Indirect immunofluorescence for γH2AX foci (using anti H2AX, 05 636, Upstate) 
in Hs68 cells expressing control vector (pBabe), RUNX1, RUNX1 ETO or H RAS
V12 
(day 7 post selection). DAPI was used to stain the nuclear DNA 
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5.7 Accumulation of PML nuclear bodies in RUNX1 and 
RUNX1-ETO induced senescence 
PML  has  recently  been  described  as  a  senescence  regulatory  protein.  PML  is 
upregulated during cellular senescence, and induces premature senescence in 
response to oncogenic H RAS (Ferbeyre et al 2000). Interestingly, PML has been 
shown to regulate the p53 response to oncogenic signals by binding MDM2 and 
sequestering it into the nucleus, thus protecting p53 from proteosome mediated 
degradation  (Bernardi  et  al  2004),  as  well  as  specifically  acetylating  p53 
(Pearson  et  al  2000).  Both  of  these  processes  stabilize  the  p53  protein. 
Interestingly  PML  is  also  a  direct  p53  target  that  modulates  p53  functions 
indicating the existence of a regulatory feedback loop between these tumour 
suppressors (de Stanchina et al 2004). 
As shown in section 5.3 of this chapter, RUNX1 and RUNX1 ETO expressing cells 
displayed substantial differences in the levels of expression of p53 protein with 
only  RUNX1 ETO  inducing  p53  as  profoundly  as  H RAS
V12.  It  was  therefore 
interesting to establish the status of PML in RUNX1 ETO or RUNX1 senescent cells 
and to determine whether PML could play a role in the differential upregulation 
of  p53  in  these  cells.  Hs68  cells  were  transduced  with  retroviral  vectors 
expressing RUNX1, RUNX1 ETO and H RAS
V12, and double stained using a specific 
antibody  recognising  PML  with  DAPI  as  a  nuclear  DNA  marker  at  day  7  post 
selection.  Visualisation  of  PML  nuclear  bodies  by  laser  scanning  confocal 
microscopy  revealed  increased  PML  bodies  in  H RAS
V12  expressing  cells,  and 
RUNX1 ETO  cells  but  not  in  RUNX1  cells  (Figure  5.7).  Again,  unlike  H RAS
V12, 
RUNX1 and RUNX1 ETO expressing cells did not exhibit SAHF. This result suggests 
that PML may be involved in the stabilisation and increased p53 expression in 
RUNX1 ETO expressing cells. 
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Figure 5.7 PML accumulation is induced by RUNX1-ETO but not RUNX1 in 
human fibroblasts Hs68 
Indirect immunofluorescence for PML (anti PML, N19, Santa Cruz) in Hs68 cells 
expressing control vector (pBabe), RUNX1, RUNX1 ETO or H RAS
V12 (day 7 post 
selection). DAPI was used to stain the nuclear DNA 
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5.8 Partial  recapitulation  of  RUNX1-ETO  induced 
senescence by ectopic expression of p53 
RUNX1 ETO profoundly elevates levels of p53 expression but importantly while 
RUNX1 ETO induces p53 it simultaneously attenuates downstream upregulation 
of p21
WAF1 expression in Hs68 cells. It was therefore particularly interesting to 
address  the  question  of  whether  the  ectopic  expression  of  p53  alone  drives 
premature senescence in Hs68 fibroblasts and if so, how does the phenotype of 
p53 expressing cells compares to that of RUNX1 ETO.  
Hs68  cells  were  infected  with  retroviruses  containing  p53  and  RUNX1 ETO  or  
control vector. Ectopic expression of RUNX1 ETO resulted in a substantial growth 
arrest  (RUNX1 ETO  vs  pBabe,  day  8  p=0.01)  (Figure  5.8a)  and  characteristic 
senescence related alterations to cellular  morphology and positive staining of 
RUNX1 ETO expressing cells for SA β Gal activity (Figure 5.8b). Overexpression 
of p53 also caused significant growth arrest (p53 vs pBabe, day 8 p≤0.01) (Figure 
5.8a), however p53 expressing cells were not as flat and enlarged as RUNX1 ETO 
expressing cells and the intensity of SA b Gal staining was not as pronounced 
(Figure 5.8b). As before (Section 5.3, Chapter 5), RUNX1 ETO expressing Hs68 
fibroblasts, in contrast to p53 expressing cells, were found to be refractory to 
the  induction  of  p21
WAF1  despite  the  upregulation  of  p53  (Figure  5.8c). 
Interestingly, overexpression of p53 did not cause the accumulation of γ H2AX 
DNA damage foci or senescence associated heterochromatin foci in Hs68 cells as 
visualised  by  laser  scanning  confocal  microscopy  using  anti γ H2AX  and  DAPI 
staining (Figure 5.8d). These data show that ectopic expression of p53 in Hs68 
cells induces senescence like growth arrest that partially recapitulates that of 
RUNX1 ETO  expressing  cells  clearly  indicating  that  RUNX1 ETO  induces 
senescence via p53 yet apparently modulates its signalling pathway. 
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Figure  5.8  Ectopic  expression  of  p53  partially  recapitulates  RUNX1-ETO 
induced senescence in Hs68 cells 
(a) Representative growth curves of Hs68 cells transduced with control vector 
(pBabe),  RUNX1 ETO  or  p53  (c)  SA b Gal  staining  of  cells  expressing  p53  or 
RUNX1 ETO (day 7 post selection) 
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Figure 5.8 continued 
(c)  Indirect  immunofluorescence  for  γ H2AX  foci  in  cells  expressing  p53  and 
visualisation of SAHF by staining with DAPI (day 7 post selection) (d) Western 
blot analysis of p53 (anti p53, sc 126, Santa Cruz) and p21
WAF1 (anti p21, sc 397, 
Santa  Cruz)  in  lysates  from  cells  containing  empty  vector  (pB),  p53  (p53)  or 
RUNX1 ETO (RX E) (day 7 post selection) 
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5.9 Discussion 
Further characterisation of RUNX1 and RUNX1 ETO induced senescence revealed 
interesting differences and common features in their respective phenotypes and 
also  highlighted  some  similarities  and  differences  to  H RAS
V12  induced 
senescence. Analysis of the cell cycle showed that whereas H RAS
V12 or RUNX1 
expressing cells arrest in G1 phase, the RUNX1 ETO cell cycle arrest was skewed 
towards G2M phase and these cells showed an increase in the proportion of bi  
and multi nucleate cells suggesting some defects in cytokinesis. The expression 
levels of well established biomarkers of senescence involved in the execution of 
growth  arrest  were  then  examined,  clearly  identifying  substantial  differences 
between RUNX1, RUNX1 ETO and H RAS
V12 induced senescent phenotypes in Hs68 
cells.  In  contrast  to  previous  reports  where  RUNX1  has  been  reported  to 
stimulate  p19
ARF  while  RUNX1 ETO  to  have  the  opposite  effect  (Linggi  et  al 
2002), p14
ARF status in Hs68 human fibroblasts was unaffected by either RUNX1 
or  RUNX1 ETO,  consistent  with  the  notion  that  the  ARF  locus  is  not  a  major 
regulator of cellular senescence in human cells (Wei et al 2001, Brookes at al 
2002). Interestingly, expression levels of the downstream target of p14
ARF, p53, 
were  profoundly  upregulated  by  RUNX1 ETO  and  to  a  much  lesser  extent  by 
RUNX1. Because PML has been shown to be involved in the regulation of p53 in 
senescence  (Ferbeyre  et  al  2000;  Langley  et  al  2002;  Pearson  et  al  2000), 
theoretically it could be responsible for these differences. Indeed, fluorescent 
confocal scanning microscopy revealed increased PML nuclear bodies in RUNX1 
ETO and H RAS
V12 expressing cells but not in RUNX1 expressing cells suggesting a 
direct link between PML and p53 status in these cells. Furthermore, although 
p53 was highly elevated by RUNX1 ETO, the expression levels of the downstream 
effector of p53, p21
WAF1, were dramatically induced by RUNX1 but not by RUNX1 
ETO. Given that the p21
WAF1 promoter contains RUNX1 DNA binding sites it is 
conceivable  that  RUNX1  and  RUNX1 ETO  exert  direct  and  opposing 
transcriptional  effects  on  p21
WAF1  promoter  in  Hs68  human  fibroblasts.  The 
antagonistic activities of RUNX1 and RUNX1 ETO were also apparent with regard 
to  the  p16
INK4a  locus  where  only  RUNX1  induced  p16
INK4a  expression  to  a 
substantial  level  although  not  as  strongly  as  H RAS
V12.  p38  MAPK  has  been 
recently  identified  as  a  major  regulator  of  cellular  senescence  caused  by  a Kamil K. Wolyniec, 2008     Chapter 5,139  
diverse spectrum of signals (Iwasa et al., 2003) and it has been proposed to be 
involved in the downstream activation of negative regulators of the cell cycle 
such as p16
INK4A and p53 during H RAS
V12 induced senescence (Iwasa et al 2003; 
Wang  et  al  2002;  Sun  et  al  2007).  Western  blot  analysis  revealed  profound 
induction  of  the  activated  form  of  p38  MAPK,  phospho p38,  in  RUNX1 ETO 
expressing  cells  and  a  much  weaker  induction  in  RUNX1  expressing  cells. 
Notably, the degree of activation of p38 in these cells appeared to correlate 
with  the  potency  of  p53  upregulation  suggesting  the  existence  of  a  common 
regulatory signalling pathway whereby p38 may regulate p53 expression and vice 
versa. Interestingly, increased p38 activation in RUNX1 ETO expressing cells did 
not have an effect on p16
INK4a, in contrast to H RAS
V12, where p38 MAPK has been 
demonstrated  to  stabilise  p16
INK4a  mRNA  levels  (Wang  et  al  2002).  The  next 
question that arose was related to the upstream signals activating p38. In H 
RAS
V12  induced  senescence  increased  ROS  levels  have  been  linked  to  the 
activation  of  p38  MAPK  (Nicke  et  al  2002;  Sun  et  al  2007).  Both  RUNX1  and 
RUNX1 ETO expressing cells were found to have elevated levels of ROS which 
paralleled the induction of p38 phosphorylation suggesting that ROS may play a 
role in the activation of p38 in RUNX1 and RUNX1 ETO expressing Hs68 human 
fibroblasts. The generation of high ROS levels has been postulated to be one of 
the potential causes of DNA double strand break accumulation and DNA damage 
responses in senescent cells (Lee et al 1999). Interestingly, despite increases in 
ROS levels induced by RUNX1 and RUNX1 ETO, convincing DSBs as visualised by γ–
H2AX foci were not observed. It is possible that the activity of ROS could be 
modulated by RUNX1 and RUNX1 ETO due to their action as second messengers 
in  signal  transduction  pathways.  The  accumulation  of  γ–H2AX  foci  associated 
with  oncogene induced  senescence  has  also  been  associated  with  ‘replicative 
stress’  occurring  due  to  a  strong  proliferative  burst  preceding  growth  arrest 
(DiMicco  et  al  2006).  Neither  RUNX1  nor  RUNX1 ETO  showed  any  hyper 
proliferation but instead displayed strong growth suppression immediately after 
viral transductions which may partially explain lack of γ–H2AX foci in these cells. 
Another  interesting  finding  was  that  both  RUNX1  and  RUNX1 ETO  induced 
senescent cells, in contrast to H RAS
V12 expressing cells, exhibited lack of SAHF. 
The  p16
INK4a/pRb  pathway  has  been  shown  to  be  involved  in  SAHF  formation 
(Narita et al 2003), therefore it is possible that RUNX1 ETO expressing cells did Kamil K. Wolyniec, 2008     Chapter 5,140  
not show SAHF because p16
INK4a was not upregulated in these cells. In support of 
this,  STAT5a  induced  senescence  in  human  primary  fibroblasts  also  does  not 
involve induction of p16
INK4a or SAHF formation (Hemann and Narita, 2008), but 
unusually despite p16
INK4a upregulation in RUNX1 induced senescent cells, SAHF 
are not present. Since the induction of p16
INK4a by RUNX1 was not as potent as 
that  of  H RAS
V12  it  is  plausible  that  a  certain  threshold  level  of  p16
INK4a 
expression  needs  to  be  achieved  in  order  to  initiate  the  process  of  SAHF 
formation. Also the mechanism of SAHF formation relies not only p16/pRb but 
also on many other components such as HIRA/ASF1a and PML that are required 
to  interact  in  a  specific  spatio temporal  manner  (Adams  2007).  RUNX1  may 
interfere  with  these  processes  especially  since  it  fails  to  induce  PML  bodies. 
These results identify RUNX1, RUNX1 ETO and H RAS
V12 induced senescence as 
distinct  programmes  engaging  diverse  signalling  pathways,  however  the 
biological relevance of these findings remains to be investigated further. 141 
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6  Dissecting  functional  requirements  of  the  host 
cell  for  RUNX1  and  RUNX1-ETO  induced 
senescence 
6.1  Introduction 
Characterisation of RUNX1 and RUNX1 ETO induced senescence has revealed a 
number  of  interesting  differences  from  the  pathways  previously  reported  to 
execute this cellular programme. Of particular importance was the finding that 
overexpression of RUNX1 or RUNX1 ETO led to differing levels of p16
INK4a, p53 
and  p38  MAPK  induction.  Hence  it  was  important  to  examine  the  functional 
requirements for these mediators in RUNX1 and RUNX1 ETO induced senescence 
in primary fibroblasts. In human cells, as opposed to murine cells, Ras has been 
reported  to  drive  premature  senescence  by  a  p53  independent  mechanism 
despite strong induction of p53 (Wei et al 2001; Bischof et al 2005). It relies, 
however, on intact p16
INK4a and p38 MAPK for senescence induction (Wang et al 
2002; Brookes et al 2002). 
6.2  The  requirement  for  p38  MAPK  in  RUNX1  and 
RUNX1-ETO induced senescence in Hs68 cells 
Inactivation  of  p38  MAPK  by  the  inhibitor  SB203580  or  dominant negative 
mutants of MKK3 and MKK6 at least partially rescues senescence induced by H 
RAS
V12 or replicative and oxidative stress induced senescence (Wang et al 2002, 
Iwasa  et  al  2003).  RUNX1 ETO  and  to  a  lesser  extent  RUNX1  activates  p38 
(Section 5.4, Chapter 5). Requirement for p38 in RUNX1 and RUNX1 ETO induced 
senescence  was  investigated  using  the  p38  inhibitor  (SB203580)  to 
pharmacologically  abrogate  p38  function.  If  p38  activation  is  an  important 
mediator of RUNX1 and or RUNX1 ETO induced senescence, its inhibition should 
prevent or delay onset of the phenotype. Kamil K. Wolyniec, 2008     Chapter 6,143  
RUNX1, RUNX1 ETO and H RAS
V12 were introduced to human neonatal foreskin 
fibroblasts via retroviral gene transfer and after puromycin selection cells were 
cultured  in  the  presence  or  absence  of  8 M  SB203580.  Cells  containing  the 
empty vector grew well in both the presence and absence of SB203580. By day 7 
there  was  a  substantial  fraction  of  cells  positive  for  SA β-Gal  in  the  RUNX1, 
RUNX1 ETO  and  H RAS
V12  expressing  cells  (Figure  6.1a).  However,  in  the 
presence  of  the  p38  MAPK  inhibitor  there  was  a  significant  increase  in  the 
growth  rate  of  RUNX1 ETO  expressing  cells  (RUNX1 ETO(SB)  vs  RUNX1 
ETO(DMSO),  day12  p≤0.005)  (Figure  6.1a),  and  fewer  cells  had  a  flattened 
morphology or SA β-Gal activity (Figure 1b). A similar effect was observed for H 
RAS
V12  expressing  cells  (RAS(SB)  vs  RAS(DMSO),  day12  p=0.01)  (Figure  6.1a) 
consistent  with  previous  reports  (Wang  et  al.,  2002).  Treatment  of  RUNX1 
expressing cells with SB203580 also resulted in a partial rescue of the growth 
arrest (Figure 6.1a) (RUNX1(SB) vs RUNX1(DMSO), day 12 p≤0.05) and reduced 
senescence associated characteristics (flat, enlarged cells with SA β-Gal activity) 
(Figure 6.1b), however the effect was clearly less pronounced relative to RUNX1 
ETO  expressing  cells.  These  results  indicate  that  RUNX1 ETO  and  RUNX1  are 
dependent at least to some extent on p38 MAPK to induce senescence in Hs68 
fibroblasts. However, the growth rates of RUNX1 ETO, RUNX1 or H RAS
V12 in the 
presence of inhibitor were still lower than that of the control cells (Figure 6.1a). 
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Figure 6.1 Inhibition of p38MAPK rescues RUNX1-ETO and RUNX1 induced 
senescence in Hs68 cells 
Cells were transduced with retroviral vectors expressing RUNX1, RUNX1 ETO, H 
Ras
V12 or control vector (pBabe), selected in puromycin and then fed daily with 
fresh  medium  containing  8 M  SB203580  (SB)  or  vehicle  alone  (DMSO)  (a) 
Representative  growth  curves  illustrating  the  effects  of  p38MAPK  inhibitor 
(SB203580) on proliferation of RUNX1 ETO, RUNX1 or H Ras
V12 cells 
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Figure 6.1 continued 
(b) SA b Gal staining of SB203580 treated (SB) cells and mock treated Hs68 cells 
(DMSO) containing control vector (pBabe), RUNX1, RUNX1 ETO or H RAS
V12 (H 
RAS
V12) on day 9 post selection 
b) 
RUNX1 
H-RAS
V12 
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6.3  RUNX1 and RUNX1-ETO differ in their requirement 
for p16
INK4a to induce senescence 
Elevated  p16
INK4a  levels  are  usually  seen  in  human  cells  that  have  undergone 
either  replicative  senescence  or  H RAS
V12  induced  senescence  (Brookes  et  al 
2004; Serrano et al 1997). While increased p16
INK4a was found in cells transduced 
with RUNX1, no such effect was found in RUNX1 ETO induced senescence in Hs68 
cells suggesting that a different mechanism may be involved. Therefore it was 
important to determine whether p16
INK4a was required for RUNX1 ETO induced 
senescence.  Leiden  human  diploid  fibroblasts  were  originally  isolated  from  a 
rare individual homozygous for an intragenic 19bp deletion in the second exon of 
CDKN2A, and therefore lacking functional p16
INK4a but retaining p14
ARF activity. It 
has  been  reported  previously  that  Leiden  cells  are  resistant  to  H RAS
V12 
mediated  senescence like  growth  arrest  (Brookes  at  al  2002)  indicating  that 
p16
INK4a is absolutely required by oncogenic RAS. 
To  this  end  Leiden  cells  previously  engineered  to  express  an  ecotropic  virus 
receptor were transduced either with control vector (pBabe), RUNX1, RUNX1 
ETO  or  H RAS
V12.  Interestingly,  these  p16 deficient  cells  underwent  profound 
premature  senescence  when  RUNX1 ETO  was  overexpressed.  The  senescent 
phenotype was confirmed by a cessation of proliferation (RUNX1 vs pBabe, day8, 
p≤0.001)  (Figure  6.2a)  morphologic  alterations  (increased  cell  volume,  gross 
flattening) and SA b Gal staining (Figure 6.2b, c). Initially, RUNX1 and H RAS
V12 
caused a moderate growth suppression but despite this, these cells continued to 
increase their numbers exponentially from day 6 onwards (RUNX1 vs RUNX1 ETO, 
day  9,  p=0.01;  H RAS
V12  vs  RUNX1 ETO,  day  9,  p≤0.005)  (Figure  6.2a)  and 
displayed no SA b Gal activity at day 8 (Figure 6.2b). All the ectopic proteins 
were readily expressed as determined by western blot analysis (Figure 6.2c). It 
seems  that  RUNX1  and  H RAS
V12  induced  senescence  share  a  requirement  for 
p16
INK4a but RUNX1 ETO can induce senescence even in the absence of p16
INK4a. 
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Figure  6.2  RUNX1-ETO  does  not  require  p16  to  induce  senescence  in 
contrast with RUNX1 
Leiden cells were transduced with retroviral vectors expressing RUNX1, RUNX1 
ETO, H Ras
V12 or control vector (pBabe) and selected for 4 days in puromycin (a) 
Representative growth curves of cells containing control vector (pBabe), RUNX1, 
RUNX1 ETO  or  H Ras
V12.  Similar  results  were  observed  in  three  independent 
experiments and each time point was determined in triplicate 
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Figure 6.2 continued 
(b) SA β Gal staining of Leiden cells containing control vector (pBabe), RUNX1, 
RUNX1 ETO or H Ras
V12 (day 8 post selection) 
(c)  Western  blot  analysis  of  RUNX1  (anti-AML1/Runx1,  3900,  Active  Motif), 
RUNX1 ETO (anti-RUNX1-ETO from Dr. Scott Hiebert) or H Ras
V12 (anti H ras, Ab 
1, Oncogene Research) expression in Leiden cells containing control vector (pB), 
RUNX1 (RX), RUNX1 ETO (RX E) or H Ras
V12 (R) (day 7 post selection) 
pBabe 
RUNX1  RUNX1-ETO 
H-RAS
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b) 
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6.4  The requirement for p53 in RUNX1 and RUNX1-ETO 
induced senescence in human primary fibroblasts 
Given that p16
INK4a was not required to mediate senescence like growth arrest in 
response to RUNX1 ETO but p53 expression was profoundly upregulated under 
the same conditions it was of interest to determine the functional role of p53 
during RUNX1 ETO induced senescence in human fibroblasts. To this end Hs68 
cell  were  transduced  with  HPV16  E6  oncoprotein  (E6),  which  acts  to 
downregulate p53, or empty vector (LXSN). It was not possible to select these 
cells  on  the  basis  of  neomycin  resistance  as  this  was  already  a  property 
conferred  on  the  cells  through  neomycin  selection  for  the  ecotropic  virus 
receptor.  However,  cultures  transduced  with  HPV16  E6  showed  an  obvious 
growth advantage over cultures transduced with the empty vector (E6 vs LXSN, 
day 7, p≤0.05) (Figure 6.3a). After 4 days neomycin pseudo selection, these cells 
were subsequently infected with retroviruses encoding RUNX1, RUNX1 ETO, H 
RAS
V12 or control vector (pBabe) and selected with puromycin. The capability of 
HPV16 E6 to downregulate p53 was confirmed by western blot analysis (Figure 
6.3b). Consistent with previous reports [Wei et al., 2001; Bischof et al., 2005], 
H RAS
V12 did not require p53 to induce senescence in human primary fibroblasts 
as  shown  by  growth  curves  (H RAS
V12  (E6)  vs  H RAS
V12  (LXSN),  day  7,  p=0.5) 
(Figure 6.3a) and SA b Gal staining (Figure 6.3b). RUNX1 induced a growth arrest 
that  was  partially  rescued  by  E6  but  only  at  day  10  was  this  statistically 
significant (RUNX1(E6) vs RUNX1(LXSN), day 10, p=0.05) (Figure 6.3a) and some 
flat  and  enlarged  cells  remained  that  exhibited  the  SA b Gal  marker  (Figure 
6.3c). In contrast, proliferation of RUNX1 ETO expressing cells was substantially 
rescued by E6 (RUNX1 ETO(E6) vs RUNX1 ETO(LXSN), day 7, p≤0.01) (Figure 6.3a) 
and  SA b Gal  staining  as  well  as  the  characteristic  flattened  cell  morphology 
were dramatically reduced (Figure 6.3c). These data suggest that RUNX1 ETO 
induced senescence has a greater dependence on p53 than RUNX1. 
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Figure 6.3 HPV16 E6 abrogates RUNX1-ETO induced senescence but only 
partially abrogates RUNX1 senescence in Hs68 cells 
Hs68 cells containing HPV16 E6 (E6) or control vector (LXSN) were cotransduced 
with  retroviral  vectors  expressing  RUNX1,  RUNX1 ETO,  H RasV12  or  control 
vector (pBabe). (a) Representative growth curves of cells containing HPV16 E6 
(E6) or control vector (LXSN) cotransduced with RUNX1, RUNX1 ETO or H RAS
V12. 
Similar results were observed in three independent experiments and each time 
point was determined in triplicate. (b) Western Blot analysis of p53 expression 
(anti p53, sc 126, Santa Cruz) in the indicated populations of cells containing 
control vector (pB),  RUNX1  (RX),  RUNX1 ETO (RX E) or H RAS
V12  (R) on day 7 
post selection 
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Figure 6.3 continued 
(c) SA b Gal staining of cells containing HPV16 E6 (E6) or control vector (LXSN) 
cotransduced with RUNX1, RUNX1 ETO, H RAS
V12 or control vector (pBabe) (day 8 
post selection) 
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6.5  RUNX1-ETO  fails  to  induce  senescence  in  p53 
deficient murine embryonic fibroblasts 
It has been shown in this laboratory previously that p53 is a critical regulator of 
RUNX1 induced senescence in MEFs since RUNX1 pro oncogenic potential can be 
revealed on p53 null genetic background (Wotton et  al 2004). Unlike RUNX1, 
RUNX1 ETO displayed obvious p53 dependence in human fibroblasts Hs68, hence 
it was interesting to see if the p53 pathway is also relevant in murine cell.  
To  determine  whether  p53  is  required  for  RUNX1 ETO  induced  senescence  in 
murine  primary  cells,  p53
 /   MEFs  were  infected  with  retroviruses  containing 
RUNX1 ETO, RUNX1 or empty vector (pBabe). RUNX1 and RUNX1 ETO transduced 
cells  expressed  detectable  levels  of  transgene  (Figure  6.4a),  accumulated 
exponentially and had comparable growth rates, although RUNX1 expressing cells 
grew slightly better (RUNX1 vs RUNX1 ETO, day 9, p≤0.05) (Figure 6.4b). The 
populations of RUNX1 ETO and RUNX1 cells were quite heterogeneous but no 
flattened  and  enlarged  cells  indicative  of  senescence  were  observed.  As 
reported previously (Wotton et al 2004), RUNX1 expressing p53 null MEFs can 
show  two  distinct  morphological  phenomena  i)  a  shift  to  an  epithelial like 
morphology (Figure 6.4c)  and ii) the sporadic appearance of transformation foci 
(Figure 6.4d). Similar changes were not observed in RUNX1 ETO expressing or 
empty vector control cells (Figure 6.4c, d). Interestingly, p53 null primary MEFs 
expressing  RUNX1 ETO  morphologically  resembled  immortalised  3T3  cells  and 
were  quite  distinct  from  either  RUNX1  expressing  or  control  cell  populations 
(Figure 6.4c, d). These results show that RUNX1 ETO requires p53 in MEFs and 
highlights the importance of p53 in RUNX1 ETO induced senescence. 
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Figure 6.4 p53null MEFs are resistant to RUNX1-ETO induced senescence 
p53
 /  MEFs were transduced with retroviral vectors expressing RUNX1, RUNX1 
ETO, H Ras
V12 or control vector (pBabe) and selected for 4 days in puromycin (a) 
Western blot analysis of RUNX1 (anti AML1/Runx1, 3900, Active Motif), RUNX1 
ETO  (anti-RUNX1-ETO  from  Dr.  Scott  Hiebert)  expression  in  p53
 /   MEFs 
containing control vector (pB), RUNX1 (RX) or RUNX1 ETO (RX E) (day 7 post 
selection);  *     non specific  bands  (b)  Representative  growth  curves  of  cells 
containing  control  vector  (pBabe),  RUNX1,  RUNX1 ETO  or  H Ras
V12.  Similar 
results were observed in three independent experiments and each time point 
was determined in triplicate  
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Figure 6.4 continued 
(c)  Phase contrast  photomicrographs  of  p53
 /   MEFs  containing  empty  vector 
(pBabe),  RUNX1  or  RUNX1 ETO  taken  on  day  7  post selection  (d)  Microscopic 
photographs of p53
 /  MEFs containing empty vector (pBabe), RUNX1 or RUNX1 
ETO taken on day 20 post selection 
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6.6  Discussion 
These  investigations into the  requirement  for p16
INK4a, p53 and p38  kinase  in 
RUNX1 and RUNX1 ETO induced senescence have revealed significant differences 
in the pathways executing these cellular programmes in primary fibroblasts. The 
exciting finding was that RUNX1 ETO, in contrast to RUNX1 and H RAS
V12 could 
drive  premature  senescence  in  the  absence  of  p16
INK4a.  Very  few  oncogenes 
bypass  p16
INK4a  signalling  in  primary  human  cells  to  provoke  a  senescence 
response. One example is RAF in human mammary epithelial cells (Olsen et al 
2002).  Further  analysis  identified  p53  and  p38  MAPK  as  important  signal 
transducers in RUNX1 ETO induced senescence since their inactivation either by 
HPV16 E6 (p53) or the selective inhibitor of p38 MAPK SB203580, substantially 
rescued the senescent phenotype. In both cases, however, it was not a complete 
effect and rescued RUNX1 ETO expressing  cells did not proliferate  as well as 
control cells. Given that HPV16 E6 profoundly downregulated p53 as determined 
by western blot it seems unlikely that it was due to incomplete p53 ablation and 
it is possible that there are other cooperating factors that regulate growth arrest 
during RUNX1 ETO induced senescence. The evidence supporting an important 
role  for  p53  in  RUNX1 ETO  induced  senescence  was  provided  by  the  lack  of 
premature  senescence  in  p53  null  primary  MEFs.  In  this  system,  RUNX1 ETO 
expressing cells proliferated slower than control cells and in contrast to RUNX1 
expressing cells displayed no signs of foci formation, indicating that RUNX1 ETO 
requires  additional  events  to  become  oncogenic.  Notably,  while  substantial 
proportion of RUNX1 expressing p53 null MEFs aquired epitheloid morphology, 
RUNX1 ETO cells remained fibroblastic. As far as p38 MAPK is concerned it should 
be stressed that the inhibitor used in this study inhibits only the α and β isoforms 
of p38, therefore the two other isoforms γ and δ may account for the partial 
complementary effect. Also, because the inhibitor was added to cultures 4 days 
after the actual viral transduction, irreversible changes refractory to the effects 
of the inhibitor might have occurred by this time. In contrast to RUNX1 ETO, 
RUNX1  was  found  to  require  p16
INK4a  since  it  failed  to  drive  premature 
senescence  in  p16  deficient  Leiden  human  fibroblasts  and  showed  a  lesser 
response to p53 inactivation in Hs68 fibroblasts. Interestingly, RUNX1 induced 
senescence also relies on p38 MAPK since its inhibition with SB203580 partially Kamil K. Wolyniec, 2008     Chapter 6,156  
rescues senescence like growth arrest. Taken together these data identify p38 
MAPK  as  a  common  signalling  pathway  in  RUNX1  and  RUNX1 ETO  induced 
senescence  in  human  fibroblasts  consistent  with  its  universal  role  in  various 
types of senescence. On the other hand differential requirements for p16
INK4a 
and  p53  by  RUNX  and  RUNX1 ETO  have  been  identified.  Unlike  RUNX1 ETO 
induced  senescence  which  is  p53  dependent,  RUNX1  induced  senescence 
predominantly requires p16
INK4a. 157 
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7  General discussion and future directions 
Currently  cellular  senescence  is  regarded  as  an  important  anti cancer 
mechanism  that  restricts  uncontrolled  proliferation  of  cells  and  prevents 
neoplastic  transformation  in  vitro  and  in  vivo  and  is  recognised  as  a  tumour 
suppressor mechanism that is equally important as apoptosis and governed by 
the  p53  and  pRb  pathways.  While  its  importance  is  beyond  doubt,  there  are 
many key questions yet to be answered: 
·  Why certain oncogenes induce senescence while others induce apoptosis, 
is this due to the strength and/or duration of a signal or perhaps to the 
cell type and specificity of oncogenic signal or both? 
·  How homogeneous is this response in different cellular contexts?  
·  Which features of senescent phenotype are of fundamental importance? 
·   How universal is DNA damage signalling or chromatin remodelling in the 
context of senescence and do they represent cause or effect?  
·  What are the fundamental mechanisms leading to senescence and why do 
they appear to differ in mouse and human cells? 
In  this  study  I  have  demonstrated  for  the  first  time  that  RUNX1  induces 
senescence  in  human  primary  fibroblasts  and  that  RUNX1/CBFβ  derived 
oncogenic fusion proteins associated with human leukaemias such as: RUNX1 
ETO and CBFβ  MYH11 also retain the potential to drive premature senescence. 
Further characterisation of RUNX1 and RUNX1 ETO induced senescence has not 
only  revealed  interesting  similarities  and  differences  with  regard  to  the 
signalling pathways underlying these senescence programmes, but also provided 
evidence that these senescent phenotypes are distinct from classical oncogene 
induced senescence as exemplified by RAS. This study has shed new light on 
central  aspects  of  cellular  senescence  and  demonstrates  how  complex  and 
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Previous studies in this laboratory showed that inducible RUNX1 ER (RUNX1 fused 
to  oestrogen  receptor)  is  a  potent  inducer  of  premature  senescence  in  MEFs 
(Wotton et al 2004). The disruption of p53 allowed bypass of senescence and 
promoted  increased  survival  and  partial  transformation  (Wotton  et  al  2004). 
Interestingly, the promotion of senescence by RUNX1 was seen in the presence 
and absence of inducer (tamoxifen) and some RUNX1 ER protein was present in 
the  nucleus  even  without  treatment  with  tamoxifen  suggesting  that  the 
senescence response was either mediated by protein protein interactions or that 
there was a leakiness in the system sufficient to induce the phenotype (Wotton 
et  al  2004).  Therefore  it  was  important  to  dissect  RUNX1  functional 
requirements for induction of premature senescence. I addressed this issue by 
testing  the  ability  of  DNA  and  CBFβ  binding  mutants  of  RUNX1  to  induce 
senescence.  Unlike  RUNX1,  ectopic  expression  of  these  constructs  failed  to 
trigger  a  senescence  response,  providing  evidence  that  RUNX1  absolutely 
requires  both  intact  DNA  and  CBFβ  binding  activity  and  indicating  that  high 
affinity binding to the target DNA sequences in the nucleus is probably critical. 
Importantly, I have found that the ability of RUNX1 to induce senescence seems 
to  be  a  universal  feature  of  RUNX1  overexpression  since  RUNX1  also  induces 
senescence in human primary fibroblasts Hs68. As found in MEFs, neither the 
DNA  binding  mutant  nor  the  CBFβ  interaction  mutant  was  able  to  induce 
senescence  in  human  cells.  Further  investigations  into  functional  domains  of 
RUNX1,  revealed  that  RUNX1  relies  on  its  C terminal  domain  to  induce 
senescence in Hs68 fibroblasts as shown by comparison with AML1a, a truncated 
isoform of RUNX1. Given that the C terminal portion of RUNX1 contains both a 
transactivation domain and a repression domain it remains unclear which mode 
of action is more important once RUNX1 has bound to the DNA target sequences. 
This could be examined by testing the ability of RUNX1 fused to constitutive 
transactivation domain such as VP16 to induce senescence in primary cells (Cao 
et al 1998). Conversely, it was also of particular interest to examine effects of 
RUNX1 ETO  overexpression  since  RUNX1 ETO,  like  AML1a,  not  only  lacks  the 
RUNX1 C terminal domain but is also thought to act as a constitutive repressor of 
wild type RUNX1. 
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The finding that RUNX1 ETO induced senescence in murine and human primary 
fibroblasts more potently than RUNX1 itself was exciting and surprising since it is 
reported to repress the ARF promoter (Linggi et al 2002). This not only suggests 
that,  in  contrast  to  RUNX1,  ARF  is  dispensable  for  RUNX1 ETO  induced 
senescence in MEFs, but also indicated that RUNX1 ETO oncoprotein may have 
additional functions independent of RUNX1 that may be attributed to its fusion 
partner  protein,  ETO.  Indeed,  overexpression  of  the  mutant  of  RUNX1 ETO 
containing the deletion of ETO corepressor binding sites (RUNX1 ETO∆469) failed 
to induce senescence, suggesting that RUNX1 ETO mediated senescence results 
from repression of important target genes whereas it is not clear whether RUNX1 
induced senescence relies on transcriptional activation and/or repression. One 
explanation may be that RUNX1 functions  as a  repressor whereas RUNX1 ETO 
acts  as  a  super repressor  and  therefore  induces  a  more  profound  senescent 
phenotype.  If  this  was  true  the  signalling  pathways  underlying  RUNX1  and 
RUNX1 ETO induced senescence would be commonly engaged.  
 
The discovery that the RUNX1 ETO oncoprotein drives premature senescence in 
murine and human fibroblasts may have more general clinical implications. The 
relevance  of  senescence  in  haematopoietic  tissues  and  cancer  is  an  area  of 
growing interest (Braig et al 2005; Wu et al 2007). Given that the RUNX1 ETO 
fusion protein,  a product of t(8;21) translocation  in AML, is  not sufficient to 
cause leukaemia alone in various experimental models (Yuan et al 2001; Higuchi 
et al., 2002, Peterson et al., 2007), one possibility is that it initially triggers 
cellular senescence, a cancer fail safe mechanism which needs to be overcome 
to induce full blown malignancy. Interestingly, a truncated form of RUNX1 ETO 
(552 amino acids) with a deleted C terminal NcoR/SMRT interacting region [Yan 
et al 2004] as well as an alternatively spliced AML ETO9a isoform (572 amino 
acids) that has been recently identified in AML patients (Yan et al 2006) both 
strongly  induce  leukaemogenesis  in  mice.  These  two  leukaemogenic  forms  of 
RUNX1 ETO show remarkable similarity to RUNX1 ETO∆469 which, in contrast to 
RUNX1 ETO, failed to induce senescence in Hs68 cells. Hence, it is tempting to 
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they  are  intrinsically  capable  of  overcoming  senescence.  In  view  of  these 
observations,  it  was  interesting  to  discover  that  another  leukaemia related 
fusion oncoprotein CBFβ MYH11 also induced senescence in human primary cells, 
although  less  potently  than  RUNX1 ETO.  Importantly,  recent  studies  show 
collaboration  between  RUNX1 ETO  and  CBFβ MYH11  oncoproteins  and  genetic 
inactivation  of  senescence  mediators  such  as  p19
ARF,  p16
INK4a  and  p21
WAF1  in 
murine in vivo models of leukaemogenesis (Peterson et al 2007; Moreno Miralles 
et  al  2005;  Yang  et  al  2002).  However,  the  TEL RUNX1  oncoprotein  which  is 
associated with B ALL, did not induce senescence in Hs68 cells suggesting that 
TEL RUNX1  functions  differently  from  RUNX1 ETO  and  CBFβ MYH1  and/or  it 
requires higher levels of expression to trigger cellular senescence in this system. 
This  may  also  suggest  an  important  loss of function  event  of  TEL RUNX1, 
intracellular misdirection or steric hindrance at crucial target gene promoters. It 
will be important to explore these hypotheses by analysis of deletion mutants of 
TEL RUNX1 lacking domains of TEL to look for rescue of the ability to induce 
senescence. 
 
The comparative characterisation of RUNX1, RUNX1 ETO and H RAS
V12 induced 
senescence  in  human  primary  fibroblasts  revealed  interesting  differences  and 
similarities  in  the  phenotypes  and  pathways  regulating  these  cellular 
programmes (Table 7.1). From the analysis of the expression of growth inhibitory 
proteins it became apparent that RUNX1 but not RUNX1 ETO expressing cells had 
elevated levels of p16
INK4a (Chapter 5, Section 5.3). The requirement for p16
INK4a 
was confirmed by the lack of senescence induction by RUNX1 in p16null Leiden 
human fibroblasts.  
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   pBABE  RUNX1  RUNX1 ETO  RAS 
P16     ++  +  +++ 
P53  +/   +  +++  +++ 
P21  +/   ++  +  +++ 
P14             
Phospho p38     +  +++  +++ 
Cell  cycle 
arrest 
   G1>G2M  G1<G2/M  G1≥G2M 
ROS     +  +++  +++ 
Hyper 
proliferation 
         + 
γ H2AX foci           + 
SAHF           + 
PML  bodies 
accumulation 
      +  + 
Senescence –
asscociated 
β gal 
   +  +  + 
 
Table 7.1 Comparison of known hallmarks of senescence 
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However,  RUNX1 ETO,  unlike  RUNX1  or  H RAS
V12,  was  able  to  drive  profound 
premature senescence even in the absence of p16
INK4a indicating that different 
pathways  are  required  by  RUNX1  and  RUNX1 ETO  (Chapter  6,  Section  6.3). 
Interestingly,  it  has  been  recently  reported  that  p16
INK4a  deficiency  does  not 
promote RUNX1 ETO associated leukaemia in mice (Ko et al 2008). In contrast to 
RUNX1, RUNX1 ETO strongly upregulated p53 and inactivation of p53 by HPV16 
E6 substantially supressed RUNX1 ETO but not the RUNX1 senescent phenotype, 
re emphasising the fact that RUNX1 and RUNX1 ETO operate via distinct routes 
(Chapter 5, Section 5.3 and Chapter 6, section 6.4). RUNX1 ETO also induces a 
p53 dependent  senescence  in  primary  MEFs  (Chapter  6,  Section  6.5).  This 
suggests  that  p53  may  play  an  important  role  in  RUNX1 ETO  driven 
tumourigenesis. While p53 is central to the process in vitro, the mechanism by 
which senescence pathways are overcome in leukaemias is as yet unknown. The 
mutations  of  tumour  suppressor  genes  are  common  events  in  human 
haematological  malignancies.  Mutations  of  p53  have  been  found  in 
haematological malignant diseases, but the frequency of theses alterations  is 
much lower than in solid tumours (14% vs >50%) (Krug et al 2002). The p53  gene 
is not commonly mutated in primary t(8;21) AML (Imamura et al 1994; Krug et al 
2002) but is frequently lost, mutated or modulated in t(8;21) cell lines such as 
Kasumi 1 and SKNO (Banker et al 1998a; Banker et al 1998b) and mutations of 
p53 are commonly associated with therapy related AML/MDS (Christiansen et al 
2001; Fenaux et al 1992; Horiike et al 1999; Jonveaux et al 1991; Lai et al 1995). 
Loss of p53 function has been also linked to drug resistance and correlates with 
poor  prognosis  in  AML  patients  (Melo  et  al  2002;  Nakano  et  al  2000). 
Paradoxically, the expression of p21
WAF1, the downstream effector of p53 was 
dramatically increased in RUNX1 but not RUNX1 ETO expressing Hs68 fibroblasts 
(Chapter  5,  Section  5.3).  Given  that  p21
WAF  is  a  well  known  direct  target  of 
RUNX1 (Lutterbach et al 2000) it is possible that RUNX1 and RUNX1 ETO exert 
opposing direct effects on the p21
WAF1 promoter in this cell system and it will be 
important to investigate the requirement for p21
WAF1 further. Given that p21
WAF1 
was not completely downregulated in RUNX1 ETO expressing cells and that the 
p21
WAF1  pathway  has  been  demonstrated  to  be  involved  in  blocking 
leukaemogenesis induced by RUNX1 ETO in mice (Paterson et al 2007) it would 
be interesting to evaluate the role of p21
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down its expression by shRNA or employing p21
 /     MEFs (Pantoja et al 1999) or 
p21
 /  human fibroblasts (Wei et al 2001). Consistent with a dominant role of p53 
in RUNX1 ETO induced senescence, the ectopic expression of p53 alone partially 
recapitulates the senescent phenotype in Hs68 cells, causing a profound growth 
arrest,  although  with  less  pronounced  alterations  to  cellular  morphology  and 
weaker  SA β Gal  staining  compared  to  RUNX1 ETO  (Chapter  5,  Section  5.8), 
indicating that RUNX1 ETO induces senescence via p53 yet apparently modulates 
its  signalling  pathway.  Therefore,  it  was  important  to  find  out  how  p53  is 
upregulated. ARF MDM2 p53 is a well established regulatory pathway whereby 
ARF  is  thought  to  antagonise  MDM2 mediated  ubiquitination  of  p53  through 
translocation of MDM2 to the nucleolus, thereby stabilising p53 (Lowe and Sherr, 
2003).  It  was  of  particular  interest  to  determine  whether  p14
ARF  is  affected 
either by RUNX1 or RUNX1 ETO expression in Hs68 cells since RUNX1 and RUNX1 
ETO have been reported to have opposing effects on this gene locus in primary 
MEFs  (Linggi  et  al  2002).  Intriguingly  p14
ARF  was  not  upregulated  neither  by 
RUNX1 ETO nor RUNX1 (Chapter 5, Section 5.3). This observation supports the 
notion that p14
ARF is not strongly implicated in cellular senescence  in human 
cells, except for its crucial role in E2F induced senescence (Dimri et al 2000). 
Another molecule that could potentially stabilise p53 is PML. PML is an important 
component of senescence pathways and has been demonstrated to regulate p53 
via several post translational modifications (Bischof et al 2002; Ferbeyre et al 
2000,  Pearson  et  al  2000).  It  has  been  also  reported  to  stabilize  p53  by 
sequestering  MDM2  to  the  nucleolus  (Bernardi  et  al  2004).  Fluorescence 
microscopy has revealed increased size of PML bodies (also known as PODs for 
PML oncogenic domains) in RUNX1 ETO but not RUNX1 expressing cells suggesting 
that  PML  may  indeed  be  at  least  partially  responsible  for  increased  p53 
expression and vice versa consistent with the notion that PML is a downstream 
target  of  p53  (DeStanchina  et  al  2004)  (Chapter  5,  Section  5.6).  It  will  be 
important to validate this finding by overexpressing RUNX1 ETO in human diploid 
fibroblasts containing shRNA for PML. Another growing body of evidence suggests 
that p38 MAPK can contribute to p53 regulation (Bulavin et al., 1999; (Huang et 
al 1999); Wang et al 2002, Sun et al 2007). Indeed, levels of the activated form 
of  p38,  phospho p38,  were  significantly  elevated  in  RUNX1 ETO  or  H RAS
V12 
expressing  cells  (Chapter  5,  Section  5.4)  as  previously  reported  (Wang  et  al Kamil K. Wolyniec, 2008     Chapter 7,165  
2002)  and  correlated  well  with  the  induction  of  p53.  Furthermore, 
pharmacological  inhibition  of  the  p38  MAPK  pathway  rescued  the  senescent 
phenotype  induced  by  RUNX1 ETO  and  therefore  implicated  p38  as  a  critical 
mediator of RUNX1 ETO induced senescence in Hs68 cells (Chapter 6, Section 
6.3). It will be important to see whether inhibition of p38 MAPK itself would 
prevent  p53  accumulation,  confirming  the  sequential  mode  of  action.  The 
involvement of p38 MAPK in t(8;21) associated AML has not been investigated but 
it  seems  possible  that  the  disruption  of  p38  could  explain  the  lack  of  p53 
mutations in primary t(8;21) AML, assuming that the p38 p53 activating pathway 
is operative in myeloid cells. A weak upregulation of p38 kinase has also been 
identified  in  RUNX1  expressing  cells  and  its  inhibition  partially  rescued  the 
senescence like growth arrest suggesting that p38 MAPK is commonly engaged by 
RUNX1 and RUNX1 ETO consistent with its established role in various types of 
senescence (Ischikawa et al 2003; Wang et al 2002). Given that p38 has been 
also  reported  to  regulate  expression  of  p16
INK4a  during  senescence  through 
stabilisation of its mRNA (Wang et al 2002) it is possible that it may contribute to 
the increase in p16
INK4a in RUNX1 induced senescent cells. However, other not 
necessarily  mutually  exclusive  mechanisms  may  be  responsible  for  p16
INK4a 
upregulation by RUNX1. It will be interesting to see if regulators of p16
INK4a such 
as ETS, ID (Itahana et al 2001) or polycomb INK4a repressors e.g. BMI1 or CBX7 
(Alani et al 2001; Bracken et al 2007; Gil et al 2003; Ohtani et al 2001) are 
affected in RUNX1 induced senescence.  Importantly inactivation of p16 and p15 
is common in human leukaemias. P15 and p16 loci are frequently found to be 
deleted in acute lymphoblastic leukaemia (>30%), whereas hypermethylation of 
the promoter region of p16 and p15 is particularly prevalent in acute myeloid 
leukaemia (40 80%) (Drexler 1998) 
 
A further consideration given the involvement of p38 MAPK is the question of 
how RUNX1 and in particular RUNX1 ETO achieve the activation of p38 MAPK? 
Gadd45α which contains bona fide RUNX DNA binding sites adjacent to p53 sites 
in intron 3 is a potential link as it has been demonstrated to be required for p38 
activation in the presence of H RAS
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RUNX1 ETO which has been previously reported to activate some genes such as 
bcl 2  (Klampfer  et  al  1996)  may  stimulate  the  expression  of  Gadd45α  more 
effectively than RUNX1 which would result in profound p38 activation. While the 
role of Gadd45α  remains to be investigated, increased ROS levels were found in 
RUNX1 and RUNX1 ETO expressing cells (Chapter 5, section 5.5) which could also 
be responsible for p38 activation.  
 
Reactive oxygen species have not only been shown to be critical mediators of H 
RAS
V12 induced senescence (Lee et al 1999) but have also been tightly linked to 
the activation of p38 MAPK (Dolado et al 2007; Iwasa et al 2003; Nicke et al 
2005; Zdanov  et al 2006). The induction of ROS by RUNX1 was much weaker 
compared to RUNX1 ETO and, importantly, ROS levels seem to parallel the levels 
of phospho p38 in the senescent human fibroblasts Hs68 (Chapter 5, Section 5.4 
and 5.5). Therefore, one can speculate that ROS may play an important role 
especially in RUNX1 ETO induced senescence where the levels of ROS were even 
higher than these observed in H RAS
V12 expressing cells. This, however, would 
need to be tested directly either by culturing cells in low oxygen tension or in 
the presence of antioxidant such as NAC (N acetyl cystein). Recently, it has been 
shown that increased levels of ROS are associated with the formation of the 
activated, catalytic fragment PKCδ (protein kinase C δ), which, in turn, seems to 
lead to further production of ROS and irreversible senescence (Takahashi et al 
2006).  Activation  of  PKCδ  causes  profound  reduction  of  WARTS  (WTS/large 
tumour suppressor 1 mitotic kinase) kinase which is required for cytokinesis and 
subsequent G2M arrest (Takahashi et al 2006). The role of PKCδ and WARTS in 
RUNX1 ETO  induced  senescence  is  of  particular  interest  given  that 
overexpression  of  RUNX1 ETO  causes  cell  cycle  arrest  with  a  strong  G2M 
component and is associated with high ROS levels. Reactive oxygen species have 
been  also  demonstrated  to  oxidise  and  inactivate  Cdc25  phosphatases  and 
therefore may control the cell cycle directly (Nilsson and Hoffmann 2000). Cdc25 
phosphatases are responsible for dephosphorylation of pThr14 and pTyr15 and 
thereby trigger the activation of the Cdk/cyclin complexes which are required 
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function  of  Cdc25  phosphatases  and  may  cause  growth  arrest  (Nilsson  and 
Hoffmann  2000).  Cdc25A  controls  G1/S  transition  by  its  activity  on  the 
Cdk2/cyclin E and Cdk2/cyclin A complexes, whereas Cdc25B and Cdc25C are 
primarly required for entry into mitosis  (Boutros et  al 2007). Interestingly, a 
contrasting  result  with  respect  to  ROS  has  been  recently  reported,  where 
overexpression of RUNX1 ETO in CD34
+ umbilical blood early progenitor cells did 
not cause the accumulation of ROS (Krejci et al  2008). This may, of course, 
reflect cell type specific differences, however there was a major difference in 
that  the  ROS  levels  in  senescent  fibroblasts  were  measured  on  day  11  after 
transduction (Chapter 5, Section 5.5) whereas Krejci at al measured ROS five 
weeks after transduction. Thus it is conceivable that ROS induction by RUNX1 
ETO is an early event. If ROS is demonstrated to be an absolute requirement for 
RUNX1 ETO or RUNX1 induced senescence the question arises as to how ROS are 
generated. Notably, none of the studies published so far has clearly defined the 
origin of ROS generation in senescence or why it is generated in the first place. 
It is still not known if this response is a mitochondrial specific ROS production or 
whether ROS are generated by, for instance, NADPH oxidase. It is clear that ROS 
generation is intimately associated with the senescent phenotype, however the 
details  of  this  association  still  need  to  be  unravelled.  Due  to  its  unspecific 
nature it is unlikely that ROS could have evolved as a specific signalling pathway 
in senescence. In RAS induced senescence, one potential candidate responsible 
for high ROS levels is 5 lipoxygenase (5LO). This enzyme generates ROS in the 
process  of  its  enzymatic  conversion  of  arachidonic  acid  to  leukotrienes.  In 
primary cells overexpressing RAS, 5LO activity increases (Catalano et al 2005) 
and  ectopic  expression  of  5LO  promotes  senescence  in  a  redox  dependent, 
p53/p21 mediated fashion (Catalano et al 2005). The involvement of this enzyme 
in other routes to senescence seems worthy of further investigation. 
 
DNA  damage  signalling  has  been  recently  proposed  to  be  an  important 
mechanism by which senescence occurs. Oncogenes such as H RAS
V12 have been 
shown to trigger a classical DNA damage response mediated by the ATM/ATR and 
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through phosphorylation (DiMicco et al 2006; Barkova et al 2006). RUNX1 ETO 
was found to induce p53 dependent senescence (Chapter 6, Section 5.4 and 5.5), 
accompanied  by  high  ROS  accumulation  (Chapter  5,  Section  5.5)  therefore  it 
seemed  possible  that  DNA  damage  signalling  may  also  underlie  RUNX1 ETO 
induced  senescence.  However,  fluorescent  confocal  microscopy  revealed  no 
convincing  γ H2AX  foci,  a  marker  of  DSB,  in  either  RUNX1 ETO  or  RUNX1 
expressing  human  fibroblasts  (Chapter  5,  Section  5.6),  although  they  were  
readily detected in H RAS
V12 expressing cells as previously reported (DiMicco et 
al 2006). This result was not surprising for RUNX1, given that it primarly involves 
p16
INK4a and does not generate large amounts of ROS. However, the result was 
unexpected in the case of RUNX1 ETO induced senescence. Nevertheless, there 
are some possible explanations. Firstly, ROS could be modulated by an as yet 
unknown mechanism such that it mainly acts as a signalling molecule more than 
as  DNA  damaging  agent.  Secondly,  neither  RUNX1  nor  RUNX1 ETO  induced 
senescence involves a preliminary hyper proliferative burst (Chapter 4, Section 
4.3) which has been linked to DNA damage signalling caused by H RAS
V12 due to 
‘replicative  stress’ related  DSB  formation  (DiMicco  et  al  2006;  Bartkova  et  al 
2006). Thirdly, lack of γ H2AX foci may not necessarily mean that DNA damage 
response is not involved in senescence as it has been demonstrated recently that 
activation of ATR by TopBP1 induces premature senescence in the absence of 
DNA  double  strand  breaks  (Toledo  et  al  2008).  Further  investigations  are 
required  to  see  if  ATM/ATR  and/or  Chk1/Chk2  are  affected  by  RUNX1  and 
RUNX1 ETO.  Finally,  RUNX1  and  RUNX1 ETO  could  exert  their  effects 
downstream  of  DNA  damage  signalling  pathways.  Interestingly,  it  has  been 
reported recently that overexpression of RUNX1 ETO in human CD34
+ cells drives 
DNA damage and p53 dependent apoptosis (Krejci et al 2008). There is however, 
one caveat in this study, which is that γ H2AX foci were detected five weeks 
after transduction. It is quite likely that by this time the secondary changes may 
occur, including accumulation of DNA damage. It was also reported that DNA 
repair enzymes were downregulated in these CD34
+ cells which may suggest that 
these cell were actually survivors that escape apoptosis or growth arrest.  It is 
also important to remember that this observation may also reflect intrinsic cell 
type  differences  in  the  propensity  to  accumulate  DSBs  (fibroblasts  vs 
haematopoetic progenitors).  Kamil K. Wolyniec, 2008     Chapter 7,169  
 
Another  interesting  finding  that  distinguishes  RUNX1  and  RUNX1 ETO  from  H 
RAS
V12 induced senescence is the lack of chromatin condensation. Senescence 
associated heterochromatin foci (SAHF) were not observed in either RUNX1 or 
RUNX1 ETO  expressing  cells  as  visualised  by  staining  with  DAPI  (Chapter  5, 
Section  5.6).  SAHF  formation  is  a  multi step  process  involving  cooperation 
between p16 pRb and HIRA/ASF1 pathways. PML bodies play an important role in 
this process as they serve as a molecular integrating platform for assembly and 
modification of HIRA containing complexes, prior to export of these complexes 
to sites of nascent SAHF. Also it has been suggested that senescent cells may 
maintain  their  irreversible  growth  arrested  state,  at  least  in  part,  by  stably 
forming  heterochromatin  and  epigenetically  silencing  proliferation promoting 
gene loci, which are resistant to E2F mediated transcriptional activation (Narita 
et al., 2003). If this is the case, why then do RUNX1 and RUNX1 ETO not induce 
SAHF and what does this tell us? Perhaps SAHF are not present in RUNX1 ETO 
induced senescent cells because this from of senescence is primarly driven via 
the  p53  pathway.  RUNX1 ETO  has  also  been  demonstrated  to  constitutively 
activate the Wnt pathway (Muller Tidow et al 2004; Simon et al 2005) whereas 
the downregulation of Wnt signalling is absolutely required for formation of SAHF 
(Ye et al 2007).  The lack of SAHF in RUNX1 expressing cells could also be related 
to a certain threshold level of p16
INK4a that RUNX1 fails to achieve and/or it 
could  be  due  to  the  inability  of  RUNX1  to  induce  PML  bodies.  Alternatively, 
RUNX1 and RUNX1 ETO induced senescence may represent a form of senescence 
which is reversible upon inactivation of the p53 and/or the p16 pRb pathways 
and therefore SAHF are not apparent. This could be addressed by co transducing 
cells with RUNX1 or RUNX1 ETO and inducible large T antigen which could be 
switched on when cells enter senescence or by infecting senescent cells with a 
lentiviral  vector  encoding  SV40  large  T  antigen  to  abrogate  p53  and  pRb 
function. Another possibility could be that DNA damage and SAHF accumulation 
are  somehow  mechanistically  linked  to  each  other.  It  is  possible  that  DNA 
damage foci might trigger SAHF formation cooperatively with p16
INK4a, HIRA/ASF1 
and PML bodies and there may be a threshold level of DNA damage above which 
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can modify chromatin and trancriptionally repress some genes (Shimada et al 
2008). In addition, at sites of DNA damage a number of chromatin modifications 
occur, most of which, however, lead to chromatin relaxation (Murr et al 2006; 
Ziv et al 2006). It could be speculated that SAHF formation is a consequence of 
cellular attempts to counteract DNA damage induced chromatin relaxation and 
DNA damage responses. Further detailed analysis of kinetics of the formation of 
DNA  damage  foci  and  SAHF  as  well  as  spatial  comparison  between  those 
structures would help to address the issue of whether DNA damage foci play a 
causative role in SAHF formation. 
 
The RUNX genes share an intriguing and paradoxical dualistic nature. This means 
that depending on the context they can act as oncogenes or tumour suppressors 
(Blyth et al 2005). Given that both RUNX1 and RUNX1 ETO senescent phenotypes 
differ significantly from classical oncogene induced senescence it is reasonable 
to  postulate  that  RUNX1  and  RUNX1 ETO  induced  senescence  reflect  failsafe 
rather than oncogenic functions. This hypothesis is supported by the fact that 
RUNX1  and  RUNX1 ETO  expressing  cells  undergo  growth  arrest  without  a 
preliminary  phase  of  hyper replication  and  do  not  trigger  a  DNA  damage 
response. In this respect they resemble p53 induced senescence where ectopic 
expression of p53 did not result in γ H2AX foci or SAHF formation (Chapter 5, 
Section  5.8)  suggesting  that  the  appearance  of  SAHF  and  γ H2AX  foci  may 
distinguish oncogene from tumour suppressor induced senescence. It has been 
demonstrated  in  our  laboratory  that  other  RUNX  genes  when  ectopically 
expressed in primary murine embryonic fibroblasts (MEFs) also induce premature 
senescence without an initial hyper replicative phase (Kilbey et al 2007; Wotton 
et  al  2004)  suggesting  that  ectopic  RUNX  may  be  activating  a  downstream 
execution phase of oncogene induced senescence. This may indicate that, in the 
context of senescence, the RUNX genes act as tumour suppressors rather than 
oncogenes.  In support of this hypothesis, primary fibroblasts lacking RUNX2 fail 
to  undergo  senescence  and  are  instead  transformed  by  oncogenic  H RAS
V12 
pointing to an intrinsic role of RUNX genes in this process (Kilbey et al 2007). 
The  requirement  for  RUNX2  may  reflect  relative  abundance  of  its  expression Kamil K. Wolyniec, 2008     Chapter 7,171  
compared to other family members in MEFs rather than a unique RUNX2 specific 
function. Consistent with this idea, it has been shown that RUNX1 is required for 
growth arrest in response to N RAS in haematopoietic progenitor cells (Motoda et 
al 2007). Taken together, this may indicate that different RUNX proteins play 
similar non redundant roles in cellular senescence. Interestingly, loss of RUNX2 
has been recently implicated in the bypass of senescence in primary osteoblasts 
and  their  immortalisation,  underpinning  the  role  of  RUNX2  as  a  tumour 
suppressor (Zaidi et al 2007). Furthermore, a RUNX1 tumour suppressive function 
has been recently linked to a number of types of solid cancers. For example, 
RUNX1 has been found to be downregulated in the early stages of hepatocellular 
carcinoma  (Miyagawa  et  al  2006)  and  gastric  cancer  (Sakakura  et  al  2005). 
Interestingly, a novel splice variant of RUNX1 which confers loss of wild type 
tumour  suppressive  functions  has  been  identified  in  ovarian  cancer  patients 
(Nanjundan et al 2007). 
 
From the observations made in this study a scenario emerges whereby RUNX1 
and RUNX1 ETO induce senescence by different yet to some extent overlapping 
pathways  (Figure  7.1).  While  it  is  clear  that  RUNX1  requires  p53  in  MEFs  to 
induce senescence (Wotton et al 2004), p53 has not been found to be essential 
for senescence in human cells where p16
INK4a appeared to be more important. 
The role of p21
WAF1 in RUNX1 induced senescence requires further investigation 
since  it  is  dramatically  induced  in  human  fibroblasts  possibly  due  to  direct 
activation  of  the  promoter.  It  is  plausible  that  both  p16
INK4a  and  p21
WAF1 
cooperate to achieve pRb activation and establish growth arrest. RUNX1 induced 
senescence partially relies on p38 MAPK signalling and p38 could contribute to 
p16
INK4a  upregulation  in  these  cells,  although  there  are  other  mediators  also 
likely to be involved in p16
INK4a regulation. Slightly elevated ROS levels in RUNX1 
expressing cells could be responsible for the activation of p38 MAPK given that 
these two events correlated well with each other, however other molecules such 
as Gadd45a must also be considered as potential candidates. Finally, the finding 
that  RUNX1  induced  senescence  does  not  entail  DNA  damage  foci  and  SAHF 
formation leads to the hypothesis that RUNX1 act as a tumour suppressor rather Kamil K. Wolyniec, 2008     Chapter 7,172  
than  an  oncogene  in  the  context  of  senescence.  Interestingly  several  genes 
belonging  to  the  ceramide  pathway  have  been  shown  to  be  up   or  down 
regulated  by  RUNX1  in  microarray  experiment  which  has  been  recently 
performed in our laboratory (Wotton et al 2008). Ceramide has been implicated 
in cellular senescence (Mouton and Venable 2000; Venable et al 1995) and even 
RAS induces senescence via ceramide accumulation (Castro et al 2008). It may 
represent another signalling pathway or another interacting factor involved in 
RUNX1  mediated  senescence  and  may  warrant  further  investigation  in  the 
future. 
 
  
Figure 7.1 Diagram illustrating the potential mechanism of RUNX1 and 
RUNX1-ETO induced senescence 
Increases in ROS levels activate p38 MAPK which in turn regulates the expression 
of p53 and p16. RUNX1 induces p16 dependent senescence whereas RUNX1 ETO 
RUNX1  RUNX1 ETO 
p38 MAPK 
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p21 
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induces p53 dependent senescence. RUNX1 and RUNX1 ETO differentially induce 
p21, possibly due to exerting direct opposing effects on the p21 promoter. PML 
may  play  a  role  in  p53  stabilisation  in  RUNX1 ETO  induced  senescence.  The 
thickness of the arrows reflect the level of upregulation of relevant mediators of 
senescence by RUNX1 or RUNX1 ETO 
 
Physical  and  functional  interactions  between  STAT5  and  RUNX1  have  been 
revealed recently (Ogawa et al 2008). This is particularly interesting given that 
STAT5 is also capable of inducing premature senescence when overexpressed in 
primary  human  fibroblasts  and,  like  RUNX1,  does  not  involve  SAHF  formation 
(Hemann  and  Narita  2008)  suggesting  that  they  may  share  some  common 
pathway to senescence. On the other hand RUNX1 ETO, in contrast to RUNX1, 
induces p16 independent but p53 dependent senescence. RUNX1 ETO potently 
induces  reactive  oxygen  species  and  ROS  may  be  responsible  for  the 
accumulation  of  phosphorylated  p38  MAPK,  which  is  required  for  the 
development  of  the  senescent  phenotype.  It  seems  that  p38  MAPK,  in  turn, 
activates p53, which is also likely to be stabilised by PML. Given that RUNX1 ETO 
seems to have a suppressive effect on p21
WAF1, it will be important to see if p21 
is indeed dispensable for RUNX1 ETO to induce senescence. If this proves to be 
the case it will be important to identify the downstream effectors of p53 that 
establish G2/M arrest in RUNX1 ETO expressing cells. The mechanism by which 
p53 regulates the G2/M transition involves regulation of the cyclin dependent 
kinase Cdc2 which is  essential for entry into mitosis (Nurse 1990; Taylor and 
Stark 2001b). Binding to cyclin B and phosphorylation by CDK activating kinase 
(CAK)  are  required  to  activate  Cdc2  (Pines  1995;  Taylor  and  Stark  2001a). 
Gadd45α and/or 14 3 3 sigma emerge as interesting effectors of p53 that may 
play a role in RUNX1 ETO induced senescence. Both Gadd45α and 14 3 3 sigma 
are direct targets of p53 and are known to inhibit Cdc2 activity. The protein 14 
3 3 sigma binds to Cdc2 Cyclin B complex and sequesters it in the cytoplasm 
(Chan  et  al  1999;  Hermeking  et  al  1997)  whereas  Gadd45α  inhibits  Cdc2  by 
blocking its binding to cyclin B (Jin et al 2000; Zhan et al 1999). Thus, it could 
be  that  RUNX1 ETO  causes  G2/M  arrest  due  to  p53 dependent  activation  of Kamil K. Wolyniec, 2008     Chapter 7,174  
Gadd45α  and/or  14 3 3  sigma.  Given  that  Gadd45α  has  been  shown  to  be 
involved in p38 activation in H RAS
V12 induced senescence (Bulavin et al 2003) it 
is tempting to speculate that the same p53 Gadd45α  p38 positive feedback loop 
is operative in RUNX1 ETO induced senescence.  
 
 
In conclusion, I have reported that RUNX1 and the RUNX1/CBFβ oncogenic fusion 
derivatives:  RUNX1 ETO  and  CBFβ MYH11  induce  premature  senescence  when 
ectopically expressed in primary cells revealing a central role for Runx regulated 
pathways in this tumour suppressive response. While the nature of CBFβ MYH11 
induced senescence remains to be investigated I have demonstrated that RUNX1 
and  RUNX1 ETO  induce  senescence  by  distinctive  yet  partially  overlapping 
cellular  mechanisms.  I  have  also  identified  DNA  binding  and  the  C terminal 
domain as an absolute requirement to induce senescence by RUNX1. In addition I 
have found that RUNX1 ETO C terminal domain containing corepressor binding 
sites of ETO protein is critical for RUNX1 ETO induced senescence. Importantly, I 
have shown that both RUNX1 and RUNX1 ETO induced senescence differ from 
prototypical H RAS
V12 induced senescence. This study emphasises the fact that 
cellular  senescence  represents  a  heterogeneous  process  driven  by  diverse 
pathways depending on the stimuli and the cell type. 
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